A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
revise and extend the user-fee programs for prescription 
drugs, medical devices, generic drugs, and biosimilar bio-
logical products, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Food and Drug 
4
Amendments of 2022’’. 
5
SEC. 2. TABLE OF CONTENTS. 
6
The table of contents of this Act is as follows: 
7
Sec. 1. Short title. 
21:28 May 06, 2022
H7667
2 
•HR 7667 IH
Sec. 2. Table of contents. 
TITLE I—FEES RELATING TO DRUGS 
Sec. 101. Short title; finding. 
Sec. 102. Definitions. 
Sec. 103. Authority to assess and use drug fees. 
Sec. 104. Reauthorization; reporting requirements. 
Sec. 105. Sunset dates. 
Sec. 106. Effective date. 
Sec. 107. Savings clause. 
TITLE II—FEES RELATING TO DEVICES 
Sec. 201. Short title; finding. 
Sec. 202. Definitions. 
Sec. 203. Authority to assess and use device fees. 
Sec. 204. Reauthorization; reporting requirements. 
Sec. 205. Conformity assessment pilot program. 
Sec. 206. Reauthorization of third-party review program. 
Sec. 207. Savings clause. 
Sec. 208. Effective date. 
Sec. 209. Sunset dates. 
TITLE III—FEES RELATING TO GENERIC DRUGS 
Sec. 301. Short title; finding. 
Sec. 302. Authority to assess and use human generic drug fees. 
Sec. 303. Reauthorization; reporting requirements. 
Sec. 304. Sunset dates. 
Sec. 305. Effective date. 
Sec. 306. Savings clause. 
TITLE IV—FEES RELATING TO BIOSIMILAR BIOLOGICAL 
PRODUCTS 
Sec. 401. Short title; finding. 
Sec. 402. Definitions. 
Sec. 403. Authority to assess and use biosimilar fees. 
Sec. 404. Reauthorization; reporting requirements. 
Sec. 405. Sunset dates. 
Sec. 406. Effective date. 
Sec. 407. Savings clause. 
TITLE V—IMPROVING DIVERSITY IN CLINICAL TRIALS 
Sec. 501. Premarket reporting of diversity action plans for clinical trials and 
studies. 
Sec. 502. Evaluation of the need for FDA authority to mandate postapproval 
studies or postmarket surveillance due to insufficient demo-
graphic subgroup data. 
Sec. 503. Public workshops to enhance clinical trial diversity. 
Sec. 504. Annual report on progress to increase diversity in clinical trials and 
studies. 
Sec. 505. Public meeting on clinical trial flexibilities initiated in response to 
COVID–19 pandemic. 
Sec. 506. Decentralized clinical trials. 
21:28 May 06, 2022
H7667
3 
•HR 7667 IH
TITLE VI—GENERIC DRUG COMPETITION 
Sec. 601. Increasing transparency in generic drug applications. 
Sec. 602. Enhancing access to affordable medicines. 
TITLE VII—RESEARCH, DEVELOPMENT, AND SUPPLY CHAIN 
IMPROVEMENTS 
Subtitle A—In General 
Sec. 701. Animal testing alternatives. 
Sec. 702. Emerging technology program. 
Sec. 703. Improving the treatment of rare diseases and conditions. 
Sec. 704. Antifungal research and development. 
Sec. 705. Advancing qualified infectious disease product innovation. 
Sec. 706. Advanced manufacturing technologies designation pilot program. 
Sec. 707. Public workshop on cell and gene therapies. 
Sec. 708. Reauthorization of best pharmaceuticals for children. 
Sec. 709. Reauthorization for humanitarian device exemption and demonstra-
tion grants for improving pediatric availability. 
Sec. 710. Reauthorization of provision related to exclusivity of certain drugs 
containing single enantiomers. 
Sec. 711. Reauthorization of the critical path public-private partnership pro-
gram. 
Sec. 712. Reauthorization of orphan drug grants. 
Subtitle B—Inspections 
Sec. 721. Factory inspection. 
Sec. 722. Uses of certain evidence. 
Sec. 723. Improving FDA inspections. 
Sec. 724. GAO report on inspections of foreign establishments manufacturing 
drugs. 
Sec. 725. Unannounced foreign facility inspections pilot program. 
Sec. 726. Reauthorization of inspection program. 
Sec. 727. Enhancing intra-agency coordination and public health assessment 
with regard to compliance activities. 
Sec. 728. Reporting of mutual recognition agreements for inspections and re-
view activities. 
Sec. 729. Enhancing transparency of drug facility inspection timelines. 
TITLE VIII—TRANSPARENCY, PROGRAM INTEGRITY, AND 
REGULATORY IMPROVEMENTS 
Sec. 801. Prompt reports of marketing status by holders of approved applica-
tions for biological products. 
Sec. 802. Encouraging blood donation. 
Sec. 803. Regulation of certain products as drugs. 
Sec. 804. Postapproval studies and program integrity for accelerated approval 
drugs. 
Sec. 805. Facilitating the use of real world evidence. 
Sec. 806. Medical devices advisory committee meetings. 
Sec. 807. Ensuring cybersecurity of medical devices. 
Sec. 808. Public docket on proposed modifications to approved strategies. 
Sec. 809. Facilitating exchange of product information prior to approval. 
Sec. 810. Bans of devices for one or more intended uses. 
21:28 May 06, 2022
H7667
4 
•HR 7667 IH
Sec. 811. Clarifying application of exclusive approval, certification, or licensure 
for drugs designated for rare diseases or conditions. 
Sec. 812. GAO report on third-party review. 
Sec. 813. Reauthorization of device pilot projects. 
Sec. 814. Reporting on pending generic drug applications and priority review 
applications. 
TITLE I—FEES RELATING TO 
1
DRUGS 
2
SEC. 101. SHORT TITLE; FINDING. 
3
(a) SHORT TITLE.—This title may be cited as the 
4
‘‘Prescription Drug User Fee Amendments of 2022’’. 
5
(b) FINDING.—The Congress finds that the fees au-
6
thorized by the amendments made in this title will be dedi-
7
cated toward expediting the drug development process and 
8
the process for the review of human drug applications, in-
9
cluding postmarket drug safety activities, as set forth in 
10
the goals identified for purposes of part 2 of subchapter 
11
C of chapter VII of the Federal Food, Drug, and Cosmetic 
12
Act, in the letters from the Secretary of Health and 
13
Human Services to the Chairman of the Committee on 
14
Health, Education, Labor, and Pensions of the Senate and 
15
the Chairman of the Committee on Energy and Commerce 
16
of the House of Representatives, as set forth in the Con-
17
gressional Record. 
18
SEC. 102. DEFINITIONS. 
19
(a) HUMAN DRUG APPLICATION.—Section 735(1) of 
20
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
21
379g(1)) is amended by striking ‘‘an allergenic extract 
22
21:28 May 06, 2022
H7667
5 
•HR 7667 IH
product, or’’ and inserting ‘‘does not include an applica-
1
tion with respect to an allergenic extract product licensed 
2
before October 1, 2022, does not include an application 
3
with respect to a standardized allergenic extract product 
4
submitted pursuant to a notification to the applicant from 
5
the Secretary regarding the existence of a potency test 
6
that measures the allergenic activity of an allergenic ex-
7
tract product licensed by the applicant before October 1, 
8
2022, does not include an application with respect to’’. 
9
(b) PRESCRIPTION DRUG PRODUCT.—Section 735(3) 
10
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
11
379g(3)) is amended— 
12
(1) by redesignating subparagraphs (A), (B), 
13
and (C) as clauses (i), (ii), and (iii), respectively; 
14
(2) by striking ‘‘(3) The term’’ and inserting 
15
‘‘(3)(A) The term’’; 
16
(3) by striking ‘‘Such term does not include’’ 
17
and inserting the following: 
18
‘‘(B) Such term does not include’’; 
19
(4) by striking ‘‘an allergenic extract product,’’ 
20
and inserting ‘‘an allergenic extract product licensed 
21
before October 1, 2022, a standardized allergenic ex-
22
tract product submitted pursuant to a notification to 
23
the applicant from the Secretary regarding the exist-
24
ence of a potency test that measures the allergenic 
25
21:28 May 06, 2022
H7667
6 
•HR 7667 IH
activity of an allergenic extract product licensed by 
1
the applicant before October 1, 2022,’’ ; and 
2
(5) by adding at the end the following: 
3
‘‘(C)(i) If a written request to place a 
4
product in the discontinued section of either of 
5
the lists referenced in subparagraph (A)(iii) is 
6
submitted to the Secretary on behalf of an ap-
7
plicant, and the request identifies the date the 
8
product is withdrawn from sale, then for pur-
9
poses of assessing the prescription drug pro-
10
gram fee under section 736(a)(2), the Secretary 
11
shall consider such product to have been in-
12
cluded in the discontinued section on the later 
13
of— 
14
‘‘(I) the date such request was re-
15
ceived; or 
16
‘‘(II) if the product will be withdrawn 
17
from sale on a future date, such future 
18
date when the product is withdrawn from 
19
sale. 
20
‘‘(ii) For purposes of this subparagraph, a 
21
product shall be considered withdrawn from 
22
sale once the applicant has ceased its own dis-
23
tribution of the product, whether or not the ap-
24
plicant has ordered recall of all previously dis-
25
21:28 May 06, 2022
H7667
7 
•HR 7667 IH
tributed lots of the product, except that a rou-
1
tine, temporary interruption in supply shall not 
2
render a product withdrawn from sale.’’. 
3
(c) SKIN-TEST DIAGNOSTIC PRODUCT.—Section 735 
4
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
5
379g) is amended by adding at the end the following: 
6
‘‘(12) The term ‘skin-test diagnostic product’— 
7
‘‘(A) means a product— 
8
‘‘(i) for prick, scratch, intradermal, or 
9
subcutaneous administration; 
10
‘‘(ii) expected to produce a limited, 
11
local reaction at the site of administration 
12
(if positive), rather than a systemic effect; 
13
‘‘(iii) not intended to be a preventive 
14
or therapeutic intervention; and 
15
‘‘(iv) intended to detect an immediate- 
16
or delayed-type skin hypersensitivity reac-
17
tion to aid in the diagnosis of— 
18
‘‘(I) an allergy to an anti-
19
microbial agent; 
20
‘‘(II) an allergy that is not to an 
21
antimicrobial agent, if the diagnostic 
22
product was authorized for marketing 
23
prior to October 1, 2022; or 
24
21:28 May 06, 2022
H7667
8 
•HR 7667 IH
‘‘(III) infection with fungal or 
1
mycobacterial pathogens; and 
2
‘‘(B) includes positive and negative con-
3
trols required to interpret the results of a prod-
4
uct described in subparagraph (A)’’. 
5
SEC. 103. AUTHORITY TO ASSESS AND USE DRUG FEES. 
6
(a) TYPES OF FEES.— 
7
(1) HUMAN DRUG APPLICATION FEE.—Section 
8
736(a) of the Federal Food, Drug, and Cosmetic Act 
9
(21 U.S.C. 379h(a)) is amended— 
10
(A) in the matter preceding paragraph (1), 
11
by striking ‘‘fiscal year 2018’’ and inserting 
12
‘‘fiscal year 2023’’. 
13
(B) in paragraph (1)(A), by striking 
14
‘‘(c)(5)’’ each place it appears and inserting 
15
‘‘(c)(6)’’; 
16
(C) in paragraph (1)(C), by inserting 
17
‘‘prior to approval’’ after ‘‘or was withdrawn’’; 
18
and 
19
(D) in paragraph (1), by adding at the end 
20
the following: 
21
‘‘(H) EXCEPTION
FOR
SKIN-TEST
DIAG-
22
NOSTIC PRODUCTS.—A human drug application 
23
for a skin-test diagnostic product shall not be 
24
subject to a fee under subparagraph (A).’’. 
25
21:28 May 06, 2022
H7667
9 
•HR 7667 IH
(2) PRESCRIPTION DRUG PROGRAM FEE.—Sec-
1
tion 736(a)(2) of the Federal Food, Drug, and Cos-
2
metic Act (21 U.S.C. 379h(a)(2)) is amended— 
3
(A) in subparagraph (A)— 
4
(i) by striking ‘‘Except as provided in 
5
subparagraphs (B) and (C)’’ and inserting 
6
the following: 
7
‘‘(i) FEE.—Except as provided in sub-
8
paragraphs (B) and (C)’’; 
9
(ii) by striking ‘‘subsection (c)(5)’’ 
10
and inserting ‘‘subsection (c)(6)’’; and 
11
(iii) by adding at the end the fol-
12
lowing: 
13
‘‘(ii) SPECIAL RULE.—If a drug prod-
14
uct that is identified in a human drug ap-
15
plication approved as of October 1 of a fis-
16
cal year is not a prescription drug product 
17
as of that date because the drug product 
18
is in the discontinued section of a list ref-
19
erenced in section 735(3)(A)(iii), and on 
20
any subsequent day during such fiscal year 
21
the drug product is a prescription drug 
22
product, then except as provided in sub-
23
paragraphs (B) and (C), each person who 
24
is named as the applicant in a human drug 
25
21:28 May 06, 2022
H7667
10 
•HR 7667 IH
application with respect to such product, 
1
and who, after September 1, 1992, had 
2
pending before the Secretary a human 
3
drug application or supplement with re-
4
spect to such product, shall pay the annual 
5
prescription drug program fee established 
6
for a fiscal year under subsection (c)(6) for 
7
such prescription drug product. Such fee 
8
shall be due on the last business day of 
9
such fiscal year and shall be paid only once 
10
for each such product for a fiscal year in 
11
which the fee is payable.’’; and 
12
(B) by amending subparagraph (B) to read 
13
as follows: 
14
‘‘(B) EXCEPTION FOR CERTAIN PRESCRIP-
15
TION
DRUG
PRODUCTS.—A prescription drug 
16
program fee shall not be assessed for a pre-
17
scription drug product under subparagraph (A) 
18
if such product is— 
19
‘‘(i) a large volume parenteral product 
20
(a sterile aqueous drug product packaged 
21
in a single-dose container with a volume 
22
greater than or equal to 100 mL, not in-
23
cluding powders for reconstitution or phar-
24
21:28 May 06, 2022
H7667
11 
•HR 7667 IH
macy bulk packages) identified on the list 
1
compiled under section 505(j)(7); 
2
‘‘(ii) pharmaceutically equivalent (as 
3
defined in section 314.3 of title 21, Code 
4
of Federal Regulations (or any successor 
5
regulation)) to another product on the list 
6
of 
products 
compiled 
under 
section 
7
505(j)(7) (not including the discontinued 
8
section of such list); or 
9
‘‘(iii) a skin-test diagnostic product.’’. 
10
(b) FEE REVENUE AMOUNTS.— 
11
(1) IN
GENERAL.—Paragraph (1) of section 
12
736(b) of the Federal Food, Drug, and Cosmetic Act 
13
(21 U.S.C. 379h(b)) is amended to read as follows: 
14
‘‘(1) IN GENERAL.—For each of the fiscal years 
15
2023 through 2027, fees under subsection (a) shall, 
16
except as provided in subsections (c), (d), (f), and 
17
(g), be established to generate a total revenue 
18
amount under such subsection that is equal to the 
19
sum of— 
20
‘‘(A) the annual base revenue for the fiscal 
21
year (as determined under paragraph (3)); 
22
‘‘(B) the dollar amount equal to the infla-
23
tion adjustment for the fiscal year (as deter-
24
mined under subsection (c)(1)); 
25
21:28 May 06, 2022
H7667
12 
•HR 7667 IH
‘‘(C) the dollar amount equal to the stra-
1
tegic hiring and reserve adjustment for the fis-
2
cal year (as determined under subsection 
3
(c)(2)); 
4
‘‘(D) the dollar amount equal to the capac-
5
ity planning adjustment for the fiscal year (as 
6
determined under subsection (c)(3)); 
7
‘‘(E) the dollar amount equal to the oper-
8
ating reserve adjustment for the fiscal year, if 
9
applicable (as determined under subsection 
10
(c)(4)); 
11
‘‘(F) the dollar amount equal to the addi-
12
tional direct cost adjustment for the fiscal year 
13
(as determined under subsection (c)(5)); and 
14
‘‘(G) additional dollar amounts for each 
15
fiscal year as follows: 
16
‘‘(i) $65,773,693 for fiscal year 2023. 
17
‘‘(ii) $25,097,671 for fiscal year 2024. 
18
‘‘(iii) $14,154,169 for fiscal year 
19
2025. 
20
‘‘(iv) $4,864,860 for fiscal year 2026. 
21
‘‘(v) 
$1,314,620 
for 
fiscal 
year 
22
2027.’’. 
23
(2) ANNUAL BASE REVENUE.—Paragraph (3) 
24
of section 736(b) of the Federal Food, Drug, and 
25
21:28 May 06, 2022
H7667
13 
•HR 7667 IH
Cosmetic Act (21 U.S.C. 379h(b)) is amended to 
1
read as follows: 
2
‘‘(3) ANNUAL BASE REVENUE.—For purposes 
3
of paragraph (1), the dollar amount of the annual 
4
base revenue for a fiscal year shall be— 
5
‘‘(A) for fiscal year 2023, $1,151,522,958; 
6
and 
7
‘‘(B) for fiscal years 2024 through 2027, 
8
the dollar amount of the total revenue amount 
9
established under paragraph (1) for the pre-
10
vious fiscal year, not including any adjustments 
11
made under subsection (c)(4) or (c)(5).’’. 
12
(c) ADJUSTMENTS; ANNUAL FEE SETTING.— 
13
(1) 
INFLATION
ADJUSTMENT.—Section 
14
736(c)(1)(B)(ii) of the Federal Food, Drug, and 
15
Cosmetic Act (21 U.S.C. 379h(c)(1)(B)(ii)) is 
16
amended by striking ‘‘Washington-Baltimore, DC– 
17
MD–VA–WV’’ and inserting ‘‘Washington-Arlington- 
18
Alexandria, DC–VA–MD–WV’’. 
19
(2) STRATEGIC
HIRING
AND
RETENTION
AD-
20
JUSTMENT.—Section 736(c) of the Federal Food, 
21
Drug, and Cosmetic Act (21 U.S.C. 379h(c)) is 
22
amended— 
23
21:28 May 06, 2022
H7667
14 
•HR 7667 IH
(A) 
by 
redesignating 
paragraphs 
(2) 
1
through (6) as paragraphs (3) through (7), re-
2
spectively; and 
3
(B) by inserting after paragraph (1) the 
4
following: 
5
‘‘(2) STRATEGIC HIRING AND RETENTION AD-
6
JUSTMENT.—For each fiscal year, after the annual 
7
base revenue established in subsection (b)(1)(A) is 
8
adjusted for inflation in accordance with paragraph 
9
(1), the Secretary shall further increase the fee rev-
10
enue and fees by the following amounts: 
11
‘‘(A) For fiscal year 2023, $9,000,000. 
12
‘‘(B) For each of fiscal years 2024 through 
13
2027, $4,000,000.’’. 
14
(3) CAPACITY PLANNING ADJUSTMENT.—Para-
15
graph (3), as redesignated, of section 736(c) of the 
16
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
17
379h(c)) is amended to read as follows: 
18
‘‘(3) CAPACITY PLANNING ADJUSTMENT.— 
19
‘‘(A) IN GENERAL.—For each fiscal year, 
20
after the annual base revenue established in 
21
subsection (b)(1)(A) is adjusted in accordance 
22
with paragraphs (1) and (2), such revenue shall 
23
be adjusted further for such fiscal year, in ac-
24
cordance with this paragraph, to reflect changes 
25
21:28 May 06, 2022
H7667
15 
•HR 7667 IH
in the resource capacity needs of the Secretary 
1
for the process for the review of human drug 
2
applications. 
3
‘‘(B) METHODOLOGY.—For purposes of 
4
this paragraph, the Secretary shall employ the 
5
capacity planning methodology utilized by the 
6
Secretary in setting fees for fiscal year 2021, as 
7
described in the notice titled ‘Prescription Drug 
8
User Fee Rates for Fiscal Year 2021’ published 
9
in the Federal Register on August 3, 2020 (85 
10
Fed. Reg. 46651). The workload categories 
11
used in applying such methodology in fore-
12
casting shall include only the activities de-
13
scribed in that notice and, as feasible, addi-
14
tional activities that are also directly related to 
15
the direct review of applications and supple-
16
ments, including additional formal meeting 
17
types, the direct review of postmarketing com-
18
mitments and requirements, the direct review of 
19
risk evaluation and mitigation strategies, and 
20
the direct review of annual reports for approved 
21
prescription drug products. Subject to the ex-
22
ceptions in the preceding sentence, the Sec-
23
retary shall not include as workload categories 
24
in applying such methodology in forecasting any 
25
21:28 May 06, 2022
H7667
16 
•HR 7667 IH
non-core review activities, including those activi-
1
ties that the Secretary referenced for potential 
2
future use in such notice but did not utilize in 
3
setting fees for fiscal year 2021. 
4
‘‘(C) 
LIMITATION.—Under 
no 
cir-
5
cumstances shall an adjustment under this 
6
paragraph result in fee revenue for a fiscal year 
7
that is less than the sum of the amounts under 
8
subsections (b)(1)(A) (the annual base revenue 
9
for the fiscal year), (b)(1)(B) (the dollar 
10
amount of the inflation adjustment for the fis-
11
cal year), and (b)(1)(C) (the dollar amount of 
12
the strategic hiring and retention adjustment 
13
for the fiscal year). 
14
‘‘(D) PUBLICATION
IN
FEDERAL
REG-
15
ISTER.—The Secretary shall publish in the Fed-
16
eral Register notice under paragraph (6) of the 
17
fee revenue and fees resulting from the adjust-
18
ment and the methodologies under this para-
19
graph.’’. 
20
(4) OPERATING RESERVE ADJUSTMENT.—Para-
21
graph (4), as redesignated, of section 736(c) of the 
22
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
23
379h(c)) is amended— 
24
21:28 May 06, 2022
H7667
17 
•HR 7667 IH
(A) by amending subparagraph (A) to read 
1
as follows: 
2
‘‘(A) INCREASE.—For fiscal year 2023 and 
3
subsequent fiscal years, the Secretary shall, in 
4
addition to adjustments under paragraphs (1), 
5
(2), and (3), further increase the fee revenue 
6
and fees if such an adjustment is necessary to 
7
provide for operating reserves of carryover user 
8
fees for the process for the review of human 
9
drug applications for each fiscal year in at least 
10
the following amounts: 
11
‘‘(i) For fiscal year 2023, at least 8 
12
weeks of operating reserves. 
13
‘‘(ii) For fiscal year 2024, at least 9 
14
weeks of operating reserves. 
15
‘‘(iii) For fiscal year 2025 and subse-
16
quent fiscal years, at least 10 weeks of op-
17
erating reserves.’’; and 
18
(B) in subparagraph (C), by striking 
19
‘‘paragraph (5)’’ and inserting ‘‘paragraph 
20
(6)’’. 
21
(5) ADDITIONAL DIRECT COST ADJUSTMENT.— 
22
Paragraph (5), as redesignated, of section 736(c) of 
23
the Federal Food, Drug, and Cosmetic Act (21 
24
U.S.C. 379h(c)) is amended to read as follows: 
25
21:28 May 06, 2022
H7667
18 
•HR 7667 IH
‘‘(5) 
ADDITIONAL
DIRECT
COST
ADJUST-
1
MENT.— 
2
‘‘(A) INCREASE.—The Secretary shall, in 
3
addition to adjustments under paragraphs (1), 
4
(2), (3), and (4), further increase the fee rev-
5
enue and fees— 
6
‘‘(i) 
for 
fiscal 
year 
2023, 
by 
7
$44,386,150; and 
8
‘‘(ii) for each of fiscal years 2024 
9
through 2027, by the amount set forth in 
10
clauses (i) through (iv) of subparagraph 
11
(B), as applicable, multiplied by the Con-
12
sumer Price Index for urban consumers 
13
(Washington-Arlington-Alexandria, 
DC– 
14
VA–MD–WV; Not Seasonally Adjusted; All 
15
Items; Annual Index) for the most recent 
16
year of available data, divided by such 
17
Index for 2021. 
18
‘‘(B) 
APPLICABLE
AMOUNTS.—The 
19
amounts referred to in subparagraph (A)(ii) are 
20
the following: 
21
‘‘(i) 
For 
fiscal 
year 
2024, 
22
$60,967,993. 
23
‘‘(ii) 
For 
fiscal 
year 
2025, 
24
$35,799,314. 
25
21:28 May 06, 2022
H7667
19 
•HR 7667 IH
‘‘(iii) For fiscal year 2026, $35,799, 
1
314. 
2
‘‘(iv) 
For 
fiscal 
year 
2027, 
3
$35,799,314.’’. 
4
(6) ANNUAL FEE SETTING.—Paragraph (6), as 
5
redesignated, of section 736(c) of the Federal Food, 
6
Drug, and Cosmetic Act (21 U.S.C. 379h(c)) is 
7
amended by striking ‘‘September 30, 2017’’ and in-
8
serting ‘‘September 30, 2022’’. 
9
(d) CREDITING AND AVAILABILITY OF FEES.—Sec-
10
tion 736(g)(3) of the Federal Food, Drug, and Cosmetic 
11
Act (21 U.S.C. 379h(g)(3)) is amended by striking ‘‘fiscal 
12
years 2018 through 2022’’ and inserting ‘‘fiscal years 
13
2023 through 2027’’. 
14
(e) WRITTEN REQUESTS
FOR WAIVERS, REDUC-
15
TIONS, EXEMPTIONS, AND RETURNS; DISPUTES CON-
16
CERNING FEES.—Section 736(i) of the Federal Food, 
17
Drug, and Cosmetic Act (21 U.S.C. 379h(i)) is amended 
18
to read as follows: 
19
‘‘(i) WRITTEN REQUESTS
FOR WAIVERS, REDUC-
20
TIONS, EXEMPTIONS, AND RETURNS; DISPUTES CON-
21
CERNING FEES.—To qualify for consideration for a waiver 
22
or reduction under subsection (d), an exemption under 
23
subsection (k), or the return of any fee paid under this 
24
21:28 May 06, 2022
H7667
20 
•HR 7667 IH
section, including if the fee is claimed to have been paid 
1
in error, a person shall— 
2
‘‘(1) not later than 180 days after such fee is 
3
due, submit to the Secretary a written request justi-
4
fying such waiver, reduction, exemption, or return; 
5
and 
6
‘‘(2) include in the request any legal authorities 
7
under which the request is made.’’. 
8
(f) ORPHAN DRUGS.—Section 736(k) of the Federal 
9
Food, Drug, and Cosmetic Act (21 U.S.C. 379h(k)) is 
10
amended— 
11
(1) in paragraph (1)(B), by striking ‘‘during 
12
the previous year’’ and inserting ‘‘as determined 
13
under paragraph (2)’’; and 
14
(2) by amending paragraph (2) to read as fol-
15
lows: 
16
‘‘(2) EVIDENCE
OF
QUALIFICATION.—An ex-
17
emption under paragraph (1) applies with respect to 
18
a drug only if the applicant involved submits a cer-
19
tification that the applicant’s gross annual revenues 
20
did not exceed $50,000,000 for the last calendar 
21
year ending prior to the fiscal year for which the ex-
22
emption is requested. Such certification shall be sup-
23
ported by— 
24
21:28 May 06, 2022
H7667
21 
•HR 7667 IH
‘‘(A) tax returns submitted to the United 
1
States Internal Revenue Service; or 
2
‘‘(B) as necessary, other appropriate finan-
3
cial information.’’. 
4
SEC. 104. REAUTHORIZATION; REPORTING REQUIREMENTS. 
5
Section 736B of the Federal Food, Drug, and Cos-
6
metic Act (21 U.S.C. 379h–2) is amended— 
7
(1) in subsection (a)(1), by striking ‘‘Beginning 
8
with fiscal year 2018, not’’ and inserting ‘‘Not’’; 
9
(2) by striking ‘‘Prescription Drug User Fee 
10
Amendments of 2017’’ each place it appears and in-
11
serting ‘‘Prescription Drug User Fee Amendments 
12
of 2022’’; 
13
(3) in subsection (a)(3)(A), by striking ‘‘Not 
14
later than 30 calendar days after the end of the sec-
15
ond quarter of fiscal year 2018, and not later than 
16
30 calendar days after the end of each quarter of 
17
each fiscal year thereafter’’ and inserting ‘‘Not later 
18
than 30 calendar days after the end of each quarter 
19
of each fiscal year for which fees are collected under 
20
this part’’; 
21
(4) in subsection (a)(3)(B), by adding at the 
22
end the following: 
23
‘‘(v) For fiscal years 2023 and 2024, 
24
of the meeting requests from sponsors for 
25
21:28 May 06, 2022
H7667
22 
•HR 7667 IH
which the Secretary has determined that a 
1
face-to-face meeting is appropriate, the 
2
number of face-to-face meetings requested 
3
by sponsors to be conducted in person (in 
4
such manner as the Secretary shall pre-
5
scribe on the internet website of the Food 
6
and Drug Administration), and the num-
7
ber of such in-person meetings granted by 
8
the Secretary.’’; 
9
(5) in subsection (a)(4), by striking ‘‘Beginning 
10
with fiscal year 2020, the’’ and inserting ‘‘The’’; 
11
(6) in subsection (b), by striking ‘‘Beginning 
12
with fiscal year 2018, not’’ and inserting ‘‘Not’’; 
13
(7) in subsection (c), by striking ‘‘Beginning 
14
with fiscal year 2018, for’’ and inserting ‘‘For’’; and 
15
(8) in subsection (f)— 
16
(A) in paragraph (1), in the matter pre-
17
ceding subparagraph (A), by striking ‘‘fiscal 
18
year 2022’’ and inserting ‘‘fiscal year 2027’’; 
19
and 
20
(B) in paragraph (5), by striking ‘‘January 
21
15, 2022’’ and inserting ‘‘January 15, 2027’’. 
22
21:28 May 06, 2022
H7667
23 
•HR 7667 IH
SEC. 105. SUNSET DATES. 
1
(a) AUTHORIZATION.—Sections 735 and 736 of the 
2
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379g; 
3
379h) shall cease to be effective October 1, 2027. 
4
(b) REPORTING REQUIREMENTS.—Section 736B of 
5
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
6
379h–2) shall cease to be effective January 31, 2028. 
7
(c) PREVIOUS SUNSET PROVISION.—Effective Octo-
8
ber 1, 2022, subsections (a) and (b) of section 104 of the 
9
FDA Reauthorization Act of 2017 (Public Law 115–52) 
10
are repealed. 
11
SEC. 106. EFFECTIVE DATE. 
12
The amendments made by this title shall take effect 
13
on October 1, 2022, or the date of the enactment of this 
14
Act, whichever is later, except that fees under part 2 of 
15
subchapter C of chapter VII of the Federal Food, Drug, 
16
and Cosmetic Act shall be assessed for all human drug 
17
applications received on or after October 1, 2022, regard-
18
less of the date of the enactment of this Act. 
19
SEC. 107. SAVINGS CLAUSE. 
20
Notwithstanding the amendments made by this title, 
21
part 2 of subchapter C of chapter VII of the Federal Food, 
22
Drug, and Cosmetic Act, as in effect on the day before 
23
the date of the enactment of this title, shall continue to 
24
be in effect with respect to human drug applications and 
25
supplements (as defined in such part as of such day) that 
26
21:28 May 06, 2022
H7667
24 
•HR 7667 IH
on or after October 1, 2017, but before October 1, 2022, 
1
were accepted by the Food and Drug Administration for 
2
filing with respect to assessing and collecting any fee re-
3
quired by such part for a fiscal year prior to fiscal year 
4
2023. 
5
TITLE II—FEES RELATING TO 
6
DEVICES 
7
SEC. 201. SHORT TITLE; FINDING. 
8
(a) SHORT TITLE.—This title may be cited as the 
9
‘‘Medical Device User Fee Amendments of 2022’’. 
10
(b) FINDING.—The Congress finds that the fees au-
11
thorized under the amendments made by this title will be 
12
dedicated toward expediting the process for the review of 
13
device applications and for assuring the safety and effec-
14
tiveness of devices, as set forth in the goals identified for 
15
purposes of part 3 of subchapter C of chapter VII of the 
16
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i 
17
et seq.) in the letters from the Secretary of Health and 
18
Human Services to the Chairman of the Committee on 
19
Health, Education, Labor, and Pensions of the Senate and 
20
the Chairman of the Committee on Energy and Commerce 
21
of the House of Representatives, as set forth in the Con-
22
gressional Record. 
23
21:28 May 06, 2022
H7667
25 
•HR 7667 IH
SEC. 202. DEFINITIONS. 
1
Section 737 of the Federal Food, Drug, and Cosmetic 
2
Act (21 U.S.C. 379i) is amended— 
3
(1) in paragraph (9)— 
4
(A) in the matter preceding subparagraph 
5
(A), by striking ‘‘and premarket notification 
6
submissions’’ and inserting ‘‘premarket notifica-
7
tion submissions, and de novo classification re-
8
quests’’; 
9
(B) in subparagraph (D), by striking ‘‘and 
10
submissions’’ and inserting ‘‘submissions, and 
11
requests’’; 
12
(C) in subparagraph (F), by striking ‘‘and 
13
premarket notification submissions’’ and insert-
14
ing ‘‘premarket notification submissions, and de 
15
novo classification requests’’; 
16
(D) in each of subparagraphs (G) and (H), 
17
by striking ‘‘or submissions’’ and inserting 
18
‘‘submissions, or requests’’; and 
19
(E) in subparagraph (K), by striking ‘‘or 
20
premarket notification submissions’’ and insert-
21
ing ‘‘premarket notification submissions, or de 
22
novo classification requests’’; and 
23
(2) in paragraph (11), by striking ‘‘2016’’ and 
24
inserting ‘‘2021’’. 
25
21:28 May 06, 2022
H7667
26 
•HR 7667 IH
SEC. 203. AUTHORITY TO ASSESS AND USE DEVICE FEES. 
1
(a) TYPES OF FEES.—Section 738(a) of the Federal 
2
Food, Drug, and Cosmetic Act (21 U.S.C. 379j(a)) is 
3
amended— 
4
(1) in paragraph (1), by striking ‘‘fiscal year 
5
2018’’ and inserting ‘‘fiscal year 2023’’; and 
6
(2) in paragraph (2)— 
7
(A) in subparagraph (A)— 
8
(i) in the matter preceding clause (i), 
9
by striking ‘‘October 1, 2017’’ and insert-
10
ing ‘‘October 1, 2022’’; 
11
(ii) in clause (iii), by striking ‘‘75 per-
12
cent’’ and inserting ‘‘80 percent’’; and 
13
(iii) in clause (viii), by striking ‘‘3.4 
14
percent’’ and inserting ‘‘4.5 percent’’; 
15
(B) in subparagraph (B)(iii), by striking 
16
‘‘or premarket notification submission’’ and in-
17
serting ‘‘premarket notification submission, or 
18
de novo classification request’’; and 
19
(C) in subparagraph (C), by striking ‘‘or 
20
periodic reporting concerning a class III device’’ 
21
and inserting ‘‘periodic reporting concerning a 
22
class III device, or de novo classification re-
23
quest’’. 
24
21:28 May 06, 2022
H7667
27 
•HR 7667 IH
(b) FEE AMOUNTS.—Section 738(b) of the Federal 
1
Food, Drug, and Cosmetic Act (21 U.S.C. 379j(b)) is 
2
amended— 
3
(1) in paragraph (1), by striking ‘‘2018 
4
through 2022’’ and inserting ‘‘2023 through 2027’’; 
5
(2) by amending paragraph (2) to read as fol-
6
lows: 
7
‘‘(2) BASE
FEE
AMOUNTS
SPECIFIED.—For 
8
purposes of paragraph (1), the base fee amounts 
9
specified in this paragraph are as follows: 
10
‘‘Fee Type 
Fiscal 
Year 
2023 
Fiscal 
Year 
2024 
Fiscal 
Year 
2025 
Fiscal 
Year 
2026 
Fiscal 
Year 
2027 
Premarket Application ........................
$425,000 
$435,000 
$445,000 
$455,000 
$470,000 
Establishment Registration ................
$6,250 
$6,875 
$7,100 
$7,575 
$8,465’’; 
and 
(3) by amending paragraph (3) to read as fol-
11
lows: 
12
‘‘(3) TOTAL REVENUE AMOUNTS SPECIFIED.— 
13
For purposes of paragraph (1), the total revenue 
14
amounts specified in this paragraph are as follows: 
15
‘‘(A) $312,606,000 for fiscal year 2023. 
16
‘‘(B) $335,750,000 for fiscal year 2024. 
17
‘‘(C) $350,746,400 for fiscal year 2025. 
18
‘‘(D) $366,486,300 for fiscal year 2026. 
19
‘‘(E) $418,343,000 for fiscal year 2027.’’. 
20
(c) ANNUAL FEE SETTING; ADJUSTMENTS.—Section 
21
738(c) of the Federal Food, Drug, and Cosmetic Act (21 
22
U.S.C. 379j(c)) is amended— 
23
21:28 May 06, 2022
H7667
28 
•HR 7667 IH
(1) in paragraph (1), by striking ‘‘2017’’ and 
1
inserting ‘‘2022’’; 
2
(2) in paragraph (2)— 
3
(A) in subparagraph (A), by striking 
4
‘‘2018’’ and inserting ‘‘2023’’; 
5
(B) in subparagraph (B)— 
6
(i) in the matter preceding clause (i), 
7
by striking ‘‘fiscal year 2018’’ and insert-
8
ing ‘‘fiscal year 2023’’; and 
9
(ii) in clause (ii), by striking ‘‘fiscal 
10
year 2016’’ and inserting ‘‘fiscal year 
11
2022’’; 
12
(C) in subparagraph (C), by striking 
13
‘‘Washington-Baltimore, 
DC–MD–VA–WV’’ 
14
and inserting ‘‘Washington-Arlington-Alexan-
15
dria, DC–VA–MD–WV’’. 
16
(D) in subparagraph (D), in the matter 
17
preceding clause (i), by striking ‘‘fiscal years 
18
2018 through 2022’’ and inserting ‘‘fiscal years 
19
2023 through 2027’’; 
20
(3) in paragraph (3), by striking ‘‘2018 
21
through 2022’’ and inserting ‘‘2023 through 2027’’; 
22
(4) by redesignating paragraphs (4) and (5) as 
23
paragraphs (7) and (8), respectively; and 
24
21:28 May 06, 2022
H7667
29 
•HR 7667 IH
(5) by inserting after paragraph (3) the fol-
1
lowing: 
2
‘‘(4) PERFORMANCE
IMPROVEMENT
ADJUST-
3
MENT.— 
4
‘‘(A) IN
GENERAL.—For each of fiscal 
5
years 2025 through 2027, after the adjust-
6
ments under paragraphs (2) and (3), the base 
7
establishment registration fee amounts for such 
8
fiscal year shall be increased to reflect changes 
9
in the resource needs of the Secretary due to 
10
improved review performance goals for the proc-
11
ess for the review of device applications identi-
12
fied in the letters described in section 201(b) of 
13
the Medical Device User Fee Amendments of 
14
2022, as the Secretary determines necessary to 
15
achieve an increase in total fee collections for 
16
such fiscal year equal to the following amounts: 
17
‘‘(i) For fiscal year 2025, the product 
18
of— 
19
‘‘(I) 
the 
amount 
determined 
20
under subparagraph (B)(i)(I); and 
21
‘‘(II) the applicable inflation ad-
22
justment under paragraph (2)(B) for 
23
such fiscal year. 
24
21:28 May 06, 2022
H7667
30 
•HR 7667 IH
‘‘(ii) For fiscal year 2026, the product 
1
of— 
2
‘‘(I) the sum of the amounts de-
3
termined 
under 
subparagraphs 
4
(B)(i)(II), (B)(ii)(I), and (B)(iii)(I); 
5
and 
6
‘‘(II) the applicable inflation ad-
7
justment under paragraph (2)(B) for 
8
such fiscal year. 
9
‘‘(iii) For fiscal year 2027, the prod-
10
uct of— 
11
‘‘(I) the sum of the amounts de-
12
termined 
under 
subparagraphs 
13
(B)(i)(III), 
(B)(ii)(II), 
and 
14
(B)(iii)(II); and 
15
‘‘(II) the applicable inflation ad-
16
justment under paragraph (2)(B) for 
17
such fiscal year. 
18
‘‘(B) AMOUNTS.— 
19
‘‘(i) PRE-SUBMISSION AMOUNT.—For 
20
purposes of subparagraph (A), with respect 
21
to the pre-submission written feedback 
22
goal, the amounts determined under this 
23
subparagraph are as follows: 
24
21:28 May 06, 2022
H7667
31 
•HR 7667 IH
‘‘(I) 
For 
fiscal 
year 
2025, 
1
$15,396,600 if such goal for fiscal 
2
year 2023 is met. 
3
‘‘(II) For fiscal year 2026: 
4
‘‘(aa) $15,396,600 if such 
5
goal for fiscal year 2023 is met 
6
and such goal for fiscal year 
7
2024 is not met. 
8
‘‘(bb) $36,792,200 if such 
9
goal for fiscal year 2024 is met. 
10
‘‘(III) For fiscal year 2027: 
11
‘‘(aa) $15,396,600 if such 
12
goal for fiscal year 2023 is met 
13
and such goal for each of fiscal 
14
years 2024 and 2025 is not met. 
15
‘‘(bb) $36,792,200 if such 
16
goal for fiscal year 2024 is met 
17
and such goal for fiscal year 
18
2025 is not met. 
19
‘‘(cc) $40,572,600 if such 
20
goal for fiscal year 2025 is met. 
21
‘‘(ii) 
DE
NOVO
CLASSIFICATION 
22
AMOUNT.—For purposes of subparagraph 
23
(A), with respect to the de novo decision 
24
21:28 May 06, 2022
H7667
32 
•HR 7667 IH
goal, the amounts determined under this 
1
subparagraph are as follows: 
2
‘‘(I) 
For 
fiscal 
year 
2026, 
3
$6,323,500 if such goal for fiscal year 
4
2023 is met. 
5
‘‘(II) For fiscal year 2027— 
6
‘‘(aa) $6,323,500 if such 
7
goal for fiscal year 2023 is met 
8
and such goal for fiscal year 
9
2024 is not met. 
10
‘‘(bb) $11,765,400 if such 
11
goal for fiscal year 2024 is met. 
12
‘‘(iii) PREMARKET NOTIFICATION AND 
13
PREMARKET
APPROVAL
AMOUNT.—For 
14
purposes of subparagraph (A), with respect 
15
to the 510(k) decision goal, 510(k) shared 
16
outcome total time to decision goal, PMA 
17
decision goal, and PMA shared outcome 
18
total time to decision goal, the amounts de-
19
termined under this subparagraph are as 
20
follows: 
21
‘‘(I) 
For 
fiscal 
year 
2026, 
22
$1,020,000 if the four goals for fiscal 
23
year 2023 are met. 
24
‘‘(II) For fiscal year 2027: 
25
21:28 May 06, 2022
H7667
33 
•HR 7667 IH
‘‘(aa) $1,020,000 if the four 
1
goals for fiscal year 2023 are met 
2
and one or more of the four goals 
3
for fiscal year 2024 is not met. 
4
‘‘(bb) $3,906,000 if the four 
5
goals for fiscal year 2024 are 
6
met. 
7
‘‘(C) PERFORMANCE
CALCULATION.—For 
8
purposes of this paragraph, performance of the 
9
goals listed in subparagraph (D) shall be deter-
10
mined as specified in the letters described in 
11
section 201(b) of the Medical Device User Fee 
12
Amendments of 2022 and based on data avail-
13
able as of the following dates: 
14
‘‘(i) The performance of the pre-sub-
15
mission written feedback goal shall be 
16
based on data available as of— 
17
‘‘(I) for fiscal year 2023, March 
18
31, 2024; 
19
‘‘(II) for fiscal year 2024, March 
20
31, 2025; and 
21
‘‘(III) for fiscal year 2025, 
22
March 31, 2026. 
23
‘‘(ii) The performance of the de novo 
24
decision goal, 510(k) decision goal, 510(k) 
25
21:28 May 06, 2022
H7667
34 
•HR 7667 IH
shared outcome total time to decision goal, 
1
PMA decision goal, and PMA shared out-
2
come total time to decision goal shall be 
3
based on data available as of— 
4
‘‘(I) for fiscal year 2023, March 
5
31, 2025; and 
6
‘‘(II) for fiscal year 2024, March 
7
31, 2026. 
8
‘‘(D) GOALS DEFINED.—For purposes of 
9
this paragraph, the terms ‘pre-submission writ-
10
ten feedback goal’, ‘de novo decision goal’, 
11
‘510(k) decision goal’, ‘510(k) shared outcome 
12
total time to decision goal’, ‘PMA decision 
13
goal’, and ‘PMA shared outcome total time to 
14
decision goal’ refer to the goals identified by the 
15
same names in the letters described in section 
16
201(b) of the Medical Device User Fee Amend-
17
ments of 2022. 
18
‘‘(5) HIRING ADJUSTMENT.— 
19
‘‘(A) IN
GENERAL.—For each of fiscal 
20
years 2025 through 2027, after the adjust-
21
ments under paragraphs (2), (3), and (4), if ap-
22
plicable, if the number of hires to support the 
23
process for the review of device applications 
24
falls below the thresholds specified in subpara-
25
21:28 May 06, 2022
H7667
35 
•HR 7667 IH
graph (B) for the applicable fiscal years, the 
1
base establishment registration fee amounts 
2
shall be decreased as the Secretary determines 
3
necessary to achieve a reduction in total fee col-
4
lections equal to the hiring adjustment amount 
5
under subparagraph (C). 
6
‘‘(B) THRESHOLDS.—The thresholds speci-
7
fied in this subparagraph are as follows: 
8
‘‘(i) For fiscal year 2025, the thresh-
9
old is 123 hires for fiscal year 2023. 
10
‘‘(ii) For fiscal year 2026, the thresh-
11
old is 38 hires for fiscal year 2024. 
12
‘‘(iii) For fiscal year 2027, the thresh-
13
old is— 
14
‘‘(I) 22 hires for fiscal year 2025 
15
if the base establishment registration 
16
fees are not increased by the amount 
17
determined 
under 
paragraph 
18
(4)(A)(i); or 
19
‘‘(II) 75 hires for fiscal year 
20
2025 if such fees are so increased. 
21
‘‘(C) HIRING ADJUSTMENT AMOUNT.—The 
22
hiring adjustment amount for fiscal year 2025 
23
and each subsequent fiscal year is the product 
24
of— 
25
21:28 May 06, 2022
H7667
36 
•HR 7667 IH
‘‘(i) the number of hires by which the 
1
hiring goal specified in subparagraph (D) 
2
for the fiscal year before the prior fiscal 
3
year was not met; 
4
‘‘(ii) $72,877; and 
5
‘‘(iii) the applicable inflation adjust-
6
ment under paragraph (2)(B) for the fiscal 
7
year for which the hiring goal was not met. 
8
‘‘(D) HIRING GOALS.—The hiring goals for 
9
each of fiscal years 2023 through 2025 are as 
10
follows: 
11
‘‘(i) For fiscal year 2023, 144 hires. 
12
‘‘(ii) For fiscal year 2024, 42 hires. 
13
‘‘(iii) For fiscal year 2025: 
14
‘‘(I) 24 hires if the base estab-
15
lishment registration fees are not in-
16
creased by the amount determined 
17
under paragraph (4)(A)(i). 
18
‘‘(II) 83 hires if the base estab-
19
lishment registration fees are in-
20
creased by the amount determined 
21
under paragraph (4)(A)(i). 
22
‘‘(E) NUMBER OF HIRES.—For purposes 
23
of this paragraph, the number of hires shall be 
24
determined by the Secretary as set forth in the 
25
21:28 May 06, 2022
H7667
37 
•HR 7667 IH
letters described in section 201(b) of the Med-
1
ical Device User Fee Amendments of 2022. 
2
‘‘(6) OPERATING RESERVE ADJUSTMENT.— 
3
‘‘(A) IN
GENERAL.—For each of fiscal 
4
years 2023 through 2027, after the adjust-
5
ments under paragraphs (2), (3), (4), and (5), 
6
if applicable, if the Secretary has operating re-
7
serves of carryover user fees for the process for 
8
the review of device applications in excess of the 
9
designated amount in subparagraph (B), the 
10
Secretary shall decrease the base establishment 
11
registration fee amounts to provide for not 
12
more than such designated amount of operating 
13
reserves. 
14
‘‘(B) DESIGNATED
AMOUNT.—Subject to 
15
subparagraph (C), for each fiscal year, the des-
16
ignated amount in this subparagraph is equal 
17
to the sum of— 
18
‘‘(i) 13 weeks of operating reserves of 
19
carryover user fees; and 
20
‘‘(ii) 1 month of operating reserves 
21
maintained pursuant to paragraph (8). 
22
‘‘(C) EXCLUDED AMOUNT.—For the period 
23
of fiscal years 2023 through 2026, a total 
24
amount equal to $118,000,000 shall not be con-
25
21:28 May 06, 2022
H7667
38 
•HR 7667 IH
sidered part of the designated amount under 
1
subparagraph (B) and shall not be subject to 
2
the decrease under subparagraph (A).’’. 
3
(d) SMALL BUSINESSES.—Section 738 of the Federal 
4
Food, Drug, and Cosmetic Act (21 U.S.C. 379j) is amend-
5
ed in each of subsections (d)(2)(B)(iii) and (e)(2)(B)(iii) 
6
by inserting ‘‘, if extant,’’ after ‘‘national taxing author-
7
ity’’. 
8
(e) CONDITIONS.—Section 738(g) of the Federal 
9
Food, Drug, and Cosmetic Act (21 U.S.C. 379j(g)) is 
10
amended— 
11
(1) 
in 
paragraph 
(1)(A), 
by 
striking 
12
‘‘$320,825,000’’ and inserting ‘‘$398,566,000’’; and 
13
(2) in paragraph (2), by inserting ‘‘de novo 
14
classification requests,’’ after ‘‘class III device,’’. 
15
(f) CREDITING AND AVAILABILITY OF FEES.—Sec-
16
tion 738(h)(3) of the Federal Food, Drug, and Cosmetic 
17
Act (21 U.S.C. 379j(h)(3)) is amended to read as follows: 
18
‘‘(3) AUTHORIZATION OF APPROPRIATIONS.— 
19
‘‘(A) IN
GENERAL.—For each of fiscal 
20
years 2023 through 2027, there is authorized to 
21
be appropriated for fees under this section an 
22
amount equal to the revenue amount deter-
23
mined under subparagraph (B), less the 
24
21:28 May 06, 2022
H7667
39 
•HR 7667 IH
amount of reductions determined under sub-
1
paragraph (C). 
2
‘‘(B) REVENUE AMOUNT.—For purposes of 
3
this paragraph, the revenue amount for each 
4
fiscal year is the sum of— 
5
‘‘(i) the total revenue amount under 
6
subsection (b)(3) for the fiscal year, as ad-
7
justed under paragraphs (2) and (3) of 
8
subsection (c); and 
9
‘‘(ii) the performance improvement 
10
adjustment amount for the fiscal year 
11
under subsection (c)(4), if applicable. 
12
‘‘(C) REDUCTIONS.—For purposes of this 
13
paragraph, the amount of reductions for each 
14
fiscal year is the sum of— 
15
‘‘(i) the hiring adjustment amount for 
16
the fiscal year under subsection (c)(5), if 
17
applicable; and 
18
‘‘(ii) the operating reserve adjustment 
19
amount for the fiscal year under sub-
20
section (c)(6), if applicable.’’. 
21
SEC. 204. REAUTHORIZATION; REPORTING REQUIREMENTS. 
22
(a) PERFORMANCE REPORTS.—Section 738A(a) of 
23
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
24
379j–1(a)) is amended— 
25
21:28 May 06, 2022
H7667
40 
•HR 7667 IH
(1) by striking ‘‘fiscal year 2018’’ each place it 
1
appears and inserting ‘‘fiscal year 2023’’; 
2
(2) by striking ‘‘Medical Device User Fee 
3
Amendments of 2017’’ each place it appears and in-
4
serting ‘‘Medical Device User Fee Amendments of 
5
2022’’; 
6
(3) in paragraph (1)— 
7
(A) in subparagraph (A), by redesignating 
8
the second clause (iv) (relating to analysis) as 
9
clause (v); and 
10
(B) in subparagraph (A)(iv), by striking 
11
‘‘fiscal year 2020’’ and inserting ‘‘fiscal year 
12
2023’’; and 
13
(4) in paragraph (4), by striking ‘‘2018 
14
through 2022’’ and inserting ‘‘2023 through 2027’’. 
15
(b) REAUTHORIZATION.—Section 738A(b) of the 
16
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j– 
17
1(b)) is amended— 
18
(1) in paragraph (1), by striking ‘‘2022’’ and 
19
inserting ‘‘2027’’; and 
20
(2) in paragraph (5), by striking ‘‘2022’’ and 
21
inserting ‘‘2027’’. 
22
21:28 May 06, 2022
H7667
41 
•HR 7667 IH
SEC. 205. CONFORMITY ASSESSMENT PILOT PROGRAM. 
1
Section 514(d) of the Federal Food, Drug, and Cos-
2
metic Act (21 U.S.C. 360d(d)) is amended to read as fol-
3
lows: 
4
‘‘(d) ACCREDITATION SCHEME FOR CONFORMITY AS-
5
SESSMENT.— 
6
‘‘(1) IN GENERAL.—The Secretary shall estab-
7
lish a program under which— 
8
‘‘(A) testing laboratories meeting criteria 
9
specified in guidance by the Secretary may be 
10
accredited by accreditation bodies meeting cri-
11
teria specified in guidance by the Secretary, to 
12
conduct testing to support the assessment of 
13
the conformity of a device to certain standards 
14
recognized under this section; and 
15
‘‘(B) subject to paragraph (2), results 
16
from tests conducted to support the assessment 
17
of conformity of devices as described in sub-
18
paragraph (A) conducted by testing laboratories 
19
accredited pursuant to this subsection shall be 
20
accepted by the Secretary for purposes of dem-
21
onstrating such conformity unless the Secretary 
22
finds that certain results of such tests should 
23
not be so accepted. 
24
‘‘(2) SECRETARIAL
REVIEW
OF
ACCREDITED 
25
LABORATORY RESULTS.—The Secretary may— 
26
21:28 May 06, 2022
H7667
42 
•HR 7667 IH
‘‘(A) review the results of tests conducted 
1
by testing laboratories accredited pursuant to 
2
this subsection, including by conducting peri-
3
odic audits of such results or of the processes 
4
of accredited bodies or testing laboratories; 
5
‘‘(B) following such review, take additional 
6
measures under this Act, as the Secretary de-
7
termines appropriate, such as— 
8
‘‘(i) suspension or withdrawal of ac-
9
creditation of a testing laboratory or rec-
10
ognition of an accreditation body under 
11
paragraph (1)(A); or 
12
‘‘(ii) requesting additional information 
13
with respect to a device; and 
14
‘‘(C) if the Secretary becomes aware of in-
15
formation materially bearing on the safety or 
16
effectiveness of a device for which an assess-
17
ment of conformity was supported by testing 
18
conducted by a testing laboratory accredited 
19
under this subsection, take such additional 
20
measures under this Act, as the Secretary de-
21
termines appropriate, such as— 
22
‘‘(i) suspension or withdrawal of ac-
23
creditation of a testing laboratory or rec-
24
21:28 May 06, 2022
H7667
43 
•HR 7667 IH
ognition of an accreditation body under 
1
paragraph (1)(A); or 
2
‘‘(ii) requesting additional information 
3
with regard to such device. 
4
‘‘(3) IMPLEMENTATION AND REPORTING.— 
5
‘‘(A) PILOT PROGRAM TRANSITION.—After 
6
September 30, 2023, the pilot program pre-
7
viously initiated under this subsection, as in ef-
8
fect prior to the date of enactment of the Med-
9
ical Device User Fee Amendments of 2022, 
10
shall be considered to be completed, and the 
11
Secretary may continue operating a program 
12
consistent with this subsection. 
13
‘‘(B) REPORT.—The Secretary shall make 
14
available on the internet website of the Food 
15
and Drug Administration an annual report on 
16
the progress of the pilot program under this 
17
subsection.’’. 
18
SEC. 206. REAUTHORIZATION OF THIRD-PARTY REVIEW 
19
PROGRAM. 
20
Section 523(c) of the Federal Food, Drug, and Cos-
21
metic Act (21 U.S.C. 360m(c)) is amended by striking 
22
‘‘2022’’ and inserting ‘‘2027’’. 
23
21:28 May 06, 2022
H7667
44 
•HR 7667 IH
SEC. 207. SAVINGS CLAUSE. 
1
Notwithstanding the amendments made by this title, 
2
part 3 of subchapter C of chapter VII of the Federal Food, 
3
Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in 
4
effect on the day before the date of the enactment of this 
5
title, shall continue to be in effect with respect to the sub-
6
missions listed in section 738(a)(2)(A) of such Act (as de-
7
fined in such part as of such day) that on or after October 
8
1, 2017, but before October 1, 2022, were accepted by 
9
the Food and Drug Administration for filing with respect 
10
to assessing and collecting any fee required by such part 
11
for a fiscal year prior to fiscal year 2023. 
12
SEC. 208. EFFECTIVE DATE. 
13
The amendments made by this title shall take effect 
14
on October 1, 2022, or the date of the enactment of this 
15
Act, whichever is later, except that fees under part 3 of 
16
subchapter C of chapter VII of the Federal Food, Drug, 
17
and Cosmetic Act (21 U.S.C. 379i et seq.) shall be as-
18
sessed for all submissions listed in section 738(a)(2)(A) 
19
of such Act received on or after October 1, 2022, regard-
20
less of the date of the enactment of this Act. 
21
SEC. 209. SUNSET DATES. 
22
(a) AUTHORIZATION.—Sections 737 and 738 of the 
23
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 739i; 
24
739j) shall cease to be effective October 1, 2027. 
25
21:28 May 06, 2022
H7667
45 
•HR 7667 IH
(b) REPORTING REQUIREMENTS.—Section 738A (21 
1
U.S.C. 739j– 1) of the Federal Food, Drug, and Cosmetic 
2
Act (regarding reauthorization and reporting require-
3
ments) shall cease to be effective January 31, 2028. 
4
(c) PREVIOUS SUNSET PROVISIONS.—Effective Octo-
5
ber 1, 2022, subsections (a) and (b) of section 210 of the 
6
Medical Device User Fee Amendments of 2017 (Public 
7
Law 115–52) are repealed. 
8
TITLE III—FEES RELATING TO 
9
GENERIC DRUGS 
10
SEC. 301. SHORT TITLE; FINDING. 
11
(a) SHORT TITLE.—This title may be cited as the 
12
‘‘Generic Drug User Fee Amendments of 2022’’. 
13
(b) FINDING.—The Congress finds that the fees au-
14
thorized by the amendments made in this title will be dedi-
15
cated to human generic drug activities, as set forth in the 
16
goals identified for purposes of part 7 of subchapter C 
17
of chapter VII of the Federal Food, Drug, and Cosmetic 
18
Act, in the letters from the Secretary of Health and 
19
Human Services to the Chairman of the Committee on 
20
Health, Education, Labor, and Pensions of the Senate and 
21
the Chairman of the Committee on Energy and Commerce 
22
of the House of Representatives, as set forth in the Con-
23
gressional Record. 
24
21:28 May 06, 2022
H7667
46 
•HR 7667 IH
SEC. 302. AUTHORITY TO ASSESS AND USE HUMAN GE-
1
NERIC DRUG FEES. 
2
(a) TYPES OF FEES.—Section 744B(a) of the Fed-
3
eral Food, Drug, and Cosmetic Act (21 U.S.C. 379j– 
4
42(a)) is amended— 
5
(1) in the matter preceding paragraph (1), by 
6
striking ‘‘fiscal year 2018’’ and inserting ‘‘fiscal year 
7
2023’’; 
8
(2) in paragraph (2)(C), by striking ‘‘2018 
9
through 2022’’ and inserting ‘‘2023 through 2027’’; 
10
(3) in paragraph (3)(B), by striking ‘‘2018 
11
through 2022’’ and inserting ‘‘2023 through 2027’’; 
12
(4) in paragraph (4)(D), by striking ‘‘2018 
13
through 2022’’ and inserting ‘‘2023 through 2027’’; 
14
and 
15
(5) in paragraph (5)(D), by striking ‘‘2018 
16
through 2022’’ and inserting ‘‘2023 through 2027’’. 
17
(b) FEE REVENUE AMOUNTS.—Section 744B(b) of 
18
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
19
379j–42(b)) is amended— 
20
(1) in paragraph (1)— 
21
(A) in subparagraph (A)— 
22
(i) in the heading, by striking ‘‘2018’’ 
23
and inserting ‘‘2023’’; 
24
(ii) by striking ‘‘2018’’ and inserting 
25
‘‘2023’’; and 
26
21:28 May 06, 2022
H7667
47 
•HR 7667 IH
(iii) by striking ‘‘$493,600,000’’ and 
1
inserting ‘‘$582,500,000’’; and 
2
(B) by amending subparagraph (B) to read 
3
as follows: 
4
‘‘(B) FISCAL YEARS 2024 THROUGH 2027.— 
5
‘‘(i) IN GENERAL.—For each of the 
6
fiscal years 2024 through 2027, fees under 
7
paragraphs (2) through (5) of subsection 
8
(a) shall be established to generate a total 
9
estimated revenue amount under such sub-
10
section that is equal to the base revenue 
11
amount for the fiscal year under clause 
12
(ii), as adjusted pursuant to subsection (c). 
13
‘‘(ii) BASE REVENUE AMOUNT.—The 
14
base revenue amount for a fiscal year re-
15
ferred to in clause (i) is equal to the total 
16
revenue amount established under this 
17
paragraph for the previous fiscal year, not 
18
including any adjustments made for such 
19
previous fiscal year under subsection 
20
(c)(3).’’; and 
21
(2) in paragraph (2)— 
22
(A) in subparagraph (C), by striking ‘‘one- 
23
third the amount’’ and inserting ‘‘twenty-four 
24
percent’’; 
25
21:28 May 06, 2022
H7667
48 
•HR 7667 IH
(B) in subparagraph (D), by striking 
1
‘‘Seven percent’’ and inserting ‘‘Six percent’’; 
2
and 
3
(C) in subparagraph (E)(i), by striking 
4
‘‘Thirty-five percent’’ and inserting ‘‘Thirty-six 
5
percent’’. 
6
(c) ADJUSTMENTS.—Section 744B(c) of the Federal 
7
Food, Drug, and Cosmetic Act (21 U.S.C. 379j–42(c)) is 
8
amended— 
9
(1) in paragraph (1)— 
10
(A) in the matter preceding subparagraph 
11
(A)— 
12
(i) by striking ‘‘2019’’ and inserting 
13
‘‘2024’’; and 
14
(ii) by striking ‘‘to equal the product 
15
of the total revenues established in such 
16
notice for the prior fiscal year multiplied’’ 
17
and inserting ‘‘to equal the base revenue 
18
amount for the fiscal year (as specified in 
19
subsection (b)(1)(B)) multiplied’’; and 
20
(B) in subparagraph (C), by striking 
21
‘‘Washington-Baltimore, 
DC–MD–VA–WV’’ 
22
and inserting ‘‘Washington-Arlington-Alexan-
23
dria, DC–VA–MD–WV’’; and 
24
21:28 May 06, 2022
H7667
49 
•HR 7667 IH
(2) by striking paragraph (2) and inserting the 
1
following: 
2
‘‘(2) CAPACITY PLANNING ADJUSTMENT.— 
3
‘‘(A) IN GENERAL.—Beginning with fiscal 
4
year 2024, the Secretary shall, in addition to 
5
the adjustment under paragraph (1), further in-
6
crease the fee revenue and fees under this sec-
7
tion for a fiscal year, in accordance with this 
8
paragraph, to reflect changes in the resource 
9
capacity needs of the Secretary for human ge-
10
neric drug activities. 
11
‘‘(B) 
CAPACITY
PLANNING
METHOD-
12
OLOGY.—The Secretary shall establish a capac-
13
ity planning methodology for purposes of this 
14
paragraph, which shall— 
15
‘‘(i) be derived from the methodology 
16
and recommendations made in the report 
17
titled ‘Independent Evaluation of the 
18
GDUFA Resource Capacity Planning Ad-
19
justment Methodology: Evaluation and 
20
Recommendations’ announced in the Fed-
21
eral Register on August 3, 2020; 
22
‘‘(ii) incorporate approaches and at-
23
tributes determined appropriate by the 
24
Secretary, including approaches and at-
25
21:28 May 06, 2022
H7667
50 
•HR 7667 IH
tributes made in such report, except that 
1
in incorporating such approaches and at-
2
tributes the workload categories used in 
3
forecasting resources shall only be the 
4
workload categories specified in section 
5
VIII.B.2.e. of the letters described in sec-
6
tion 301(b) of the Generic Drug User Fee 
7
Amendments of 2022; and 
8
‘‘(iii) be effective beginning with fiscal 
9
year 2024. 
10
‘‘(C) LIMITATIONS.— 
11
‘‘(i) IN
GENERAL.—Under no cir-
12
cumstances shall an adjustment under this 
13
paragraph result in fee revenue for a fiscal 
14
year that is less than the sum of the 
15
amounts under subsection (b)(1)(B)(ii) 
16
(the base revenue amount for the fiscal 
17
year) and paragraph (1) (the dollar 
18
amount of the inflation adjustment for the 
19
fiscal year). 
20
‘‘(ii) PERCENTAGE
LIMITATION.—An 
21
adjustment under this paragraph shall not 
22
exceed three percent of the sum described 
23
in clause (i) for the fiscal year, except that 
24
such limitation shall be four percent if— 
25
21:28 May 06, 2022
H7667
51 
•HR 7667 IH
‘‘(I) for purposes of a fiscal year 
1
2024 adjustment, the Secretary deter-
2
mines that during the period from 
3
April 1, 2021, through March 31, 
4
2023— 
5
‘‘(aa) the total number of 
6
abbreviated new drug applica-
7
tions submitted was greater than 
8
or equal to 2,000; or 
9
‘‘(bb) thirty-five percent or 
10
more of abbreviated new drug ap-
11
plications submitted related to 
12
complex products (as that term is 
13
defined in section XI of the let-
14
ters described in section 301(b) 
15
of the Generic Drug User Fee 
16
Amendments of 2022); 
17
‘‘(II) for purposes of a fiscal year 
18
2025 adjustment, the Secretary deter-
19
mines that during the period from 
20
April 1, 2022, through March 31, 
21
2024— 
22
‘‘(aa) the total number of 
23
abbreviated new drug applica-
24
21:28 May 06, 2022
H7667
52 
•HR 7667 IH
tions submitted was greater than 
1
or equal to 2,300; or 
2
‘‘(bb) thirty-five percent or 
3
more of abbreviated new drug ap-
4
plications submitted related to 
5
complex products (as so defined); 
6
‘‘(III) for purposes of a fiscal 
7
year 2026 adjustment, the Secretary 
8
determines that during the period 
9
from April 1, 2023, through March 
10
31, 2025— 
11
‘‘(aa) the total number of 
12
abbreviated new drug applica-
13
tions submitted was greater than 
14
or equal to 2,300; or 
15
‘‘(bb) thirty-five percent or 
16
more of abbreviated new drug ap-
17
plications submitted related to 
18
complex products (as so defined); 
19
and 
20
‘‘(IV) for purposes of a fiscal 
21
year 2027 adjustment, the Secretary 
22
determines that during the period 
23
from April 1, 2024, through March 
24
31, 2026— 
25
21:28 May 06, 2022
H7667
53 
•HR 7667 IH
‘‘(aa) the total number of 
1
abbreviated new drug applica-
2
tions submitted was greater than 
3
or equal to 2,300; or 
4
‘‘(bb) thirty-five percent or 
5
more of abbreviated new drug ap-
6
plications submitted related to 
7
complex products (as so defined). 
8
‘‘(D) PUBLICATION
IN
FEDERAL
REG-
9
ISTER.—The Secretary shall publish in the Fed-
10
eral Register notice referred to in subsection (a) 
11
the fee revenue and fees resulting from the ad-
12
justment and the methodology under this para-
13
graph. 
14
‘‘(3) OPERATING RESERVE ADJUSTMENT.— 
15
‘‘(A) IN GENERAL.—For fiscal year 2024 
16
and each subsequent fiscal year, the Secretary 
17
may, in addition to adjustments under para-
18
graphs (1) and (2), further increase the fee rev-
19
enue and fees under this section for such fiscal 
20
year if such an adjustment is necessary to pro-
21
vide operating reserves of carryover user fees 
22
for human generic drug activities for not more 
23
than the number of weeks specified in subpara-
24
graph (B) with respect to that fiscal year. 
25
21:28 May 06, 2022
H7667
54 
•HR 7667 IH
‘‘(B) NUMBER OF WEEKS.—The number of 
1
weeks specified in this subparagraph is— 
2
‘‘(i) 8 weeks for fiscal year 2024; 
3
‘‘(ii) 9 weeks for fiscal year 2025; and 
4
‘‘(iii) 10 weeks for each of fiscal year 
5
2026 and 2027. 
6
‘‘(C) DECREASE.—If the Secretary has 
7
carryover balances for human generic drug ac-
8
tivities in excess of 12 weeks of the operating 
9
reserves referred to in subparagraph (A), the 
10
Secretary shall decrease the fee revenue and 
11
fees referred to in such subparagraph to provide 
12
for not more than 12 weeks of such operating 
13
reserves. 
14
‘‘(D) RATIONALE
FOR
ADJUSTMENT.—If 
15
an adjustment under this paragraph is made, 
16
the rationale for the amount of the increase or 
17
decrease (as applicable) in fee revenue and fees 
18
shall be contained in the annual Federal Reg-
19
ister notice under subsection (a) publishing the 
20
fee revenue and fees for the fiscal year in-
21
volved.’’. 
22
(d) ANNUAL FEE SETTING.—Section 744B(d)(1) of 
23
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
24
379j–42(d)(1)) is amended— 
25
21:28 May 06, 2022
H7667
55 
•HR 7667 IH
(1) in the paragraph heading, by striking ‘‘2018 
1
THROUGH 2022’’and inserting ‘‘2023 THROUGH 2027’’; 
2
and 
3
(2) by striking ‘‘more than 60 days before the 
4
first day of each of fiscal years 2018 through 2022’’ 
5
and inserting ‘‘later than 60 days before the first 
6
day of each of fiscal years 2023 through 2027’’. 
7
(e) CREDITING AND AVAILABILITY OF FEES.—Sec-
8
tion 744B(i)(3) of the Federal Food, Drug, and Cosmetic 
9
Act (21 U.S.C. 379j–42(i)(3)) is amended by striking ‘‘fis-
10
cal years 2018 through 2022’’ and inserting ‘‘fiscal years 
11
2023 through 2027’’. 
12
SEC. 303. REAUTHORIZATION; REPORTING REQUIREMENTS. 
13
Section 744C of the Federal Food, Drug, and Cos-
14
metic Act (21 U.S.C. 379j–43) is amended— 
15
(1) in subsection (a)(1), by striking ‘‘Beginning 
16
with fiscal year 2018, not’’ and inserting ‘‘Not’’; 
17
(2) by striking ‘‘Generic Drug User Fee 
18
Amendments of 2017’’ each place it appears and in-
19
serting ‘‘Generic Drug User Fee Amendments of 
20
2022’’; 
21
(3) in subsection (a)(2), by striking ‘‘Not later 
22
than 30 calendar days after the end of the second 
23
quarter of fiscal year 2018, and not later than 30 
24
calendar days after the end of each quarter of each 
25
21:28 May 06, 2022
H7667
56 
•HR 7667 IH
fiscal year thereafter’’ and inserting ‘‘Not later than 
1
30 calendar days after the end of each quarter of 
2
each fiscal year for which fees are collected under 
3
this part’’; 
4
(4) in subsection (a)(3), by striking ‘‘Beginning 
5
with fiscal year 2020, the’’ and inserting ‘‘The’’; 
6
(5) in subsection (b), by striking ‘‘Beginning 
7
with fiscal year 2018, not’’ and inserting ‘‘Not’’; 
8
(6) in subsection (c), by striking ‘‘Beginning 
9
with fiscal year 2018, for’’ and inserting ‘‘For’’; and 
10
(7) in subsection (f)— 
11
(A) in paragraph (1), in the matter pre-
12
ceding subparagraph (A), by striking ‘‘fiscal 
13
year 2022’’ and inserting ‘‘fiscal year 2027’’; 
14
and 
15
(B) in paragraph (5), by striking ‘‘January 
16
15, 2022’’ and inserting ‘‘January 15, 2027’’. 
17
SEC. 304. SUNSET DATES. 
18
(a) AUTHORIZATION.—Sections 744A and 744B of 
19
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
20
379j–41; 379j–42) shall cease to be effective October 1, 
21
2027. 
22
(b) REPORTING REQUIREMENTS.—Section 744C of 
23
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
24
379j–43) shall cease to be effective January 31, 2028. 
25
21:28 May 06, 2022
H7667
57 
•HR 7667 IH
(c) PREVIOUS SUNSET PROVISION.—Effective Octo-
1
ber 1, 2022, subsections (a) and (b) of section 305 of the 
2
FDA Reauthorization Act of 2017 (Public Law 115–52) 
3
are repealed. 
4
SEC. 305. EFFECTIVE DATE. 
5
The amendments made by this title shall take effect 
6
on October 1, 2022, or the date of the enactment of this 
7
Act, whichever is later, except that fees under part 7 of 
8
subchapter C of chapter VII of the Federal Food, Drug, 
9
and Cosmetic Act shall be assessed for all abbreviated new 
10
drug applications received on or after October 1, 2022, 
11
regardless of the date of the enactment of this Act. 
12
SEC. 306. SAVINGS CLAUSE. 
13
Notwithstanding the amendments made by this title, 
14
part 7 of subchapter C of chapter VII of the Federal Food, 
15
Drug, and Cosmetic Act, as in effect on the day before 
16
the date of the enactment of this title, shall continue to 
17
be in effect with respect to abbreviated new drug applica-
18
tions (as defined in such part as of such day) that were 
19
received by the Food and Drug Administration within the 
20
meaning of section 505(j)(5)(A) of such Act (21 U.S.C. 
21
355(j)(5)(A)), prior approval supplements that were sub-
22
mitted, and drug master files for Type II active pharma-
23
ceutical ingredients that were first referenced on or after 
24
October 1, 2017, but before October 1, 2022, with respect 
25
21:28 May 06, 2022
H7667
58 
•HR 7667 IH
to assessing and collecting any fee required by such part 
1
for a fiscal year prior to fiscal year 2023. 
2
TITLE IV—FEES RELATING TO 
3
BIOSIMILAR 
BIOLOGICAL 
4
PRODUCTS 
5
SEC. 401. SHORT TITLE; FINDING. 
6
(a) SHORT TITLE.—This title may be cited as the 
7
‘‘Biosimilar User Fee Amendments of 2022’’. 
8
(b) FINDING.—The Congress finds that the fees au-
9
thorized by the amendments made in this title will be dedi-
10
cated to expediting the process for the review of biosimilar 
11
biological product applications, including postmarket safe-
12
ty activities, as set forth in the goals identified for pur-
13
poses of part 8 of subchapter C of chapter VII of the Fed-
14
eral Food, Drug, and Cosmetic Act, in the letters from 
15
the Secretary of Health and Human Services to the Chair-
16
man of the Committee on Health, Education, Labor, and 
17
Pensions of the Senate and the Chairman of the Com-
18
mittee on Energy and Commerce of the House of Rep-
19
resentatives, as set forth in the Congressional Record. 
20
SEC. 402. DEFINITIONS. 
21
(a) ADJUSTMENT FACTOR.—Section 744G(1) of the 
22
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j– 
23
51(1)) is amended to read as follows: 
24
21:28 May 06, 2022
H7667
59 
•HR 7667 IH
‘‘(1) The term ‘adjustment factor’ applicable to 
1
a fiscal year is the Consumer Price Index for urban 
2
consumers (Washington-Arlington-Alexandria, DC– 
3
VA–MD–WV; Not Seasonally Adjusted; All items; 
4
Annual Index) for September of the preceding fiscal 
5
year divided by such Index for September 2011.’’. 
6
(b) BIOSIMILAR BIOLOGICAL PRODUCT APPLICA-
7
TION.—Section 744G(4)(B)(iii) of the Federal Food, 
8
Drug, and Cosmetic Act (21 U.S.C. 379j–51(4)(B)(iii)) 
9
is amended— 
10
(1) by striking subclause (II) (relating to an al-
11
lergenic extract product); and 
12
(2) by redesignating subclauses (III) and (IV) 
13
as subclauses (II) and (III), respectively. 
14
SEC. 403. AUTHORITY TO ASSESS AND USE BIOSIMILAR 
15
FEES. 
16
(a) TYPES OF FEES.— 
17
(1) IN GENERAL.—The matter preceding para-
18
graph (1) in section 744H(a) of the Federal Food, 
19
Drug, and Cosmetic Act (21 U.S.C. 379j–52(a)) is 
20
amended by striking ‘‘fiscal year 2018’’ and insert-
21
ing ‘‘fiscal year 2023’’. 
22
(2) INITIAL BIOSIMILAR BIOLOGICAL PRODUCT 
23
DEVELOPMENT FEE.—Clauses (iv)(I) and (v)(II) of 
24
section 744H(a)(1)(A) of the Federal Food, Drug, 
25
21:28 May 06, 2022
H7667
60 
•HR 7667 IH
and Cosmetic Act (21 U.S.C. 379j–52(a)(1)(A)) are 
1
each amended by striking ‘‘5 days’’ and inserting ‘‘7 
2
days’’. 
3
(3) ANNUAL BIOSIMILAR BIOLOGICAL PRODUCT 
4
DEVELOPMENT FEE.—Section 744H(a)(1)(B) of the 
5
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
6
379j–52(a)(1)(B)) is amended— 
7
(A) in clause (i), by inserting before the 
8
period at the end the following: ‘‘, except where 
9
such product (including, where applicable, own-
10
ership of the relevant investigational new drug 
11
application) is transferred to a licensee, as-
12
signee, or successor of such person, and written 
13
notice of such transfer is provided to the Sec-
14
retary, in which case such licensee, assignee, or 
15
successor shall pay the annual biosimilar bio-
16
logical product development fee’’; 
17
(B) in clause (iii)— 
18
(i) in subclause (I), by striking ‘‘or’’ 
19
at the end; 
20
(ii) in subclause (II), by striking the 
21
period at the end and inserting ‘‘; or’’; and 
22
(iii) by adding at the end the fol-
23
lowing: 
24
21:28 May 06, 2022
H7667
61 
•HR 7667 IH
‘‘(III) been administratively re-
1
moved from the biosimilar biological 
2
product development program for the 
3
product under subparagraph (E)(v).’’; 
4
and 
5
(C) in clause (iv), by striking ‘‘is accepted 
6
for filing on or after October 1 of such fiscal 
7
year’’ and inserting ‘‘is subsequently accepted 
8
for filing’’. 
9
(4) 
REACTIVATION
FEE.—Section 
10
744H(a)(1)(D) of the Federal Food, Drug, and Cos-
11
metic Act (21 U.S.C. 379j–52(a)(1)(D)) is amended 
12
to read as follows: 
13
‘‘(D) REACTIVATION FEE.— 
14
‘‘(i) IN GENERAL.—A person that has 
15
discontinued participation in the biosimilar 
16
biological product development program for 
17
a product under subparagraph (C), or who 
18
has been administratively removed from 
19
the biosimilar biological product develop-
20
ment program for a product under sub-
21
paragraph (E)(v), shall, if the person seeks 
22
to resume participation in such program, 
23
pay all annual biosimilar biological product 
24
development fees previously assessed for 
25
21:28 May 06, 2022
H7667
62 
•HR 7667 IH
such product and still owed and a fee (re-
1
ferred to in this section as ‘reactivation 
2
fee’) by the earlier of the following: 
3
‘‘(I) Not later than 7 days after 
4
the Secretary grants a request by 
5
such person for a biosimilar biological 
6
product development meeting for the 
7
product (after the date on which such 
8
participation was discontinued or the 
9
date of administrative removal, as ap-
10
plicable). 
11
‘‘(II) Upon the date of submis-
12
sion (after the date on which such 
13
participation was discontinued or the 
14
date of administrative removal, as ap-
15
plicable) by such person of an inves-
16
tigational new drug application de-
17
scribing an investigation that the Sec-
18
retary determines is intended to sup-
19
port a biosimilar biological product 
20
application for that product. 
21
‘‘(ii) 
APPLICATION
OF
ANNUAL 
22
FEE.—A person that pays a reactivation 
23
fee for a product shall pay for such prod-
24
uct, beginning in the next fiscal year, the 
25
21:28 May 06, 2022
H7667
63 
•HR 7667 IH
annual biosimilar biological product devel-
1
opment fee under subparagraph (B), ex-
2
cept where such product (including, where 
3
applicable, ownership of the relevant inves-
4
tigational new drug application) is trans-
5
ferred to a licensee, assignee, or successor 
6
of such person, and written notice of such 
7
transfer is provided to the Secretary, in 
8
which case such licensee, assignee, or suc-
9
cessor shall pay the annual biosimilar bio-
10
logical product development fee.’’. 
11
(5) EFFECT OF FAILURE TO PAY FEES.—Sec-
12
tion 744H(a)(1)(E) of the Federal Food, Drug, and 
13
Cosmetic Act (21 U.S.C. 379j–52(a)(1)(E)) is 
14
amended by adding at the end the following: 
15
‘‘(v) ADMINISTRATIVE REMOVAL FROM 
16
THE
BIOSIMILAR
BIOLOGICAL
PRODUCT 
17
DEVELOPMENT PROGRAM.—If a person has 
18
failed to pay an annual biosimilar biologi-
19
cal product development fee for a product 
20
as required under subparagraph (B) for a 
21
period of two consecutive fiscal years, the 
22
Secretary may administratively remove 
23
such person from the biosimilar biological 
24
product development program for the prod-
25
21:28 May 06, 2022
H7667
64 
•HR 7667 IH
uct. At least 30 days prior to administra-
1
tively removing a person from the bio-
2
similar biological product development pro-
3
gram for a product under this clause, the 
4
Secretary shall provide written notice to 
5
such person of the intended administrative 
6
removal.’’. 
7
(6) BIOSIMILAR BIOLOGICAL PRODUCT APPLICA-
8
TION FEE.—Section 744H(a)(2)(D) of the Federal 
9
Food, Drug, and Cosmetic Act (21 U.S.C. 379j– 
10
52(a)(2)(D)) is amended by inserting after ‘‘or was 
11
withdrawn’’ the following: ‘‘prior to approval’’. 
12
(7) BIOSIMILAR
BIOLOGICAL
PRODUCT
PRO-
13
GRAM
FEE.—Section 744H(a)(3) of the Federal 
14
Food, Drug, and Cosmetic Act (21 U.S.C. 379j– 
15
52(a)(3)) is amended— 
16
(A) in subparagraph (A)— 
17
(i) in clause (i), by striking ‘‘and’’ at 
18
the end; 
19
(ii) by redesignating clause (ii) as 
20
clause (iii); and 
21
(iii) by inserting after clause (i) the 
22
following: 
23
21:28 May 06, 2022
H7667
65 
•HR 7667 IH
‘‘(ii) may be dispensed only under pre-
1
scription pursuant to section 503(b); and’’; 
2
and 
3
(B) by adding at the end the following: 
4
‘‘(E) 
MOVEMENT
TO
DISCONTINUED 
5
LIST.— 
6
‘‘(i) DATE OF INCLUSION.—If a writ-
7
ten request to place a product on the list 
8
referenced in subparagraph (A) of discon-
9
tinued biosimilar biological products is sub-
10
mitted to the Secretary on behalf of an ap-
11
plicant, and the request identifies the date 
12
the product is withdrawn from sale, then 
13
for purposes of assessing the biosimilar bi-
14
ological product program fee, the Secretary 
15
shall consider such product to have been 
16
included on such list on the later of— 
17
‘‘(I) the date such request was 
18
received; or 
19
‘‘(II) if the product will be with-
20
drawn from sale on a future date, 
21
such future date when the product is 
22
withdrawn from sale. 
23
‘‘(ii) TREATMENT
AS
WITHDRAWN 
24
FROM SALE.—For purposes of clause (i), a 
25
21:28 May 06, 2022
H7667
66 
•HR 7667 IH
product shall be considered withdrawn 
1
from sale once the applicant has ceased its 
2
own distribution of the product, whether or 
3
not the applicant has ordered recall of all 
4
previously distributed lots of the product, 
5
except that a routine, temporary interrup-
6
tion in supply shall not render a product 
7
withdrawn from sale. 
8
‘‘(iii) SPECIAL RULE.—If a biosimilar 
9
biological product that is identified in a 
10
biosimilar biological product application 
11
approved as of October 1 of a fiscal year 
12
appears, as of October 1 of such fiscal 
13
year, on the list referenced in subpara-
14
graph (A) of discontinued biosimilar bio-
15
logical products, and on any subsequent 
16
day during such fiscal year the biosimilar 
17
biological product does not appear on such 
18
list, then except as provided in subpara-
19
graph (D), each person who is named as 
20
the applicant in a biosimilar biological 
21
product application with respect to such 
22
product shall pay the annual biosimilar bi-
23
ological product program fee established 
24
for a fiscal year under subsection (c)(5) for 
25
21:28 May 06, 2022
H7667
67 
•HR 7667 IH
such biosimilar biological product. Not-
1
withstanding subparagraph (B), such fee 
2
shall be due on the last business day of 
3
such fiscal year and shall be paid only once 
4
for each such product for each fiscal 
5
year.’’. 
6
(8) BIOSIMILAR BIOLOGICAL PRODUCT FEE.— 
7
Section 744H(a) of the Federal Food, Drug, and 
8
Cosmetic Act (21 U.S.C. 379j–52(a)) is amended by 
9
striking paragraph (4). 
10
(c) FEE REVENUE AMOUNTS.—Subsection (b) of sec-
11
tion 744H of the Federal Food, Drug, and Cosmetic Act 
12
(21 U.S.C. 379j–52) is amended— 
13
(1) by striking paragraph (1); 
14
(2) by redesignating paragraphs (2) through 
15
(4) as paragraphs (1) through (3), respectively; 
16
(3) by amending paragraph (1) (as so redesig-
17
nated) to read as follows: 
18
‘‘(1) IN GENERAL.—For each of the fiscal years 
19
2023 through 2027, fees under subsection (a) shall, 
20
except as provided in subsection (c), be established 
21
to generate a total revenue amount equal to the sum 
22
of— 
23
‘‘(A) the annual base revenue for the fiscal 
24
year (as determined under paragraph (3)); 
25
21:28 May 06, 2022
H7667
68 
•HR 7667 IH
‘‘(B) the dollar amount equal to the infla-
1
tion adjustment for the fiscal year (as deter-
2
mined under subsection (c)(1)); 
3
‘‘(C) the dollar amount equal to the stra-
4
tegic hiring and retention adjustment (as deter-
5
mined under subsection (c)(2)); 
6
‘‘(D) the dollar amount equal to the capac-
7
ity planning adjustment for the fiscal year (as 
8
determined under subsection (c)(3)); 
9
‘‘(E) the dollar amount equal to the oper-
10
ating reserve adjustment for the fiscal year, if 
11
applicable (as determined under subsection 
12
(c)(4)); 
13
‘‘(F) for fiscal year 2023 an additional 
14
amount of $4,428,886; and 
15
‘‘(G) for fiscal year 2024 an additional 
16
amount of $320,569.’’; 
17
(4) in paragraph (2) (as so redesignated)— 
18
(A) in the paragraph heading, by striking 
19
‘‘; LIMITATIONS ON FEE AMOUNTS’’; 
20
(B) by striking subparagraph (B); and 
21
(C) by redesignating subparagraphs (C) 
22
and (D) as subparagraphs (B) and (C), respec-
23
tively; and 
24
21:28 May 06, 2022
H7667
69 
•HR 7667 IH
(5) by amending paragraph (3) (as so redesig-
1
nated) to read as follows: 
2
‘‘(3) ANNUAL BASE REVENUE.—For purposes 
3
of paragraph (1), the dollar amount of the annual 
4
base revenue for a fiscal year shall be— 
5
‘‘(A) for fiscal year 2023, $43,376,922; 
6
and 
7
‘‘(B) for fiscal years 2024 through 2027, 
8
the dollar amount of the total revenue amount 
9
established under paragraph (1) for the pre-
10
vious fiscal year, excluding any adjustments to 
11
such revenue amount under subsection (c)(4).’’. 
12
(d) ADJUSTMENTS; ANNUAL FEE SETTING.—Section 
13
744H(c) of the Federal Food, Drug, and Cosmetic Act 
14
(21 U.S.C. 379j–52(c)) is amended— 
15
(1) in paragraph (1)— 
16
(A) in subparagraph (A)— 
17
(i) in the matter preceding clause (i), 
18
by striking ‘‘subsection (b)(2)(B)’’ and in-
19
serting ‘‘subsection (b)(1)(B)’’; and 
20
(ii) in clause (i), by striking ‘‘sub-
21
section (b)’’ and inserting ‘‘subsection 
22
(b)(1)(A)’’; and 
23
(B) in subparagraph (B)(ii), by striking 
24
‘‘Washington-Baltimore, 
DC–MD–VA–WV’’ 
25
21:28 May 06, 2022
H7667
70 
•HR 7667 IH
and inserting ‘‘Washington-Arlington-Alexan-
1
dria, DC–VA–MD–WV’’; 
2
(2) by striking paragraphs (2) through (4) and 
3
inserting the following: 
4
‘‘(2) STRATEGIC HIRING AND RETENTION AD-
5
JUSTMENT.—For each fiscal year, after the annual 
6
base revenue under subsection (b)(1)(A) is adjusted 
7
for inflation in accordance with paragraph (1), the 
8
Secretary shall further increase the fee revenue and 
9
fees by $150,000. 
10
‘‘(3) CAPACITY PLANNING ADJUSTMENT.— 
11
‘‘(A) IN GENERAL.—For each fiscal year, 
12
the Secretary shall, in addition to the adjust-
13
ments under paragraphs (1) and (2), further 
14
adjust the fee revenue and fees under this sec-
15
tion for a fiscal year to reflect changes in the 
16
resource capacity needs of the Secretary for the 
17
process for the review of biosimilar biological 
18
product applications. 
19
‘‘(B) METHODOLOGY.— For purposes of 
20
this paragraph, the Secretary shall employ the 
21
capacity planning methodology utilized by the 
22
Secretary in setting fees for fiscal year 2021, as 
23
described in the notice titled ‘Biosimilar User 
24
Fee Rates for Fiscal Year 2021’ published in 
25
21:28 May 06, 2022
H7667
71 
•HR 7667 IH
the Federal Register on August 4, 2020 (85 
1
Fed. Reg. 47220). The workload categories 
2
used in applying such methodology in fore-
3
casting shall include only the activities de-
4
scribed in that notice and, as feasible, addi-
5
tional activities that are also directly related to 
6
the direct review of biosimilar biological product 
7
applications and supplements, including addi-
8
tional formal meeting types, the direct review of 
9
postmarketing commitments and requirements, 
10
the direct review of risk evaluation and mitiga-
11
tion strategies, and the direct review of annual 
12
reports for approved biosimilar biological prod-
13
ucts. Subject to the exceptions in the preceding 
14
sentence, the Secretary shall not include as 
15
workload categories in applying such method-
16
ology in forecasting any non-core review activi-
17
ties, including those activities that the Sec-
18
retary referenced for potential future use in 
19
such notice but did not utilize in setting fees for 
20
fiscal year 2021. 
21
‘‘(C) 
LIMITATIONS.—Under 
no 
cir-
22
cumstances shall an adjustment under this 
23
paragraph result in fee revenue for a fiscal year 
24
that is less than the sum of the amounts under 
25
21:28 May 06, 2022
H7667
72 
•HR 7667 IH
subsections (b)(1)(A)(the annual base revenue 
1
for the fiscal year), (b)(1)(B) (the dollar 
2
amount of the inflation adjustment for the fis-
3
cal year), and (b)(1)(C) (the dollar amount of 
4
the strategic hiring and retention adjustment). 
5
‘‘(D) PUBLICATION
IN
FEDERAL
REG-
6
ISTER.—The Secretary shall publish in the Fed-
7
eral Register notice under paragraph (5) the fee 
8
revenue and fees resulting from the adjustment 
9
and the methodologies under this paragraph. 
10
‘‘(4) OPERATING RESERVE ADJUSTMENT.— 
11
‘‘(A) INCREASE.—For fiscal year 2023 and 
12
subsequent fiscal years, the Secretary shall, in 
13
addition to adjustments under paragraphs (1), 
14
(2), and (3), further increase the fee revenue 
15
and fees if such an adjustment is necessary to 
16
provide for at least 10 weeks of operating re-
17
serves of carryover user fees for the process for 
18
the review of biosimilar biological product appli-
19
cations. 
20
‘‘(B) DECREASE.— 
21
‘‘(i) FISCAL
YEAR
2023.—For fiscal 
22
year 2023, if the Secretary has carryover 
23
balances for such process in excess of 33 
24
weeks of such operating reserves, the Sec-
25
21:28 May 06, 2022
H7667
73 
•HR 7667 IH
retary shall decrease such fee revenue and 
1
fees to provide for not more than 33 weeks 
2
of such operating reserves. 
3
‘‘(ii) FISCAL
YEAR
2024.—For fiscal 
4
year 2024, if the Secretary has carryover 
5
balances for such process in excess of 27 
6
weeks of such operating reserves, the Sec-
7
retary shall decrease such fee revenue and 
8
fees to provide for not more than 27 weeks 
9
of such operating reserves. 
10
‘‘(iii) FISCAL YEAR 2025 AND SUBSE-
11
QUENT
FISCAL
YEARS.—For fiscal year 
12
2025 and subsequent fiscal years, if the 
13
Secretary has carryover balances for such 
14
process in excess of 21 weeks of such oper-
15
ating reserves, the Secretary shall decrease 
16
such fee revenue and fees to provide for 
17
not more than 21 weeks of such operating 
18
reserves. 
19
‘‘(C) FEDERAL REGISTER NOTICE.—If an 
20
adjustment under subparagraph (A) or (B) is 
21
made, the rationale for the amount of the in-
22
crease or decrease in fee revenue and fees shall 
23
be contained in the annual Federal Register no-
24
tice under paragraph (5)(B) establishing fee 
25
21:28 May 06, 2022
H7667
74 
•HR 7667 IH
revenue and fees for the fiscal year involved.’’; 
1
and 
2
(3) in paragraph (5), in the matter preceding 
3
subparagraph (A), by striking ‘‘2018’’ and inserting 
4
‘‘2023’’. 
5
(e) CREDITING AND AVAILABILITY OF FEES.—Sub-
6
section (f)(3) of section 744H of the Federal Food, Drug, 
7
and Cosmetic Act (21 U.S.C. 379j–52(f)(3)) is amended 
8
by striking ‘‘2018 through 2022’’ and inserting ‘‘2023 
9
through 2027’’. 
10
(f) WRITTEN REQUESTS
FOR WAIVERS
AND RE-
11
TURNS; DISPUTES CONCERNING FEES.—Section 744H(h) 
12
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
13
379j–52(h)) is amended to read as follows: 
14
‘‘(h) WRITTEN REQUESTS FOR WAIVERS AND RE-
15
TURNS; DISPUTES CONCERNING FEES.—To qualify for 
16
consideration for a waiver under subsection (d), or for the 
17
return of any fee paid under this section, including if the 
18
fee is claimed to have been paid in error, a person shall 
19
submit to the Secretary a written request justifying such 
20
waiver or return and, except as otherwise specified in this 
21
section, such written request shall be submitted to the Sec-
22
retary not later than 180 days after such fee is due. A 
23
request submitted under this paragraph shall include any 
24
legal authorities under which the request is made.’’. 
25
21:28 May 06, 2022
H7667
75 
•HR 7667 IH
SEC. 404. REAUTHORIZATION; REPORTING REQUIREMENTS. 
1
Section 744I of the Federal Food, Drug, and Cos-
2
metic Act (21 U.S.C. 379j–53) is amended— 
3
(1) in subsection (a)(1), by striking ‘‘Beginning 
4
with fiscal year 2018, not’’ and inserting ‘‘Not’’; 
5
(2) by striking ‘‘Biosimilar User Fee Amend-
6
ments of 2017’’ each place it appears and inserting 
7
‘‘Biosimilar User Fee Amendments of 2022’’; 
8
(3) in subsection (a)(2), by striking ‘‘Beginning 
9
with fiscal year 2018, the’’ and inserting ‘‘The’’; 
10
(4) in subsection (a)(3)(A), by striking ‘‘Not 
11
later than 30 calendar days after the end of the sec-
12
ond quarter of fiscal year 2018, and not later than 
13
30 calendar days after the end of each quarter of 
14
each fiscal year thereafter’’ and inserting ‘‘Not later 
15
than 30 calendar days after the end of each quarter 
16
of each fiscal year for which fees are collected under 
17
this part’’; 
18
(5) in subsection (b), by striking ‘‘Not later 
19
than 120 days after the end of fiscal year 2018 and 
20
each subsequent fiscal year for which fees are col-
21
lected under this part’’ and inserting ‘‘Not later 
22
than 120 days after the end of each fiscal year for 
23
which fees are collected under this part’’; 
24
21:28 May 06, 2022
H7667
76 
•HR 7667 IH
(6) in subsection (c), by striking ‘‘Beginning 
1
with fiscal year 2018, and for’’ and inserting ‘‘For’’; 
2
and 
3
(7) in subsection (f)— 
4
(A) in paragraph (1), in the matter pre-
5
ceding subparagraph (A), by striking ‘‘fiscal 
6
year 2022’’ and inserting ‘‘fiscal year 2027’’; 
7
and 
8
(B) in paragraph (3), by striking ‘‘January 
9
15, 2022’’ and inserting ‘‘January 15, 2027’’. 
10
SEC. 405. SUNSET DATES. 
11
(a) AUTHORIZATION.—Sections 744G and 744H of 
12
the Federal Food, Drug, and Cosmetic Act shall cease to 
13
be effective October 1, 2027. 
14
(b) REPORTING REQUIREMENTS.—Section 744I of 
15
the Federal Food, Drug, and Cosmetic Act shall cease to 
16
be effective January 31, 2028. 
17
(c) PREVIOUS SUNSET PROVISION.—Effective Octo-
18
ber 1, 2022, subsections (a) and (b) of section 405 of the 
19
FDA Reauthorization Act of 2017 (Public Law 115–52) 
20
are repealed. 
21
SEC. 406. EFFECTIVE DATE. 
22
The amendments made by this title shall take effect 
23
on October 1, 2022, or the date of the enactment of this 
24
Act, whichever is later, except that fees under part 8 of 
25
21:28 May 06, 2022
H7667
77 
•HR 7667 IH
subchapter C of chapter VII of the Federal Food, Drug, 
1
and Cosmetic Act shall be assessed for all biosimilar bio-
2
logical product applications received on or after October 
3
1, 2022, regardless of the date of the enactment of this 
4
Act. 
5
SEC. 407. SAVINGS CLAUSE. 
6
Notwithstanding the amendments made by this title, 
7
part 8 of subchapter C of chapter VII of the Federal Food, 
8
Drug, and Cosmetic Act, as in effect on the day before 
9
the date of the enactment of this title, shall continue to 
10
be in effect with respect to biosimilar biological product 
11
applications and supplements (as defined in such part as 
12
of such day) that were accepted by the Food and Drug 
13
Administration for filing on or after October 1, 2017, but 
14
before October 1, 2022, with respect to assessing and col-
15
lecting any fee required by such part for a fiscal year prior 
16
to fiscal year 2023. 
17
TITLE V—IMPROVING DIVERSITY 
18
IN CLINICAL TRIALS 
19
SEC. 501. PREMARKET REPORTING OF DIVERSITY ACTION 
20
PLANS FOR CLINICAL TRIALS AND STUDIES. 
21
(a) DRUGS.—Section 505(i) of the Federal Food, 
22
Drug, and Cosmetic Act (21 U.S.C. 355(i)) is amended 
23
by adding at the end the following: 
24
21:28 May 06, 2022
H7667
78 
•HR 7667 IH
‘‘(5)(A) In order for a new drug to be exempt pursu-
1
ant to this subsection, the sponsor of a clinical investiga-
2
tion of such new drug shall submit to the Secretary a di-
3
versity action plan. 
4
‘‘(B) Such diversity action plan shall include— 
5
‘‘(i) the sponsor’s goals for enrollment in such 
6
clinical investigation; 
7
‘‘(ii) the sponsor’s rationale for such goals; and 
8
‘‘(iii) an explanation of how the sponsor intends 
9
to meet such goals. 
10
‘‘(C) The sponsor shall, in such form and manner as 
11
specified in the guidance required by section 524B, submit 
12
such diversity action plan as soon as practicable during 
13
drug development, but not later than— 
14
‘‘(i) one month prior to an End-of-Phase 2 
15
meeting, as described in section 312.47(b) of title 
16
21, Code of Federal Regulations (or successor regu-
17
lations); or 
18
‘‘(ii) if there is no End-of-Phase 2 meeting, one 
19
month prior to commencing enrollment for a Phase 
20
3 study. 
21
‘‘(D) The Secretary may waive the requirement in 
22
subparagraph (A) if the Secretary determines that a waiv-
23
er is necessary based on what is known about the preva-
24
21:28 May 06, 2022
H7667
79 
•HR 7667 IH
lence of the disease in terms of the patient population that 
1
may use the new drug.’’. 
2
(b) BIOLOGICAL PRODUCTS.—Section 351(a)(3) of 
3
the Public Health Service Act (42 U.S.C. 262(a)(3)) is 
4
amended— 
5
(1) by striking ‘‘(3) The Secretary’’ and insert-
6
ing ‘‘(3)(A) The Secretary’’; and 
7
(2) by adding at the end the following: 
8
‘‘(B)(i) In order for a biological product to be exempt 
9
pursuant to this paragraph, the sponsor of a clinical inves-
10
tigation of such biological product shall submit to the Sec-
11
retary a diversity action plan. 
12
‘‘(ii) Such diversity action plan shall include— 
13
‘‘(I) the sponsor’s goals for enrollment in such 
14
clinical investigation; 
15
‘‘(II) the sponsor’s rationale for such goals; and 
16
‘‘(III) an explanation of how the sponsor in-
17
tends to meet such goals. 
18
‘‘(iii) The sponsor shall, in such form and manner 
19
as specified in the guidance required by section 524B, sub-
20
mit such diversity action plan as soon as practicable dur-
21
ing biological product development, but not later than— 
22
‘‘(I) one month prior to an End-of-Phase 2 
23
meeting, as described in section 312.47(b) of title 
24
21:28 May 06, 2022
H7667
80 
•HR 7667 IH
21, Code of Federal Regulations (or successor regu-
1
lations); or 
2
‘‘(II) if there is no End-of-Phase 2 meeting, one 
3
month prior to commencing enrollment for a Phase 
4
3 study. 
5
‘‘(iv) The Secretary may waive the requirement in 
6
subparagraph (A) if the Secretary determines that a waiv-
7
er is necessary based on what is known about the preva-
8
lence of the disease in terms of the patient population that 
9
may use the biological product.’’. 
10
(c) DEVICES.—Section 520(g) of the Federal Food, 
11
Drug, and Cosmetic Act (21 U.S.C. 360j(g)) is amended 
12
by adding at the end the following: 
13
‘‘(9)(A) In order for a device to be exempt under this 
14
subsection, the sponsor of a clinical investigation of such 
15
device shall submit to the Secretary a diversity action plan 
16
the sponsor of a clinical investigation of such device shall 
17
submit to the Secretary a diversity action plan. 
18
‘‘(B) Such diversity action plan shall include— 
19
‘‘(i) the sponsor’s goals for enrollment in such 
20
clinical investigation; 
21
‘‘(ii) the sponsor’s rationale for such goals; and 
22
‘‘(iii) an explanation of how the sponsor intends 
23
to meet such goals. 
24
‘‘(C) Such diversity action plan shall be— 
25
21:28 May 06, 2022
H7667
81 
•HR 7667 IH
‘‘(i) if submission of an application for an inves-
1
tigational device exemption is required, submitted in 
2
such application; and 
3
‘‘(ii) if submission of an application for inves-
4
tigational device exemption is not required, sub-
5
mitted as soon as practicable during device develop-
6
ment, but no later than one month prior to com-
7
mencing enrollment for a study. 
8
‘‘(D) The Secretary may waive the requirement in 
9
subparagraph (A) if the Secretary determines that a waiv-
10
er is necessary based on what is known about the preva-
11
lence of the disease in terms of the patient population that 
12
may use the device.’’. 
13
(d) GUIDANCE.—Subchapter A of chapter V of the 
14
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 
15
et seq.) is amended by adding at the end the following: 
16
‘‘SEC. 524B. GUIDANCE ON DIVERSITY ACTION PLANS FOR 
17
CLINICAL TRIALS AND STUDIES. 
18
‘‘(a) IN GENERAL.—The Secretary shall by guidance 
19
provide recommendations relating to— 
20
‘‘(1) the format and content of the diversity ac-
21
tion plans required by sections 505(i)(5) and 
22
520(g)(9) of this Act, and section 351(a)(3) of the 
23
Public Health Service Act, pertaining to the spon-
24
sor’s goals for clinical trial enrollment, disaggregated 
25
21:28 May 06, 2022
H7667
82 
•HR 7667 IH
by age group, sex, race, geographic location, and 
1
ethnicity, including with respect to— 
2
‘‘(A) the rationale for the sponsor’s enroll-
3
ment goals, which may include— 
4
‘‘(i) the estimated prevalence in the 
5
United States of the disease or condition 
6
for which the drug or device is being devel-
7
oped or investigated, if such estimated 
8
prevalence is known or can be determined 
9
based on available data; 
10
‘‘(ii) what is known about the disease 
11
or condition for which the drug or device 
12
is being developed or investigated; 
13
‘‘(iii) any relevant pharmacokinetic or 
14
pharmacogenomic data; 
15
‘‘(iv) what is known about the patient 
16
population for such disease or condition, 
17
including, to the extent data is available— 
18
‘‘(I) demographic information, in-
19
cluding age group, sex, race, geo-
20
graphic location and ethnicity; 
21
‘‘(II) co-morbidities frequently 
22
affecting the patient population; and 
23
‘‘(III) potential barriers to enroll-
24
ing diverse participants, such as pa-
25
21:28 May 06, 2022
H7667
83 
•HR 7667 IH
tient population size and geographic 
1
location; and 
2
‘‘(v) any other data or information the 
3
sponsor deems relevant to selecting appro-
4
priate enrollment goals, disaggregated by 
5
demographic subgroup, such as the inclu-
6
sion of pregnant and lactating women; 
7
‘‘(B) an explanation for how the sponsor 
8
intends to meet such goals, including demo-
9
graphic-specific outreach and enrollment strate-
10
gies, study-site selection, clinical trial inclusion 
11
and exclusion practices, and any diversity train-
12
ing for trial personnel; and 
13
‘‘(C) procedures for the public posting of 
14
key information from the diversity action plan 
15
that would be useful to patients and providers 
16
on the sponsor’s website; and 
17
‘‘(2) how sponsors should include in regular re-
18
ports to the Secretary— 
19
‘‘(A) the sponsor’s progress in meeting the 
20
goals referred to in paragraph (1)(A); and 
21
‘‘(B) if the sponsor does not expect to meet 
22
such goals— 
23
21:28 May 06, 2022
H7667
84 
•HR 7667 IH
‘‘(i) any updates needed to be made to 
1
a diversity action plan referred to in para-
2
graph (1) to help meet such goals; and 
3
‘‘(ii) the sponsor’s reasons for why the 
4
sponsor does not expect to meet such 
5
goals. 
6
‘‘(b) ISSUANCE.—The Secretary shall— 
7
‘‘(1) not later than 12 months after the date of 
8
enactment of this section, issue new draft guidance 
9
or update existing draft guidance described in sub-
10
section (a); and 
11
‘‘(2) not later than 6 months after closing the 
12
comment period on such draft guidance, finalize 
13
such guidance.’’. 
14
(e) 
APPLICABILITY.—Sections 
505(i)(5) 
and 
15
520(g)(9) of the Federal Food, Drug, and Cosmetic Act, 
16
and section 351(a)(3)(B) of the Public Health Service Act, 
17
as added by subsections (a), (b), and (c) of this section, 
18
apply only with respect to clinical investigations with re-
19
spect to which enrollment commences after the date that 
20
is 180 days after the publication of final guidance under 
21
section 524B(b)(2) of the Federal Food, Drug, and Cos-
22
metic Act, as added by subsection (d). 
23
21:28 May 06, 2022
H7667
85 
•HR 7667 IH
SEC. 502. EVALUATION OF THE NEED FOR FDA AUTHORITY 
1
TO MANDATE POSTAPPROVAL STUDIES OR 
2
3
FICIENT DEMOGRAPHIC SUBGROUP DATA. 
4
(a) IN GENERAL.—Not later than 2 years after the 
5
date of publication of final guidance pursuant to section 
6
524B(b)(2) of the Federal Food, Drug, and Cosmetic Act, 
7
as added by section 501(d) of this Act, the Secretary of 
8
Health and Human Services shall commence an evaluation 
9
to assess whether additions or changes to statutes or regu-
10
lations are needed to assure that sponsors conduct post-
11
approval studies or postmarket surveillance when they do 
12
not meet the enrollment goals submitted in their diversity 
13
action plan under section 505(i)(5) or 520(g)(9) of the 
14
Federal Food, Drug, and Cosmetic Act, or section 
15
351(a)(3)(B) of the Public Health Service Act, as added 
16
by subsection (a), (b), or (c) of section 501 of this Act. 
17
(b) DETERMINATION
AND REPORTING.—Not later 
18
than 180 days after the commencement of the evaluation 
19
under subsection (a), the Secretary of Health and Human 
20
Services shall submit a report to the Congress on the out-
21
come of the such evaluation, including any recommenda-
22
tions related to additional needed authorities. 
23
21:28 May 06, 2022
H7667
86 
•HR 7667 IH
SEC. 503. PUBLIC WORKSHOPS TO ENHANCE CLINICAL 
1
TRIAL DIVERSITY. 
2
(a) IN GENERAL.—Not later than September 30, 
3
2023, the Secretary of Health and Human Services, in 
4
consultation with drug sponsors, medical device manufac-
5
turers, patients, and other stakeholders, shall convene one 
6
or more public workshops to solicit input from stake-
7
holders on increasing the enrollment of historically under-
8
represented populations in clinical trials and encouraging 
9
clinical trial participation that reflects the prevalence of 
10
the disease or condition among demographic subgroups, 
11
and other topics, including— 
12
(1) how and when to collect and present demo-
13
graphic subgroup and disease or condition preva-
14
lence data from clinical trials, including with respect 
15
to— 
16
(A) such data intended to support post-
17
approval study requirements; and 
18
(B) the utilization of real world evidence 
19
(as defined in section 505F(b) of the Federal 
20
Food, Drug, and Cosmetic Act (21 U.S.C. 
21
355g(b))); 
22
(2) methodologies for assessing the diversity of 
23
a patient population; 
24
21:28 May 06, 2022
H7667
87 
•HR 7667 IH
(3) methodologies for the dissemination of in-
1
formation to the public on clinical trial enrollment 
2
demographic data; 
3
(4) the establishment of goals for enrollment in 
4
clinical trials with respect to the estimated preva-
5
lence in the United States of the disease or condition 
6
for which the drug is being developed or inves-
7
tigated, disaggregated by demographic subgroup (in-
8
cluding by age group, race, ethnicity, and sex); and 
9
(5) approaches to support inclusion of under-
10
represented populations and to encourage clinical 
11
trial participation that reflects the prevalence of the 
12
disease or condition in certain demographic sub-
13
groups, including with respect to— 
14
(A) the establishment of inclusion and ex-
15
clusion criteria for certain demographic sub-
16
groups, such as pregnant and lactating women 
17
and individuals with disabilities, including intel-
18
lectual or developmental disabilities; 
19
(B) considerations regarding informed con-
20
sent with respect to individuals with intellectual 
21
or developmental disabilities; 
22
(C) clinical trial designs, including utiliza-
23
tion of decentralized trials or digital health 
24
tools; 
25
21:28 May 06, 2022
H7667
88 
•HR 7667 IH
(D) clinical endpoints; 
1
(E) biomarker selection; and 
2
(F) studying analysis. 
3
(b) PUBLIC DOCKET.—The Secretary of Health and 
4
Human Services shall establish a public comment period 
5
to receive written comments related to the topics ad-
6
dressed during each public workshop convened under this 
7
section. The public comment period shall remain open for 
8
60 days following the date on which each public workshop 
9
is convened. 
10
(c) REPORT.—Not later than 180 days after the date 
11
of each public workshop convened under this section, the 
12
Secretary of Health and Human Services shall make avail-
13
able on the public website of the Food and Drug Adminis-
14
tration a report on the topics discussed at such workshop. 
15
The report shall include a summary of, and response to, 
16
recommendations raised in such workshop. 
17
SEC. 504. ANNUAL REPORT ON PROGRESS TO INCREASE DI-
18
VERSITY IN CLINICAL TRIALS AND STUDIES. 
19
(a) IN GENERAL.—Beginning not later than 2 years 
20
after the date of enactment of this Act, and each year 
21
thereafter, the Secretary of Health and Human Services 
22
shall submit to the Congress, and publish on the public 
23
website of the Food and Drug Administration, a report 
24
that— 
25
21:28 May 06, 2022
H7667
89 
•HR 7667 IH
(1) summarizes, in aggregate, the diversity ac-
1
tion plans received pursuant to section 505(i)(5) or 
2
520(g)(9) of the Federal Food, Drug, and Cosmetic 
3
Act, or section 351(a)(3)(B) of the Public Health 
4
Service Act, as added by subsection (a), (b), or (c) 
5
of section 501 of this Act; and 
6
(2) contains information on— 
7
(A) whether the clinical trials conducted 
8
with respect to such applications met the demo-
9
graphic subgroup enrollment goals from the di-
10
versity action plan submitted for such applica-
11
tions; 
12
(B) the reasons provided for why enroll-
13
ment goals from submitted diversity action 
14
plans were not met; 
15
(C) any postmarket studies of a drug or 
16
device in a demographic subgroup or subgroups 
17
required or recommended by the Secretary 
18
based on inadequate premarket clinical trial di-
19
versity, including the status and completion 
20
date of any such study; and 
21
(D) additional authorities, if any, the Sec-
22
retary plans to use or considers necessary to en-
23
sure compliance with the requirements of the 
24
amendments made by section 501. 
25
21:28 May 06, 2022
H7667
90 
•HR 7667 IH
(b) CONFIDENTIALITY.—Nothing in this section shall 
1
be construed as authorizing the Secretary of Health and 
2
Human Services to disclose any information that is a 
3
trade secret or confidential information subject to section 
4
552(b)(4) of title 5, United States Code, or section 1905 
5
of title 18, United States Code. 
6
SEC. 505. PUBLIC MEETING ON CLINICAL TRIAL FLEXIBILI-
7
TIES INITIATED IN RESPONSE TO COVID–19 
8
PANDEMIC. 
9
(a) IN GENERAL.—Not later than 180 days after the 
10
date on which the COVID–19 emergency period ends, the 
11
Secretary of Health and Human Services shall convene a 
12
public meeting to discuss the recommendations provided 
13
by the Food and Drug Administration during the COVID– 
14
19 emergency period to mitigate disruption of clinical 
15
trials, including recommendations detailed in the March 
16
2020 guidance entitled ‘‘Conduct of Clinical Trials of 
17
Medical Products During the COVID–19 Public Health 
18
Emergency, Guidance for Industry, Investigators, and In-
19
stitutional Review Boards’’, and any subsequent updates 
20
to such guidance. The Secretary of Health and Human 
21
Services shall invite to such meeting representatives from 
22
the pharmaceutical and medical device industries who 
23
sponsored clinical trials during the COVID–19 emergency 
24
period and organizations representing patients. 
25
21:28 May 06, 2022
H7667
91 
•HR 7667 IH
(b) TOPICS.—Not later than 90 days after the date 
1
on which the public meeting under subsection (a) is con-
2
vened, the Secretary of Health and Human Services shall 
3
make available on the public website of the Food and Drug 
4
Administration a report on the topics discussed at such 
5
meeting. Such topics shall include discussion of— 
6
(1) the actions drug sponsors took to utilize 
7
such recommendations and the frequency at which 
8
such recommendations were employed; 
9
(2) the characteristics of the sponsors, trials, 
10
and patient populations impacted by such rec-
11
ommendations; 
12
(3) a consideration of how recommendations in-
13
tended to mitigate disruption of clinical trials during 
14
the COVID–19 emergency period, including any rec-
15
ommendations to consider decentralized clinical 
16
trials when appropriate, may have affected access to 
17
clinical trials for certain patient populations, espe-
18
cially unrepresented racial and ethnic minorities; 
19
and 
20
(4) recommendations for incorporating certain 
21
clinical trial disruption mitigation recommendations 
22
into current or additional guidance to improve clin-
23
ical trial access and enrollment of diverse patient 
24
populations. 
25
21:28 May 06, 2022
H7667
92 
•HR 7667 IH
(c) COVID–19 EMERGENCY PERIOD DEFINED.—In 
1
this section, the term ‘‘COVID–19 emergency period’’ has 
2
the meaning given the term ‘‘emergency period’’ in section 
3
1135(g)(1)(B) of the Social Security Act (42 U.S.C. 
4
1320b–5(g)(1)(B)). 
5
SEC. 506. DECENTRALIZED CLINICAL TRIALS. 
6
(a) GUIDANCE.—The Secretary of Health and 
7
Human Services shall— 
8
(1) not later than 12 months after the date of 
9
enactment of this Act, issue draft guidance that ad-
10
dresses considerations for decentralized clinical 
11
trials, including considerations regarding the engage-
12
ment, enrollment, and retention of a meaningfully 
13
diverse clinical population, with respect to race, eth-
14
nicity, age, gender, and geographic location, when 
15
appropriate; and 
16
(2) not later than 6 months after closing the 
17
comment period on such draft guidance, finalize 
18
such guidance. 
19
(b) CONTENT OF GUIDANCE.—The guidance under 
20
subsection (a) shall address the following: 
21
(1) Recommendations for how digital health 
22
technology or other remote assessment options, such 
23
as telehealth, could support decentralized clinical 
24
trials, including guidance on considerations for se-
25
21:28 May 06, 2022
H7667
93 
•HR 7667 IH
lecting technological platforms and mediums, data 
1
collection and use, data integrity and security, and 
2
communication to study participants through digital 
3
technology. 
4
(2) Recommendations for subject recruitment 
5
and retention, including considerations for sponsors 
6
to minimize or reduce burdens for clinical trial par-
7
ticipants through the use of digital heath technology, 
8
telehealth, local health care providers and labora-
9
tories, or other means. 
10
(3) Recommendations with respect to the eval-
11
uation of data collected within a decentralized clin-
12
ical trial setting. 
13
(c) DEFINITION.—In this section, the term ‘‘decen-
14
tralized clinical trial’’ means a clinical trial in which some 
15
or all of the trial-related activities occur at a location sepa-
16
rate from the investigator’s location. 
17
TITLE VI—GENERIC DRUG 
18
COMPETITION 
19
SEC. 601. INCREASING TRANSPARENCY IN GENERIC DRUG 
20
APPLICATIONS. 
21
(a) IN GENERAL.—Section 505(j)(3) of the Federal 
22
Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(3)) is 
23
amended by adding at the end the following: 
24
21:28 May 06, 2022
H7667
94 
•HR 7667 IH
‘‘(H)(i) Upon request (in controlled correspondence 
1
or otherwise) by a person that has submitted or intends 
2
to submit an abbreviated application for a new drug under 
3
this subsection or on the Secretary’s own initiative during 
4
the review of such abbreviated application, the Secretary 
5
shall inform the person whether such new drug is quali-
6
tatively and quantitatively the same as the listed drug. 
7
‘‘(ii) If the Secretary determines that such new drug 
8
is not qualitatively or quantitatively the same as the listed 
9
drug, the Secretary shall identify and disclose to the per-
10
son— 
11
‘‘(I) the ingredient or ingredients that cause the 
12
new drug not to be qualitatively or quantitatively the 
13
same as the listed drug; and 
14
‘‘(II) for any ingredient for which there is an 
15
identified quantitative deviation, the amount of such 
16
deviation. 
17
‘‘(iii) If the Secretary determines that such new drug 
18
is qualitatively and quantitatively the same as the listed 
19
drug, the Secretary shall not change or rescind such deter-
20
mination after the submission of an abbreviated applica-
21
tion for such new drug under this subsection unless— 
22
‘‘(I) the formulation of the listed drug has been 
23
changed and the Secretary has determined that the 
24
21:28 May 06, 2022
H7667
95 
•HR 7667 IH
prior listed drug formulation was withdrawn for rea-
1
sons of safety or effectiveness; or 
2
‘‘(II) the Secretary makes a written determina-
3
tion that the prior determination must be changed 
4
because an error has been identified. 
5
‘‘(iv) If the Secretary makes a written determination 
6
described in clause (iii)(II), the Secretary shall provide no-
7
tice and a copy of the written determination to the person 
8
making the request under clause (i). 
9
‘‘(v) The disclosures required by this subparagraph 
10
are disclosures authorized by law under section 1905 of 
11
title 18, United States Code.’’. 
12
(b) GUIDANCE.— 
13
(1) IN
GENERAL.—Not later than one year 
14
after the date of enactment of this Act, the Sec-
15
retary of Health and Human Services shall issue 
16
guidance describing how the Secretary will deter-
17
mine whether a new drug is qualitatively and quan-
18
titatively the same as the listed drug (as such terms 
19
are used in section 505(j)(3)(H) of the Federal 
20
Food, Drug, and Cosmetic Act, as added by sub-
21
section (a)), including with respect to assessing pH 
22
adjusters. 
23
21:28 May 06, 2022
H7667
96 
•HR 7667 IH
(2) PROCESS.—In issuing guidance as required 
1
by paragraph (1), the Secretary of Health and 
2
Human Services shall— 
3
(A) publish draft guidance; 
4
(B) provide a period of at least 60 days for 
5
comment on the draft guidance; and 
6
(C) after considering any comments re-
7
ceived, publish final guidance. 
8
(c) APPLICABILITY.—Section 505(j)(3)(H) of the 
9
Federal Food, Drug, and Cosmetic Act, as added by sub-
10
section (a), applies beginning on the date of enactment 
11
of this Act, irrespective of the date on which the guidance 
12
required by subsection (b) is finalized. 
13
SEC. 602. ENHANCING ACCESS TO AFFORDABLE MEDI-
14
CINES. 
15
Section 505(j)(10)(A) of the Federal Food, Drug, 
16
and Cosmetic Act (21 U.S.C. 355(j)(10)(A)) is amended 
17
by striking clauses (i) through (iv) and inserting the fol-
18
lowing: 
19
‘‘(i) a revision to the labeling of the listed drug 
20
has been approved by the Secretary within 90 days 
21
of when the application is otherwise eligible for ap-
22
proval under this subsection; 
23
‘‘(ii) the sponsor of the application agrees to 
24
submit revised labeling for the drug that is the sub-
25
21:28 May 06, 2022
H7667
97 
•HR 7667 IH
ject of the application not later than 60 days after 
1
approval under this subsection of the application; 
2
and 
3
‘‘(iii) the labeling revision described under 
4
clause (i) does not include a change to the ‘Warn-
5
ings’ section of the labeling.’’. 
6
TITLE VII—RESEARCH, DEVEL-
7
OPMENT, AND SUPPLY CHAIN 
8
IMPROVEMENTS 
9
Subtitle A—In General 
10
SEC. 701. ANIMAL TESTING ALTERNATIVES. 
11
Section 505 of the Federal Food, Drug, and Cosmetic 
12
Act (21 U.S.C. 355) is amended— 
13
(1) in subsection (b)(5)(B)(i)(II), by striking 
14
‘‘animal’’ and inserting ‘‘nonclinical tests’’; 
15
(2) in subsection (i)— 
16
(A) in paragraph (1)(A), by striking ‘‘pre-
17
clinical tests (including tests on animals)’’ and 
18
inserting ‘‘nonclinical tests’’; and 
19
(B) in paragraph (2)(B), by striking ‘‘ani-
20
mal’’ and inserting ‘‘nonclinical tests’’; and 
21
(3) after subsection (y), by inserting the fol-
22
lowing: 
23
‘‘(z) NONCLINICAL TEST DEFINED.—For purposes 
24
of this section, the term ‘nonclinical test’ means a test con-
25
21:28 May 06, 2022
H7667
98 
•HR 7667 IH
ducted in vitro, in silico, or in chemico, or a nonhuman 
1
in vivo test, that occurs before or during the clinical trial 
2
phase of the investigation of the safety and effectiveness 
3
of a drug. Such test may include the following: 
4
‘‘(1) Cell-based assays. 
5
‘‘(2) Organ chips and microphysiological sys-
6
tems. 
7
‘‘(3) Sophisticated computer modeling. 
8
‘‘(4) Other nonhuman or human biology-based 
9
test methods. 
10
‘‘(5) Animal tests.’’. 
11
SEC. 702. EMERGING TECHNOLOGY PROGRAM. 
12
Chapter V of the Federal Food, Drug, and Cosmetic 
13
Act (21 U.S.C. 201 et seq.) is amended by inserting after 
14
section 566 of such Act (21 U.S.C. 360bbb–5) the fol-
15
lowing: 
16
‘‘SEC. 566A. EMERGING TECHNOLOGY PROGRAM. 
17
‘‘(a) PROGRAM ESTABLISHMENT.— 
18
‘‘(1) IN GENERAL.—The Secretary shall estab-
19
lish a program to support the adoption of, and im-
20
prove the development of, innovative approaches to 
21
drug product design and manufacturing. 
22
‘‘(2) ACTIONS.—In carrying out the program 
23
under paragraph (1), the Secretary may— 
24
21:28 May 06, 2022
H7667
99 
•HR 7667 IH
‘‘(A) facilitate and increase communication 
1
between public and private entities, consortia, 
2
and individuals with respect to innovative drug 
3
product design and manufacturing; 
4
‘‘(B) solicit information regarding, and 
5
conduct or support research on, innovative ap-
6
proaches to drug product design and manufac-
7
turing; 
8
‘‘(C) convene meetings with representatives 
9
of industry, academia, other Federal agencies, 
10
international agencies, and other interested per-
11
sons, as appropriate; 
12
‘‘(D) convene working groups to support 
13
drug product design and manufacturing re-
14
search and development; 
15
‘‘(E) support education and training for 
16
regulatory staff and scientists related to innova-
17
tive approaches to drug product design and 
18
manufacturing; 
19
‘‘(F) advance regulatory science related to 
20
the development and review of innovative ap-
21
proaches to drug product design and manufac-
22
turing; 
23
‘‘(G) convene or participate in working 
24
groups to support the harmonization of inter-
25
21:28 May 06, 2022
H7667
100 
•HR 7667 IH
national regulatory requirements related to in-
1
novative approaches to drug product design and 
2
manufacturing; and 
3
‘‘(H) award grants or contracts to carry 
4
out or support the program under paragraph 
5
(1). 
6
‘‘(3) GRANTS
AND
CONTRACTS.—To seek a 
7
grant or contract under this section, an entity shall 
8
submit an application— 
9
‘‘(A) in such form and manner as the Sec-
10
retary may require; and 
11
‘‘(B) containing such information as the 
12
Secretary may require, including a description 
13
of— 
14
‘‘(i) how the entity will conduct the 
15
activities to be supported through the 
16
grant or contract; and 
17
‘‘(ii) how such activities will further 
18
research and development related to, or 
19
adoption of, innovative approaches to drug 
20
product design and manufacturing. 
21
‘‘(b) GUIDANCE.—The Secretary shall— 
22
‘‘(1) issue or update guidance to help facilitate 
23
the adoption of, and advance the development of, in-
24
21:28 May 06, 2022
H7667
101 
•HR 7667 IH
novative approaches to drug product design and 
1
manufacturing; and 
2
‘‘(2) include in such guidance descriptions of— 
3
‘‘(A) any regulatory requirements related 
4
to the development or review of technologies re-
5
lated to innovative approaches to drug product 
6
design and manufacturing, including updates 
7
and improvements to such technologies after 
8
product approval; and 
9
‘‘(B) data that can be used to demonstrate 
10
the identity, safety, purity, and potency of 
11
drugs manufactured using such technologies. 
12
‘‘(c) REPORT TO CONGRESS.—Not later than 4 years 
13
after the date of enactment of this section, the Secretary 
14
shall submit to the Committee on Energy and Commerce 
15
of the House of Representatives and the Committee on 
16
Health, Education, Labor, and Pensions of the Senate a 
17
report containing— 
18
‘‘(1) an annual accounting of the allocation of 
19
funds made available to carry out this section; 
20
‘‘(2) a description of how Food and Drug Ad-
21
ministration staff were utilized to carry out this sec-
22
tion and, as applicable, any challenges or limitations 
23
related to staffing; 
24
21:28 May 06, 2022
H7667
102 
•HR 7667 IH
‘‘(3) the number of meetings held or partici-
1
pated in by the Food and Drug Administration, in-
2
cluding meetings convened as part of a working 
3
group described in subparagraph (D) or (G) of sub-
4
section (a)(2), and the topics of each such meeting; 
5
and 
6
‘‘(4) the number of drug products approved or 
7
licensed, after the date of enactment of this section, 
8
using an innovative approach to drug product design 
9
and manufacturing. 
10
‘‘(d) AUTHORIZATION
OF
APPROPRIATIONS.—To 
11
carry out this section, there is authorized to be appro-
12
priated $20,000,000 for each fiscal year 2023 through 
13
2027.’’. 
14
SEC. 703. IMPROVING THE TREATMENT OF RARE DISEASES 
15
AND CONDITIONS. 
16
(a) REPORT ON ORPHAN DRUG PROGRAM.— 
17
(1) IN GENERAL.—Not later than September 
18
30, 2026, the Secretary shall submit to the Com-
19
mittee on Energy and Commerce of the House of 
20
Representatives and the Committee on Health, Edu-
21
cation, Labor, and Pensions of the Senate a report 
22
summarizing the activities of the Food and Drug 
23
Administration related to designating drugs under 
24
section 526 of the Federal Food, Drug, and Cos-
25
21:28 May 06, 2022
H7667
103 
•HR 7667 IH
metic Act (21 U.S.C. 360bb) for a rare disease or 
1
condition and approving such drugs under section 
2
505 of such Act (21 U.S.C. 355) or licensing such 
3
drugs under section 351 of the Public Health Serv-
4
ice Act (42 U.S.C. 262), including— 
5
(A) the number of applications for such 
6
drugs under section 505 of the Federal Food, 
7
Drug, and Cosmetic Act (21 U.S.C. 355) or li-
8
censing such drugs under section 351 of the 
9
Public Health Service Act (42 U.S.C. 262) re-
10
ceived by the Food and Drug Administration, 
11
the number of such applications accepted and 
12
rejected for filing, and the number of such ap-
13
plications pending, approved, and disapproved 
14
by the Food and Drug Administration; 
15
(B) a description of trends in drug approv-
16
als for rare diseases and conditions across re-
17
view divisions at the Food and Drug Adminis-
18
tration; 
19
(C) the extent to which the Food and Drug 
20
Administration is consulting with external ex-
21
perts pursuant to section 569(a)(2) of the Fed-
22
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
23
360bbb–8(a)(2)) on topics pertaining to drugs 
24
for a rare disease or condition, including how 
25
21:28 May 06, 2022
H7667
104 
•HR 7667 IH
and when any such consultation is occurring; 
1
and 
2
(D) the Food and Drug Administration’s 
3
efforts to promote best practices in the develop-
4
ment of novel treatments for rare diseases, in-
5
cluding— 
6
(i) reviewer training on rare disease- 
7
related policies, methods, and tools; and 
8
(ii) new regulatory science and coordi-
9
nated support for patient and stakeholder 
10
engagement. 
11
(2) 
PUBLIC
AVAILABILITY.—The 
Secretary 
12
shall make the report under paragraph (1) available 
13
to the public, including by posting the report on the 
14
website of the Food and Drug Administration. 
15
(3) INFORMATION
DISCLOSURE.—Nothing in 
16
this subsection shall be construed to authorize the 
17
disclosure of information that is prohibited from dis-
18
closure under section 1905 of title 18, United States 
19
Code, or subject to withholding under paragraph (4) 
20
of section 552(b), United States Code (commonly re-
21
ferred to as the ‘‘Freedom of Information Act’’). 
22
(b) STUDY ON EUROPEAN UNION SAFETY AND EFFI-
23
CACY REVIEWS OF DRUGS FOR RARE DISEASES AND CON-
24
DITIONS.— 
25
21:28 May 06, 2022
H7667
105 
•HR 7667 IH
(1) IN GENERAL.—The Secretary of Health and 
1
Human Services shall enter into a contract with an 
2
appropriate entity to conduct a study on processes 
3
for evaluating the safety and efficacy of drugs for 
4
rare diseases or conditions in the United States and 
5
the European Union, including— 
6
(A) flexibilities, authorities, or mechanisms 
7
available to regulators in the United States and 
8
the European Union specific to rare diseases or 
9
conditions; 
10
(B) the consideration and use of supple-
11
mental data submitted during review processes 
12
in the United States and the European Union, 
13
including data associated with open label exten-
14
sion studies and expanded access programs spe-
15
cific to rare diseases or conditions; 
16
(C) an assessment of collaborative efforts 
17
between United States and European Union 
18
regulators related to— 
19
(i) product development programs 
20
under review; 
21
(ii) policies under development re-
22
cently issued; and 
23
(iii) scientific information related to 
24
product development or regulation; and 
25
21:28 May 06, 2022
H7667
106 
•HR 7667 IH
(D) recommendations for how Congress 
1
can support collaborative efforts described in 
2
subparagraph (C). 
3
(2) CONSULTATION.—The contract under para-
4
graph (1) shall provide for consultation with relevant 
5
stakeholders, including— 
6
(A) representatives from the Food and 
7
Drug Administration and the European Medi-
8
cines Agency; 
9
(B) rare disease or condition patients; and 
10
(C) patient groups that— 
11
(i) represent rare disease or condition 
12
patients; and 
13
(ii) have international patient out-
14
reach. 
15
(3) REPORT.—The contract under paragraph 
16
(1) shall provide for, not later than 2 years after the 
17
date of enactment of this Act— 
18
(A) the completion of the study under 
19
paragraph (1); and 
20
(B) the submission of a report on the re-
21
sults of such study to the Committee on Energy 
22
and Commerce of the House of Representatives 
23
and the Committee on Health, Education, 
24
Labor, and Pensions of the Senate. 
25
21:28 May 06, 2022
H7667
107 
•HR 7667 IH
(4) PUBLIC AVAILABILITY.—The contract under 
1
paragraph (1) shall provide for the appropriate enti-
2
ty referred to in paragraph (1) to make the report 
3
under paragraph (3) available to the public, includ-
4
ing by posting the report on the website of the ap-
5
propriate entity. 
6
(c) PUBLIC MEETING.— 
7
(1) IN GENERAL.—Not later than December 31, 
8
2023, the Secretary of Health and Human Services, 
9
acting through the Commissioner of Food and 
10
Drugs, shall convene one or more public meetings to 
11
solicit input from stakeholders regarding the ap-
12
proaches described in paragraph (2). 
13
(2) APPROACHES.—The public meeting or 
14
meetings under paragraph (1) shall address ap-
15
proaches to increasing and improving engagement 
16
with rare disease or condition patients, groups rep-
17
resenting such patients, rare disease or condition ex-
18
perts, and experts on small population studies, in 
19
order to improve the understanding with respect to 
20
rare diseases or conditions of— 
21
(A) patient burden; 
22
(B) treatment options; and 
23
(C) side effects of treatments, including— 
24
21:28 May 06, 2022
H7667
108 
•HR 7667 IH
(i) comparing the side effects of treat-
1
ments; and 
2
(ii) understanding the risks of side ef-
3
fects relative to the health status of the pa-
4
tient and the progression of the disease or 
5
condition. 
6
(3) PUBLIC DOCKET.—The Secretary of Health 
7
and Human Services shall establish a public docket 
8
to receive written comments related to the ap-
9
proaches addressed during each public meeting 
10
under paragraph (1). Such public docket shall re-
11
main open for 60 days following the date of each 
12
such public meeting. 
13
(4) REPORTS.—Not later than 180 days after 
14
each public meeting under paragraph (1), the Com-
15
missioner of Food and Drugs shall develop and pub-
16
lish on the website of the Food and Drug Adminis-
17
tration a report on— 
18
(A) the approaches discussed at the public 
19
meeting; and 
20
(B) any related recommendations. 
21
(d) CONSULTATION
ON
THE SCIENCE
OF SMALL 
22
23
Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–8(b)) 
24
is amended by adding at the end the following: 
25
21:28 May 06, 2022
H7667
109 
•HR 7667 IH
‘‘(C) SMALL POPULATION STUDIES.—The 
1
external experts on the list maintained pursuant 
2
to subparagraph (A) may include experts on the 
3
science of small population studies.’’. 
4
(e) STUDY
ON SUFFICIENCY
AND USE
OF FDA 
5
MECHANISMS FOR INCORPORATING THE PATIENT AND 
6
CLINICIAN PERSPECTIVE IN FDA PROCESSES RELATED 
7
TO APPLICATIONS CONCERNING DRUGS FOR RARE DIS-
8
EASES OR CONDITIONS.— 
9
(1) IN GENERAL.—The Comptroller General of 
10
the United States shall conduct a study on the use 
11
of Food and Drug Administration mechanisms and 
12
tools to ensure that patient and physician perspec-
13
tives are considered and incorporated throughout the 
14
processes of the Food and Drug Administration— 
15
(A) for approving or licensing under sec-
16
tion 505 of the Federal Food, Drug, or Cos-
17
metic Act (21 U.S.C. 355) or section 351 of the 
18
Public Health Service Act (42 U.S.C. 262) a 
19
drug designated as a drug for a rare disease or 
20
condition under section 526 of the Federal 
21
Food, Drug, and Cosmetic Act (21 U.S.C. 
22
360bb); and 
23
21:28 May 06, 2022
H7667
110 
•HR 7667 IH
(B) in making any determination related 
1
to such a drug’s approval, including assessment 
2
of the drug’s— 
3
(i) safety or effectiveness; or 
4
(ii) postapproval safety monitoring. 
5
(2) TOPICS.—The study under paragraph (1) 
6
shall— 
7
(A) identify and compare the processes 
8
that the Food and Drug Administration has 
9
formally put in place and utilized to gather ex-
10
ternal expertise (including patients, patient 
11
groups, and physicians) on specific applications 
12
for diseases or conditions affecting 20,000 or 
13
fewer patients in the United States and specific 
14
applications for diseases or conditions affecting 
15
200,000 or fewer patients in the United States; 
16
(B) examine tools or mechanisms to im-
17
prove efforts and initiatives of the Food and 
18
Drug Administration to collect and consider 
19
such external expertise with respect to applica-
20
tions for diseases or conditions affecting 20,000 
21
or fewer patients in the United States com-
22
pared to applications for diseases or conditions 
23
affecting 200,000 or fewer patients in the 
24
United States throughout the application review 
25
21:28 May 06, 2022
H7667
111 
•HR 7667 IH
and approval or licensure processes, including 
1
within internal benefit-risk assessments, advi-
2
sory committee processes, and postapproval 
3
safety monitoring; and 
4
(C) examine processes or alternatives to 
5
address or resolve conflicts of interest that im-
6
pede the Food and Drug Administration in 
7
gaining external expert input on rare diseases 
8
or conditions with a limited set of clinical and 
9
research experts. 
10
(3) REPORT.—Not later than 2 years after the 
11
date of enactment of this Act, the Comptroller Gen-
12
eral of the United States shall— 
13
(A) complete the study under paragraph 
14
(1); 
15
(B) submit a report on the results of such 
16
study to the Congress; and 
17
(C) include in such report recommenda-
18
tions, if appropriate, for changes to the proc-
19
esses and authorities of the Food and Drug Ad-
20
ministration to improve the collection and con-
21
sideration of external expert opinions of pa-
22
tients, patient groups, and physicians with ex-
23
pertise in rare diseases or conditions, including 
24
any specific recommendations for diseases or 
25
21:28 May 06, 2022
H7667
112 
•HR 7667 IH
conditions affecting 20,000 or fewer patients in 
1
the United States. 
2
(f) DEFINITION.—In this section, the term ‘‘rare dis-
3
ease or condition’’ has the meaning given such term in 
4
section 526(a)(2) of the Federal Food, Drug, and Cos-
5
metic Act (21 U.S.C. 360bb(a)(2)). 
6
SEC. 704. ANTIFUNGAL RESEARCH AND DEVELOPMENT. 
7
(a) DRAFT GUIDANCE.—Not later than 3 years after 
8
the date of the enactment of this Act, the Secretary of 
9
Health and Human Services, acting through the Commis-
10
sioner of Food and Drugs, shall issue draft guidance for 
11
industry for the purposes of assisting entities seeking ap-
12
proval under section 505 of the Federal Food, Drug, and 
13
Cosmetic Act (21 U.S.C. 355) or licensure under section 
14
351 of the Public Health Service Act (42 U.S.C. 262) of 
15
antifungal therapies designed to treat coccidioidomycosis 
16
(commonly known as Valley Fever). 
17
(b) FINAL GUIDANCE.—Not later than 18 months 
18
after the close of the public comment period on the draft 
19
guidance issued pursuant to subsection (a), the Secretary 
20
of Health and Human Services, acting through the Com-
21
missioner of Food and Drugs, shall finalize the draft guid-
22
ance. 
23
(c) WORKSHOP.—To assist entities developing pre-
24
ventive vaccines for fungal infections and coccidioidomy-
25
21:28 May 06, 2022
H7667
113 
•HR 7667 IH
cosis, the Secretary of Health and Human Services shall 
1
hold a public workshop. 
2
SEC. 705. ADVANCING QUALIFIED INFECTIOUS DISEASE 
3
PRODUCT INNOVATION. 
4
(a) IN GENERAL.—Section 505E of the Federal 
5
Food, Drug, and Cosmetic Act (21 U.S.C. 355f) is amend-
6
ed— 
7
(1) in subsection (c)— 
8
(A) in paragraph (2), by striking ‘‘or’’ at 
9
the end; 
10
(B) in paragraph (3), by striking the pe-
11
riod at the end and inserting ‘‘; or’’; and 
12
(C) by adding at the end the following: 
13
‘‘(4) an application pursuant to section 351(a) 
14
of the Public Health Service Act.’’; 
15
(2) in subsection (d)(1), by inserting ‘‘of this 
16
Act or section 351(a) of the Public Health Service 
17
Act’’ after ‘‘section 505(b)’’; and 
18
(3) by amending subsection (g) to read as fol-
19
lows: 
20
‘‘(g) QUALIFIED INFECTIOUS DISEASE PRODUCT.— 
21
The term ‘qualified infectious disease product’ means a 
22
drug, including an antibacterial or antifungal drug or a 
23
biological product, for human use that— 
24
21:28 May 06, 2022
H7667
114 
•HR 7667 IH
‘‘(1) acts directly on bacteria or fungi or on 
1
substances produced by such bacteria or fungi; and 
2
‘‘(2) is intended to treat a serious or life-threat-
3
ening infection, including such an infection caused 
4
by— 
5
‘‘(A) an antibacterial or antifungal resist-
6
ant pathogen, including novel or emerging in-
7
fectious pathogens; or 
8
‘‘(B) qualifying pathogens listed by the 
9
Secretary under subsection (f).’’. 
10
(b) PRIORITY REVIEW.—Section 524A(a) of the Fed-
11
eral Food, Drug, and Cosmetic Act (21 U.S.C. 360n–1(a)) 
12
is amended by inserting ‘‘of this Act or section 351(a) of 
13
the Public Health Service Act that requires clinical data 
14
(other than bioavailability studies) to demonstrate safety 
15
or effectiveness’’ before the period at the end. 
16
SEC. 706. ADVANCED MANUFACTURING TECHNOLOGIES 
17
DESIGNATION PILOT PROGRAM. 
18
Subchapter A of chapter V of the Federal Food, 
19
Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
20
ed by inserting after section 506J (21 U.S.C. 356j) the 
21
following: 
22
21:28 May 06, 2022
H7667
115 
•HR 7667 IH
‘‘SEC. 506K. ADVANCED MANUFACTURING TECHNOLOGIES 
1
DESIGNATION PILOT PROGRAM. 
2
‘‘(a) IN GENERAL.—Not later than 1 year after the 
3
date of enactment of this section, the Secretary shall ini-
4
tiate a pilot program under which persons may request 
5
designation of an advanced manufacturing technology as 
6
described in subsection (b). 
7
‘‘(b) DESIGNATION PROCESS.—The Secretary shall 
8
establish a process for the designation under this section 
9
of methods of manufacturing drugs, including biological 
10
products, and active pharmaceutical ingredients of such 
11
drugs, as advanced manufacturing technologies. A method 
12
of manufacturing, or a combination of manufacturing 
13
methods, is eligible for designation as an advanced manu-
14
facturing technology if such method or combination of 
15
methods incorporates a novel technology, or uses an estab-
16
lished technique or technology in a novel way, that will 
17
substantially improve the manufacturing process for a 
18
drug and maintain equivalent or provide superior drug 
19
quality, including by— 
20
‘‘(1) reducing development time for a drug 
21
using the designated manufacturing method; or 
22
‘‘(2) increasing or maintaining the supply of— 
23
‘‘(A) a drug that is described in section 
24
506C(a) and is intended to treat a serious or 
25
life-threatening condition; or 
26
21:28 May 06, 2022
H7667
116 
•HR 7667 IH
‘‘(B) a drug that is on the drug shortage 
1
list under section 506E. 
2
‘‘(c) EVALUATION AND DESIGNATION OF AN AD-
3
VANCED MANUFACTURING TECHNOLOGY.— 
4
‘‘(1) SUBMISSION.—A person who requests des-
5
ignation of a method of manufacturing as an ad-
6
vanced manufacturing technology under this section 
7
shall submit to the Secretary data or information 
8
demonstrating that the method of manufacturing 
9
meets the criteria described in subsection (b) in a 
10
particular context of use. The Secretary may facili-
11
tate the development and review of such data or in-
12
formation by— 
13
‘‘(A) providing timely advice to, and inter-
14
active communication with, such person regard-
15
ing the development of the method of manufac-
16
turing; and 
17
‘‘(B) involving senior managers and experi-
18
enced staff of the Food and Drug Administra-
19
tion, as appropriate, in a collaborative, cross- 
20
disciplinary review of the method of manufac-
21
turing, as applicable. 
22
‘‘(2) EVALUATION
AND
DESIGNATION.—Not 
23
later than 180 calendar days after the receipt of a 
24
request under paragraph (1), the Secretary shall de-
25
21:28 May 06, 2022
H7667
117 
•HR 7667 IH
termine whether to designate such method of manu-
1
facturing as an advanced manufacturing technology, 
2
in a particular context of use, based on the data and 
3
information submitted under paragraph (1) and the 
4
criteria described in subsection (b). 
5
‘‘(d) REVIEW
OF
ADVANCED
MANUFACTURING 
6
TECHNOLOGIES.—If the Secretary designates a method of 
7
manufacturing as an advanced manufacturing technology, 
8
the Secretary shall— 
9
‘‘(1) expedite the development and review of an 
10
application submitted under section 505 of this Act 
11
or section 351 of the Public Health Service Act, in-
12
cluding supplemental applications, for drugs that are 
13
manufactured using a designated advanced manufac-
14
turing technology and could help mitigate or prevent 
15
a shortage or improve manufacturing processes and 
16
maintain equivalent or provide superior drug quality, 
17
as described in subsection (b); and 
18
‘‘(2) allow the holder of an advanced technology 
19
designation, or a person authorized by the advanced 
20
manufacturing technology designation holder, to ref-
21
erence or rely upon, in an application submitted 
22
under section 505 of this Act or section 351 of the 
23
Public Health Service Act, including a supplemental 
24
application, data and information about the des-
25
21:28 May 06, 2022
H7667
118 
•HR 7667 IH
ignated advanced manufacturing technology for use 
1
in manufacturing drugs in the same context of use 
2
for which the designation was granted. 
3
‘‘(e) IMPLEMENTATION AND EVALUATION OF AD-
4
VANCED MANUFACTURING TECHNOLOGIES PILOT.— 
5
‘‘(1) PUBLIC
MEETING.—The Secretary shall 
6
publish in the Federal Register a notice of a public 
7
meeting, to be held not later than 180 days after the 
8
date of enactment of this section, to discuss, and ob-
9
tain input and recommendations from relevant 
10
stakeholders regarding— 
11
‘‘(A) the goals and scope of the pilot pro-
12
gram, and a suitable framework, procedures, 
13
and requirements for such program; and 
14
‘‘(B) ways in which the Food and Drug 
15
Administration will support the use of advanced 
16
manufacturing technologies and other innova-
17
tive manufacturing approaches for drugs. 
18
‘‘(2) PILOT PROGRAM GUIDANCE.— 
19
‘‘(A) IN GENERAL.—The Secretary shall— 
20
‘‘(i) not later than 180 days after the 
21
public meeting under paragraph (1), issue 
22
draft guidance regarding the goals and im-
23
plementation of the pilot program under 
24
this section; and 
25
21:28 May 06, 2022
H7667
119 
•HR 7667 IH
‘‘(ii) not later than 2 years after the 
1
date of enactment of this section, issue 
2
final guidance regarding the implementa-
3
tion of such program. 
4
‘‘(B) CONTENT.—The guidance described 
5
in subparagraph (A) shall address— 
6
‘‘(i) the process by which a person 
7
may request a designation under sub-
8
section (b); 
9
‘‘(ii) the data and information that a 
10
person requesting such a designation is re-
11
quired to submit under subsection (c), and 
12
how the Secretary intends to evaluate such 
13
submissions; 
14
‘‘(iii) the process to expedite the de-
15
velopment and review of applications under 
16
subsection (d); and 
17
‘‘(iv) the criteria described in sub-
18
section (b) for eligibility for such a des-
19
ignation. 
20
‘‘(3) REPORT.—Not later than 3 years after the 
21
date of enactment of this section and annually there-
22
after, the Secretary shall publish on the website of 
23
the Food and Drug Administration and submit to 
24
the Committee on Health, Education, Labor, and 
25
21:28 May 06, 2022
H7667
120 
•HR 7667 IH
Pensions of the Senate and the Committee on En-
1
ergy and Commerce of the House of Representatives 
2
a report containing a description and evaluation of 
3
the pilot program being conducted under this sec-
4
tion, including the types of innovative manufacturing 
5
approaches supported under the program. Such re-
6
port shall include the following: 
7
‘‘(A) The number of persons that have re-
8
quested designations and that have been grant-
9
ed designations. 
10
‘‘(B) The number of methods of manufac-
11
turing that have been the subject of designation 
12
requests and that have been granted designa-
13
tions. 
14
‘‘(C) The average number of calendar days 
15
for completion of evaluations under subsection 
16
(c)(2). 
17
‘‘(D) An analysis of the factors in data 
18
submissions that result in determinations to 
19
designate and not to designate after evaluation 
20
under subsection (c)(2). 
21
‘‘(E) The number of applications received 
22
under section 505 of this Act or section 351 of 
23
the Public Health Service Act, including supple-
24
mental applications, that have included an ad-
25
21:28 May 06, 2022
H7667
121 
•HR 7667 IH
vanced manufacturing technology designated 
1
under this section, and the number of such ap-
2
plications approved. 
3
‘‘(f) SUNSET.—The Secretary— 
4
‘‘(1) may not consider any requests for designa-
5
tion submitted under subsection (c) after October 1, 
6
2029; and 
7
‘‘(2) may continue all activities under this sec-
8
tion with respect to advanced manufacturing tech-
9
nologies that were designated pursuant to subsection 
10
(d) prior to such date, if the Secretary determines 
11
such activities are in the interest of the public 
12
health.’’. 
13
SEC. 707. PUBLIC WORKSHOP ON CELL AND GENE THERA-
14
PIES. 
15
Not later than 3 years after the date of the enact-
16
ment of this Act, the Secretary of Health and Human 
17
Services, acting through the Commissioner of Food and 
18
Drugs, shall convene a public workshop with relevant 
19
stakeholders to discuss best practices on generating sci-
20
entific data necessary to further facilitate the development 
21
of human cell-, tissue-, and cellular-based medical prod-
22
ucts, and the latest scientific information about such prod-
23
ucts. 
24
21:28 May 06, 2022
H7667
122 
•HR 7667 IH
SEC. 708. REAUTHORIZATION OF BEST PHARMACEUTICALS 
1
FOR CHILDREN. 
2
Section 409I(d)(1) of the Public Health Service Act 
3
(42 U.S.C. 284m) is amended by striking ‘‘2018 through 
4
2022’’ and inserting ‘‘2023 through 2027’’. 
5
SEC. 709. REAUTHORIZATION FOR HUMANITARIAN DEVICE 
6
EXEMPTION AND DEMONSTRATION GRANTS 
7
FOR IMPROVING PEDIATRIC AVAILABILITY. 
8
(a) HUMANITARIAN DEVICE EXEMPTION.—Section 
9
520(m)(6)(A)(iv) of the Federal Food, Drug, and Cos-
10
metic Act (21 U.S.C. 360j(m)(6)(A)(iv)) is amended by 
11
striking ‘‘2022’’ and inserting ‘‘2027’’. 
12
(b) PEDIATRIC MEDICAL DEVICE SAFETY AND IM-
13
PROVEMENT ACT.—Section 305(e) of the Pediatric Med-
14
ical Device Safety and Improvement Act (Public Law 
15
110–85) is amended by striking ‘‘2018 through 2022’’ and 
16
inserting ‘‘2023 through 2027’’. 
17
SEC. 710. REAUTHORIZATION OF PROVISION RELATED TO 
18
EXCLUSIVITY 
OF 
CERTAIN 
DRUGS 
CON-
19
TAINING SINGLE ENANTIOMERS. 
20
Section 505(u)(4) of the Federal Food, Drug, and 
21
Cosmetic Act (21 U.S.C. 355(u)(4)) is amended by strik-
22
ing ‘‘2022’’ and inserting ‘‘2027’’. 
23
21:28 May 06, 2022
H7667
123 
•HR 7667 IH
SEC. 711. REAUTHORIZATION OF THE CRITICAL PATH PUB-
1
LIC-PRIVATE PARTNERSHIP PROGRAM. 
2
Section 566(f) of the Federal Food, Drug, and Cos-
3
metic Act (21 U.S.C. 360bbb–5(f)) is amended by striking 
4
‘‘$6,000,000 for each of fiscal years 2018 through 2022’’ 
5
and inserting ‘‘$10,000,000 for each of fiscal years 2023 
6
through 2027’’. 
7
SEC. 712. REAUTHORIZATION OF ORPHAN DRUG GRANTS. 
8
Section 5 of the Orphan Drug Act (21 U.S.C. 360ee) 
9
is amended— 
10
(1) in subsection (a)— 
11
(A) by striking ‘‘and (3)’’ and inserting 
12
‘‘(3)’’; and 
13
(B) by inserting before the period at the 
14
end the following: ‘‘, and (4) developing regu-
15
latory science pertaining to the chemistry, man-
16
ufacturing, regulatory approval of, and controls 
17
of individualized medical products to treat indi-
18
viduals with rare diseases or conditions’’; and 
19
(2) in subsection (c), by striking ‘‘2018 through 
20
2022’’ and inserting ‘‘2023 through 2027’’. 
21
Subtitle B—Inspections 
22
SEC. 721. FACTORY INSPECTION. 
23
(a) IN GENERAL.—Section 704(a)(1) of the Federal 
24
Food, Drug, and Cosmetic Act (21 U.S.C. 374(a)(1)) is 
25
21:28 May 06, 2022
H7667
124 
•HR 7667 IH
amended by striking ‘‘restricted devices’’ each place it ap-
1
pears and inserting ‘‘devices’’. 
2
(b) RECORDS OR OTHER INFORMATION.— 
3
(1) ESTABLISHMENTS.—Section 704(a)(4)(A) 
4
of the Federal Food, Drug, and Cosmetic Act (21 
5
U.S.C. 374(a)(4)(A)) is amended— 
6
(A) by striking ‘‘an establishment that is 
7
engaged in the manufacture, preparation, prop-
8
agation, compounding, or processing of a drug’’ 
9
and inserting ‘‘an establishment that is engaged 
10
in the manufacture, preparation, propagation, 
11
compounding, or processing of a drug or device, 
12
or that is subject to inspection under paragraph 
13
5(C),’’; and 
14
(B) by inserting after ‘‘a sufficient descrip-
15
tion of the records requested’’ the following: 
16
‘‘and a rationale for requesting such records or 
17
other information in advance of, or in lieu of, 
18
an inspection’’. 
19
(2) GUIDANCE.— 
20
(A) 
IN
GENERAL.—The 
Secretary 
of 
21
Health and Human Services shall issue guid-
22
ance describing— 
23
(i) circumstances in which the Sec-
24
retary intends to issue requests for records 
25
21:28 May 06, 2022
H7667
125 
•HR 7667 IH
or other information in advance of, or in 
1
lieu of, an inspection under section 
2
704(a)(4) of the Federal Food, Drug, and 
3
Cosmetic Act, as amended by paragraph 
4
(1); 
5
(ii) processes for responding to such 
6
requests electronically or in physical form; 
7
and 
8
(iii) factors the Secretary intends to 
9
consider 
in 
evaluating 
whether 
such 
10
records and other information are provided 
11
within a reasonable timeframe, within rea-
12
sonable limits, and in a reasonable man-
13
ner, accounting for resource and other lim-
14
itations that may exist, including for small 
15
businesses. 
16
(B) TIMING.—The Secretary of Health 
17
and Human Services shall— 
18
(i) not later than 1 year after the date 
19
of enactment of this Act, issue draft guid-
20
ance under subparagraph (A); and 
21
(ii) not later than 1 year after the 
22
close of the comment period for such draft 
23
guidance, issue final guidance under sub-
24
paragraph (A). 
25
21:28 May 06, 2022
H7667
126 
•HR 7667 IH
(c) BIORESEARCH MONITORING INSPECTIONS.— 
1
(1) IN GENERAL.—Section 704(a) of the Fed-
2
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
3
374(a)) is amended by adding at the end the fol-
4
lowing: 
5
‘‘(5) BIORESEARCH MONITORING INSPECTIONS.— 
6
‘‘(A) IN GENERAL.—The Secretary may, to en-
7
sure the accuracy and reliability of studies and 
8
records or other information described in subpara-
9
graph (B) and to assess compliance with applicable 
10
requirements under this Act or the Public Health 
11
Service Act, enter sites and facilities specified in 
12
subparagraph (C) in order to inspect such records or 
13
other information. 
14
‘‘(B) INFORMATION
SUBJECT
TO
INSPEC-
15
TION.—An inspection under this paragraph shall ex-
16
tend to all records and other information related to 
17
the studies and submissions described in subpara-
18
graph (E), including records and information related 
19
to the conduct, results, and analyses of, and the pro-
20
tection of human and animal trial participants par-
21
ticipating in, such studies. 
22
‘‘(C) SITES AND FACILITIES SUBJECT TO IN-
23
SPECTION.— 
24
21:28 May 06, 2022
H7667
127 
•HR 7667 IH
‘‘(i) SITES AND FACILITIES DESCRIBED.— 
1
The sites and facilities subject to inspection by 
2
the Secretary under this paragraph are those 
3
owned or operated by a person described in 
4
clause (ii) and which are (or were) utilized by 
5
such person in connection with— 
6
‘‘(I) developing an application or other 
7
submission to the Secretary under this Act 
8
or the Public Health Service Act related to 
9
marketing authorization for a product de-
10
scribed in paragraph (1); 
11
‘‘(II) preparing, conducting, or ana-
12
lyzing the results of a study described in 
13
subparagraph (E); or 
14
‘‘(III) holding any records or other in-
15
formation described in subparagraph (B). 
16
‘‘(ii) PERSONS DESCRIBED.—A person de-
17
scribed in this clause is— 
18
‘‘(I) the sponsor of an application or 
19
submission specified in clause (i)(I); 
20
‘‘(II) a person engaged in any activity 
21
described in clause (i) on behalf of such a 
22
sponsor, through a contract, grant, or 
23
other business arrangement with such 
24
sponsor; 
25
21:28 May 06, 2022
H7667
128 
•HR 7667 IH
‘‘(III) an institutional review board, 
1
or other individual or entity, engaged by 
2
contract, grant, or other business arrange-
3
ment with a nonsponsor in preparing, col-
4
lecting, or analyzing records or other infor-
5
mation described in subparagraph (B); or 
6
‘‘(IV) any person not otherwise de-
7
scribed in this clause that conducts, or has 
8
conducted, a study described in subpara-
9
graph (E) yielding records or other infor-
10
mation described in subparagraph (B). 
11
‘‘(D) CONDITIONS OF INSPECTION.— 
12
‘‘(i) ACCESS TO INFORMATION SUBJECT TO 
13
INSPECTION.—Subject to clause (ii), an entity 
14
that owns or operates any site or facility sub-
15
ject to inspection under this paragraph shall 
16
provide the Secretary with access to records 
17
and other information described in subpara-
18
graph (B) that is held by or under the control 
19
of such entity, including— 
20
‘‘(I) permitting the Secretary to 
21
record or copy such information for pur-
22
poses of this paragraph; 
23
‘‘(II) providing the Secretary with ac-
24
cess to any electronic information system 
25
21:28 May 06, 2022
H7667
129 
•HR 7667 IH
utilized by such entity to hold, process, 
1
analyze, or transfer any records or other 
2
information described in subparagraph 
3
(B); and 
4
‘‘(III) permitting the Secretary to in-
5
spect the facilities, equipment, written pro-
6
cedures, processes, and conditions through 
7
which records or other information de-
8
scribed in subparagraph (B) is or was gen-
9
erated, held, processed, analyzed, or trans-
10
ferred. 
11
‘‘(ii) NO
EFFECT
ON
APPLICABILITY
OF 
12
PROVISIONS FOR PROTECTION OF PROPRIETARY 
13
INFORMATION OR TRADE SECRETS.—Nothing in 
14
clause (i) shall negate, supersede, or otherwise 
15
affect the applicability of provisions, under this 
16
or any other Act, preventing or limiting the dis-
17
closure of confidential commercial information 
18
or other information considered proprietary or 
19
trade secret. 
20
‘‘(iii) 
REASONABLENESS
OF
INSPEC-
21
TIONS.—An inspection under this paragraph 
22
shall be conducted at reasonable times and 
23
within reasonable limits and in a reasonable 
24
manner. 
25
21:28 May 06, 2022
H7667
130 
•HR 7667 IH
‘‘(E) 
STUDIES
AND
SUBMISSIONS
DE-
1
SCRIBED.—The studies and submissions described in 
2
this subparagraph are each of the following: 
3
‘‘(i) Clinical and nonclinical studies sub-
4
mitted to the Secretary in support of, or other-
5
wise related to, applications and other submis-
6
sions to the Secretary under this Act or the 
7
Public Health Service Act for marketing au-
8
thorization of a product described in paragraph 
9
(1). 
10
‘‘(ii) Postmarket safety activities conducted 
11
under this Act or the Public Health Service 
12
Act. 
13
‘‘(iii) Any other clinical investigation of— 
14
‘‘(I) a drug subject to section 505 or 
15
512 of this Act or section 351 of the Pub-
16
lic Health Service Act; or 
17
‘‘(II) a device subject to section 
18
520(g). 
19
‘‘(iv) Any other submissions made under 
20
this Act or the Public Health Service Act with 
21
respect to which the Secretary determines an 
22
inspection under this paragraph is warranted in 
23
the interest of public health. 
24
21:28 May 06, 2022
H7667
131 
•HR 7667 IH
‘‘(F) CLARIFICATION.—This paragraph clarifies 
1
the authority of the Secretary to conduct inspections 
2
of the type described in this paragraph and shall not 
3
be construed as a basis for inferring that, prior to 
4
the date of enactment of this paragraph, the Sec-
5
retary lacked the authority to conduct such inspec-
6
tions, including under this Act or the Public Health 
7
Service Act.’’. 
8
(2) REVIEW
OF
PROCESSES
AND
PRACTICES; 
9
GUIDANCE FOR INDUSTRY.— 
10
(A) 
IN
GENERAL.—The 
Secretary 
of 
11
Health and Human Services shall— 
12
(i) review processes and practices in 
13
effect as of the date of enactment of this 
14
Act applicable to inspections of foreign and 
15
domestic sites and facilities described in 
16
subparagraph (C)(i) of section 704(a)(5) of 
17
the Federal Food, Drug, and Cosmetic 
18
Act, as added by paragraph (1); and 
19
(ii) evaluate whether any updates are 
20
needed to facilitate the consistency of such 
21
processes and practices. 
22
(B) GUIDANCE.— 
23
(i) IN
GENERAL.—The Secretary of 
24
Health and Human Services shall issue 
25
21:28 May 06, 2022
H7667
132 
•HR 7667 IH
guidance describing the processes and 
1
practices applicable to inspections of sites 
2
and facilities described in subparagraph 
3
(C)(i) of section 704(a)(5) of the Federal 
4
Food, Drug, and Cosmetic Act, as added 
5
by paragraph (1), including with respect to 
6
the types of records and information re-
7
quired to be provided, best practices for 
8
communication between the Food and 
9
Drug Administration and industry in ad-
10
vance of or during an inspection or request 
11
for records or other information, and other 
12
inspections-related conduct, to the extent 
13
not specified in existing publicly available 
14
Food and Drug Administration guides and 
15
manuals for such inspections. 
16
(ii) TIMING.—The Secretary of Health 
17
and Human Services shall— 
18
(I) not later than 18 months 
19
after the date of enactment of this 
20
Act, issue draft guidance under clause 
21
(i); and 
22
(II) not later than 1 year after 
23
the close of the public comment period 
24
21:28 May 06, 2022
H7667
133 
•HR 7667 IH
for such draft guidance, issue final 
1
guidance under clause (i). 
2
SEC. 722. USES OF CERTAIN EVIDENCE. 
3
Section 703 of the of the Federal Food, Drug, and 
4
Cosmetic Act (21 U.S.C. 373) is amended by adding at 
5
the end the following: 
6
‘‘(c) APPLICABILITY.—The limitations on the Sec-
7
retary’s use of evidence obtained under this section, or any 
8
evidence which is directly or indirectly derived from such 
9
evidence, in a criminal prosecution of the person from 
10
whom such evidence was obtained shall not apply to evi-
11
dence obtained under authorities other than this section, 
12
unless such limitations are specifically incorporated by ref-
13
erence in such other authorities.’’. 
14
SEC. 723. IMPROVING FDA INSPECTIONS. 
15
(a) RISK FACTORS FOR ESTABLISHMENTS.—Section 
16
510(h)(4) of the Federal Food, Drug, and Cosmetic Act 
17
(21 U.S.C. 360(h)(4)) is amended— 
18
(1) by redesignating subparagraph (F) as sub-
19
paragraph (G); and 
20
(2) by inserting after subparagraph (E) the fol-
21
lowing: 
22
‘‘(F) The compliance history of establish-
23
ments in the country or region in which the es-
24
tablishment is located that are subject to regu-
25
21:28 May 06, 2022
H7667
134 
•HR 7667 IH
lation under this Act, including the history of 
1
violations related to products exported from 
2
such country or region that are subject to such 
3
regulation.’’. 
4
(b) USE OF RECORDS.—Section 704(a)(4) of the 
5
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 374) 
6
is amended— 
7
(1) by redesignating subparagraph (C) as sub-
8
paragraph (D); and 
9
(2) by inserting after subparagraph (B) the fol-
10
lowing: 
11
‘‘(C) The Secretary may rely on any records or other 
12
information that the Secretary may inspect under this sec-
13
tion to satisfy requirements that may pertain to a 
14
preapproval or risk-based surveillance inspection, or to re-
15
solve deficiencies found in such inspections, if applicable 
16
and appropriate.’’. 
17
(c) RECOGNITION OF FOREIGN GOVERNMENT IN-
18
SPECTIONS.—Section 809 of the Federal Food, Drug, and 
19
Cosmetic Act (21 U.S.C. 384e) is amended— 
20
(1) 
in 
subsection 
(a)(1), 
by 
inserting 
21
‘‘preapproval or’’ before ‘‘risk-based inspections’’; 
22
and 
23
(2) by adding at the end the following: 
24
‘‘(c) PERIODIC REVIEW.— 
25
21:28 May 06, 2022
H7667
135 
•HR 7667 IH
‘‘(1) IN GENERAL.—Beginning not later than 1 
1
year after the date of the enactment of the Food 
2
and Drug Amendments of 2022 the Secretary shall 
3
periodically assess whether additional arrangements 
4
and agreements with a foreign government or an 
5
agency of a foreign government, as allowed under 
6
this section, are appropriate. 
7
‘‘(2) REPORTS TO CONGRESS.—Beginning not 
8
later than 4 years after the date of the enactment 
9
of the Food and Drug Amendments of 2022, and 
10
every 4 years thereafter, the Secretary shall submit 
11
to the Committee on Energy and Commerce of the 
12
House of Representatives and the Committee on 
13
Health, Education, Labor, and Pensions a report de-
14
scribing the findings and conclusions of each review 
15
conducted under paragraph (1).’’. 
16
SEC. 724. GAO REPORT ON INSPECTIONS OF FOREIGN ES-
17
TABLISHMENTS MANUFACTURING DRUGS. 
18
(a) IN GENERAL.—Not later than 18 months after 
19
the date of the enactment of this Act, the Comptroller 
20
General of the United States shall submit to the Com-
21
mittee on Energy and Commerce of the House of Rep-
22
resentatives and the Committee on Health, Education, 
23
Labor and Pensions of the Senate a report on inspections 
24
conducted by— 
25
21:28 May 06, 2022
H7667
136 
•HR 7667 IH
(1) the Secretary of Health and Human Serv-
1
ices (in this section referred to as the ‘‘Secretary’’) 
2
of foreign establishments pursuant to subsections (h) 
3
and (i) of section 510 and 704 of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 360, 374); or 
5
(2) a foreign government or an agency of a for-
6
eign government pursuant to section 809 of such 
7
Act (21 U.S.C. 384e). 
8
(b) CONTENTS.—The report conducted under sub-
9
section (a) shall include— 
10
(1) what alternative tools, including remote in-
11
spections or remote evaluations, other countries are 
12
utilizing to facilitate inspections of foreign establish-
13
ments; 
14
(2) how frequently trusted foreign regulators 
15
conduct inspections of foreign facilities that could be 
16
useful to the Food and Drug Administration to re-
17
view in lieu of its own inspections; 
18
(3) how frequently and under what cir-
19
cumstances, including for what types of inspections, 
20
the Secretary utilizes existing agreements or ar-
21
rangements under section 809 of the Federal Food, 
22
Drug, and Cosmetic Act (21 U.S.C. 384e) and 
23
whether the use of such agreements could be appro-
24
priately expanded; 
25
21:28 May 06, 2022
H7667
137 
•HR 7667 IH
(4) whether the Secretary has accepted reports 
1
of inspections of facilities in China and India con-
2
ducted by entities with which they have entered into 
3
such an agreement or arrangement; 
4
(5) what additional foreign governments or 
5
agencies of foreign governments the Secretary has 
6
considered entering into a mutual recognition agree-
7
ment with and, if applicable, reasons why the Sec-
8
retary declined to enter into a mutual recognition 
9
agreement with such foreign governments or agen-
10
cies; 
11
(6) what tools, if any, the Secretary used to fa-
12
cilitate inspections of domestic facilities that could 
13
also be effectively utilized to appropriately inspect 
14
foreign facilities; 
15
(7) what steps the Secretary has taken to iden-
16
tify and evaluate tools and strategies the Secretary 
17
may use to continue oversight with respect to inspec-
18
tions when in-person inspections are disrupted; 
19
(8) how the Secretary is considering incor-
20
porating alternative tools into the inspection activi-
21
ties conducted pursuant to the Federal Food, Drug, 
22
and Cosmetic Act (21 U.S.C. 321 et seq.); and 
23
(9) what steps the Secretary has taken to iden-
24
tify and evaluate how the Secretary may use alter-
25
21:28 May 06, 2022
H7667
138 
•HR 7667 IH
native tools to address workforce shortages to carry 
1
out such inspection activities. 
2
SEC. 725. UNANNOUNCED FOREIGN FACILITY INSPECTIONS 
3
PILOT PROGRAM. 
4
(a) IN GENERAL.—The Secretary of Health and 
5
Human Services (referred to in this section as the ‘‘Sec-
6
retary’’) shall conduct a pilot program under which the 
7
Secretary increases the conduct of unannounced surveil-
8
lance inspections of foreign human drug establishments 
9
and evaluates the differences between such inspections of 
10
domestic and foreign human drug establishments, includ-
11
ing the impact of announcing inspections to persons who 
12
own or operate foreign human drug establishments in ad-
13
vance of an inspection. Such pilot program shall evalu-
14
ate— 
15
(1) differences in the number and type of viola-
16
tions of section 501(a)(2)(B) of the Federal Food, 
17
Drug, and Cosmetic Act (21 U.S.C. 351(a)(2)(B)) 
18
identified during unannounced and announced in-
19
spections of foreign human drug establishments and 
20
any other significant differences between each type 
21
of inspection; 
22
(2) costs and benefits associated with con-
23
ducting announced and unannounced inspections of 
24
foreign human drug establishments; 
25
21:28 May 06, 2022
H7667
139 
•HR 7667 IH
(3) barriers to conducting unannounced inspec-
1
tions of foreign human drug establishments and any 
2
challenges to achieving parity between domestic and 
3
foreign human drug establishment inspections; and 
4
(4) approaches for mitigating any negative ef-
5
fects of conducting announced inspections of foreign 
6
human drug establishments. 
7
(b) PILOT PROGRAM SCOPE.—The inspections evalu-
8
ated under the pilot program under this section shall be 
9
routine surveillance inspections and shall not include in-
10
spections conducted as part of the Secretary’s evaluation 
11
of a request for approval to market a drug submitted 
12
under the Federal Food, Drug, and Cosmetic Act (21 
13
U.S.C. 301 et seq.) or the Public Health Service Act (42 
14
U.S.C. 201 et seq.). 
15
(c) PILOT PROGRAM INITIATION.—The Secretary 
16
shall initiate the pilot program under this section not later 
17
than 180 days after the date of enactment of this Act. 
18
(d) REPORT.—The Secretary shall, not later than 
19
180 days following the completion of the pilot program 
20
under this section, make available on the website of the 
21
Food and Drug Administration a final report on the pilot 
22
program under this section, including— 
23
(1) findings and any associated recommenda-
24
tions with respect to the evaluation under subsection 
25
21:28 May 06, 2022
H7667
140 
•HR 7667 IH
(a), including any recommendations to address iden-
1
tified barriers to conducting unannounced inspec-
2
tions of foreign human drug establishments; 
3
(2) findings and any associated recommenda-
4
tions regarding how the Secretary may achieve par-
5
ity between domestic and foreign human drug in-
6
spections; and 
7
(3) the number of unannounced inspections 
8
during the pilot program that would not be unan-
9
nounced under existing practices. 
10
SEC. 726. REAUTHORIZATION OF INSPECTION PROGRAM. 
11
Section 704(g)(11) of the Federal Food, Drug, and 
12
Cosmetic Act (21 U.S.C. 374(g)(11)) is amended by strik-
13
ing ‘‘2022’’ and inserting ‘‘2027’’. 
14
SEC. 727. ENHANCING INTRA-AGENCY COORDINATION AND 
15
PUBLIC HEALTH ASSESSMENT WITH REGARD 
16
TO COMPLIANCE ACTIVITIES. 
17
(a) COORDINATION.—Section 506D of the Federal 
18
Food, Drug, and Cosmetic Act (21 U.S.C. 356d) is 
19
amended by adding at the end the following: 
20
‘‘(g) COORDINATION.—The Secretary shall ensure 
21
timely and effective internal coordination and alignment 
22
among the field investigators of the Food and Drug Ad-
23
ministration and the staff of the Center for Drug Evalua-
24
21:28 May 06, 2022
H7667
141 
•HR 7667 IH
tion and Research’s Office of Compliance and Drug Short-
1
age Program regarding— 
2
‘‘(1) the reviews of reports shared pursuant to 
3
section 704(b)(2); and 
4
‘‘(2) any feedback or corrective or preventive 
5
actions in response to such reports.’’. 
6
(b) REPORTING.— 
7
(1) IN GENERAL.—Section 506C–1(a)(2) of the 
8
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
9
356c–1(a)(2)) is amended to read as follows: 
10
‘‘(2)(A) describes the communication between 
11
the field investigators of the Food and Drug Admin-
12
istration and the staff of the Center for Drug Eval-
13
uation and Research’s Office of Compliance and 
14
Drug Shortage Program, including the Food and 
15
Drug Administration’s procedures for enabling and 
16
ensuring such communication; 
17
‘‘(B) provides the number of reports described 
18
in section 704(b)(2) that were required to be sent to 
19
the appropriate offices of the Food and Drug Ad-
20
ministration and the number of such reports that 
21
were sent; and 
22
‘‘(C) describes the coordination and alignment 
23
activities undertaken pursuant to section 506D(g);’’. 
24
21:28 May 06, 2022
H7667
142 
•HR 7667 IH
(2) APPLICABILITY.—The amendment made by 
1
paragraph (1) shall apply with respect to reports 
2
submitted on or after March 31, 2023. 
3
SEC. 728. REPORTING OF MUTUAL RECOGNITION AGREE-
4
MENTS FOR INSPECTIONS AND REVIEW AC-
5
TIVITIES. 
6
(a) IN GENERAL.—Not later than December 31, 
7
2022, and annually thereafter, the Secretary of Health 
8
and Human Services (referred to in this section as the 
9
‘‘Secretary’’) shall publish a report on the public website 
10
of the Food and Drug Administration on the utilization 
11
of agreements entered into pursuant to section 809 of the 
12
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384e) 
13
or otherwise entered into by the Secretary in the previous 
14
fiscal year to recognize inspections between drug regu-
15
latory authorities across countries and international re-
16
gions with analogous review criteria to the Food and Drug 
17
Administration, such as the Pharmaceutical Inspection 
18
Co-Operation Scheme, the Mutual Recognition Agreement 
19
with the European Union, and the Australia-Canada- 
20
Singapore-Switzerland Consortium. 
21
(b) CONTENT.—The report under subsection (a) shall 
22
include each of the following: 
23
(1) The total number of establishments that are 
24
registered under section 510(i) of the Federal Food, 
25
21:28 May 06, 2022
H7667
143 
•HR 7667 IH
Drug, and Cosmetic Act (21 U.S.C. 360(i)), and the 
1
number of such establishments in each region of in-
2
terest. 
3
(2) The total number of inspections conducted 
4
at establishments described in paragraph (1), 
5
disaggregated by inspections conducted— 
6
(A) pursuant to an agreement or other rec-
7
ognition described in subsection (a); and 
8
(B) by employees or contractors of the 
9
Food and Drug Administration. 
10
(3) Of the inspections described in paragraph 
11
(2), the total number of inspections in each region 
12
of interest. 
13
(4) Of the inspections in each region of interest 
14
reported pursuant to paragraph (3), the number of 
15
inspections in each FDA inspection category. 
16
(5) Of the number of inspections reported 
17
under each of paragraphs (3) and (4)— 
18
(A) the number of inspections which have 
19
been conducted pursuant to an agreement or 
20
other recognition described in subsection (a); 
21
and 
22
(B) the number of inspections which have 
23
been conducted by employees or contractors of 
24
the Food and Drug Administration. 
25
21:28 May 06, 2022
H7667
144 
•HR 7667 IH
(c) DEFINITIONS.—In this subsection: 
1
(1) FDA INSPECTION
CATEGORY.—The term 
2
‘‘FDA inspection category’’ means the following in-
3
spection categories: 
4
(A) Inspections to support approvals of 
5
changes to the manufacturing process of drugs 
6
approved under section 505 of the Federal 
7
Food, Drug, and Cosmetic Act (21 U.S.C. 355) 
8
or section 351 of the Public Health Service Act 
9
(42 U.S.C. 262). 
10
(B) Surveillance inspections. 
11
(C) For-cause inspections. 
12
(2) REGION OF INTEREST.—The term ‘‘region 
13
of interest’’ means China, India, the European 
14
Union, and any other geographic region as the Sec-
15
retary determines appropriate. 
16
SEC. 729. ENHANCING TRANSPARENCY OF DRUG FACILITY 
17
INSPECTION TIMELINES. 
18
Section 902 of the FDA Reauthorization Act of 2017 
19
(21 U.S.C. 355 note) is amended to read as follows: 
20
‘‘SEC. 902. ANNUAL REPORT ON INSPECTIONS. 
21
‘‘Not later than 120 days after the end of each fiscal 
22
year, the Secretary of Health and Human Services shall 
23
post on the public website of the Food and Drug Adminis-
24
tration information related to inspections of facilities, in-
25
21:28 May 06, 2022
H7667
145 
•HR 7667 IH
cluding inspections that are necessary for approval of a 
1
drug under subsection (c) or (j) of section 505 of the Fed-
2
eral Food, Drug, and Cosmetic Act (21 U.S.C. 355), ap-
3
proval of a device under section 515 of such Act (21 
4
U.S.C. 360e), or clearance of a device under section 
5
510(k) of such Act (21 U.S.C. 360(k)) that were con-
6
ducted during the previous fiscal year. Such information 
7
shall include the following: 
8
‘‘(1) The median time following a request from 
9
staff of the Food and Drug Administration review-
10
ing an application or report to the beginning of the 
11
inspection, including— 
12
‘‘(A) the median time for drugs described 
13
in section 505(j)(11)(A)(i) of the Federal Food, 
14
Drug, 
and 
Cosmetic 
Act 
(21 
U.S.C. 
15
355(j)(11)(A)(i)); 
16
‘‘(B) the median time for drugs described 
17
in section 506C(a) of such Act (21 U.S.C. 
18
356c(a)) only; and 
19
‘‘(C) the median time for drugs on the 
20
drug shortage list in effect under section 506E 
21
of such Act (21 U.S.C. 356f). 
22
‘‘(2) The median time from the issuance of a 
23
report pursuant to section 704(b) of such Act (21 
24
U.S.C. 374(b)) to the sending of a warning letter, 
25
21:28 May 06, 2022
H7667
146 
•HR 7667 IH
issuance of an import alert, or holding of a regu-
1
latory meeting for inspections for which the Sec-
2
retary concluded that regulatory or enforcement ac-
3
tion was indicated, including the median time for 
4
each category of drugs listed in subparagraphs (A) 
5
through (C) of paragraph (1). 
6
‘‘(3) The median time from the sending of a 
7
warning letter, issuance of an import alert, or hold-
8
ing of a regulatory meeting to resolution of the ac-
9
tions indicated to address the conditions or practices 
10
observed during an inspection. 
11
‘‘(4) The number of facilities that were unable 
12
to implement requested corrective or preventive ac-
13
tions following a report pursuant to such section 
14
704(b), resulting in a withhold recommendation, in-
15
cluding the number of such times for each category 
16
of drugs listed in subparagraphs (A) through (C) of 
17
paragraph (1).’’. 
18
21:28 May 06, 2022
H7667
147 
•HR 7667 IH
TITLE 
VIII—TRANSPARENCY, 
1
PROGRAM 
INTEGRITY, 
AND 
2
REGULATORY 
IMPROVE-
3
MENTS 
4
SEC. 801. PROMPT REPORTS OF MARKETING STATUS BY 
5
HOLDERS OF APPROVED APPLICATIONS FOR 
6
BIOLOGICAL PRODUCTS. 
7
(a) IN GENERAL.—Section 506I of the Federal Food, 
8
Drug, and Cosmetic Act (21 U.S.C. 356i) is amended— 
9
(1) in subsection (a)— 
10
(A) in the matter preceding paragraph (1), 
11
by striking ‘‘The holder of an application ap-
12
proved under subsection (c) or (j) of section 
13
505’’ and inserting ‘‘The holder of an applica-
14
tion approved under subsection (c) or (j) of sec-
15
tion 505 of this Act or subsection (a) or (k) of 
16
section 351 of the Public Health Service Act’’; 
17
(B) in paragraph (2), by striking ‘‘estab-
18
lished name’’ and inserting ‘‘established name 
19
(for biological products, by proper name)’’; and 
20
(C) in paragraph (3), by striking ‘‘or ab-
21
breviated application number’’ and inserting ‘‘, 
22
abbreviated application number, or biologics li-
23
cense application number’’; and 
24
(2) in subsection (b)— 
25
21:28 May 06, 2022
H7667
148 
•HR 7667 IH
(A) in the matter preceding paragraph (1), 
1
by striking ‘‘The holder of an application ap-
2
proved under subsection (c) or (j)’’ and insert-
3
ing ‘‘The holder of an application approved 
4
under subsection (c) or (j) of section 505 of 
5
this Act or subsection (a) or (k) of section 351 
6
of the Public Health Service Act’’; 
7
(B) in paragraph (1), by striking ‘‘estab-
8
lished name’’ and inserting ‘‘established name 
9
(for biological products, by proper name)’’; and 
10
(C) in paragraph (2), by striking ‘‘or ab-
11
breviated application number’’ and inserting ‘‘, 
12
abbreviated application number, or biologics li-
13
cense application number’’. 
14
(b) ADDITIONAL ONE-TIME REPORT.—Subsection 
15
(c) of section 506I of the Federal Food, Drug, and Cos-
16
metic Act (21 U.S.C. 356i) is amended to read as follows: 
17
‘‘(c) ADDITIONAL ONE-TIME REPORT.—Within 180 
18
days of the date of enactment of the Food and Drug 
19
Amendments of 2022, all holders of applications approved 
20
under subsection (a) or (k) of section 351 of the Public 
21
Health Service Act shall review the information in the list 
22
published under section 351(k)(9)(A) and shall submit a 
23
written notice to the Secretary— 
24
21:28 May 06, 2022
H7667
149 
•HR 7667 IH
‘‘(1) stating that all of the application holder’s 
1
biological products in the list published under sec-
2
tion 351(k)(9)(a) that are not listed as discontinued 
3
are available for sale; or 
4
‘‘(2) including the information required pursu-
5
ant to subsection (a) or (b), as applicable, for each 
6
of the application holder’s biological products that 
7
are in the list published under section 351(k)(9)(a) 
8
and not listed as discontinued, but have been discon-
9
tinued from sale or never have been available for 
10
sale.’’. 
11
(c) PURPLE BOOK.—Section 506I of the Federal 
12
Food, Drug, and Cosmetic Act (21 U.S.C. 356i) is amend-
13
ed— 
14
(1) by striking subsection (d) and inserting the 
15
following: 
16
‘‘(d) FAILURE TO MEET REQUIREMENTS.—If a hold-
17
er of an approved application fails to submit the informa-
18
tion required under subsection (a), (b), or (c), the Sec-
19
retary may— 
20
‘‘(1) move the application holder’s drugs from 
21
the active section of the list published under section 
22
505(j)(7)(A) to the discontinued section of the list, 
23
except that the Secretary shall remove from the list 
24
in accordance with section 505(j)(7)(C) drugs the 
25
21:28 May 06, 2022
H7667
150 
•HR 7667 IH
Secretary determines have been withdrawn from sale 
1
for reasons of safety of effectiveness; and 
2
‘‘(2) identify the application holder’s biological 
3
products as discontinued in the list published under 
4
section 351(k)(9)(A) of the Public Health Service 
5
Act, except that the Secretary shall remove from the 
6
list in accordance with section 351(k)(9)(B) of such 
7
Act biological products for which the license has 
8
been revoked or suspended for reasons of safety, pu-
9
rity, or potency.’’; and 
10
(2) in subsection (e)— 
11
(A) by inserting after the first sentence the 
12
following: ‘‘The Secretary shall update the list 
13
published under section 351(k)(9)(A) of the 
14
Public Health Service Act based on information 
15
provided under subsections (a), (b), and (c) by 
16
identifying as discontinued biological products 
17
that are not available for sale, except that bio-
18
logical products for which the license has been 
19
revoked or suspended for safety, purity, or po-
20
tency reasons shall be removed from the list in 
21
accordance with section 351(k)(9)(B) of the 
22
Public Health Service Act.’’; 
23
21:28 May 06, 2022
H7667
151 
•HR 7667 IH
(B) by striking ‘‘monthly updates to the 
1
list’’ and inserting ‘‘monthly updates to the lists 
2
referred to in the preceding sentences’’; and 
3
(C) by striking ‘‘and shall update the list 
4
based on’’ and inserting ‘‘and shall update such 
5
lists based on’’. 
6
(d) TECHNICAL CORRECTIONS.—Section 506I(e) of 
7
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
8
356i(e)) is amended— 
9
(1) by striking ‘‘subsection 505(j)(7)(A)’’ and 
10
inserting ‘‘section 505(j)(7)(A)’’; and 
11
(2) by striking ‘‘subsection 505(j)(7)(C)’’ and 
12
inserting ‘‘section 505(j)(7)(C)’’. 
13
SEC. 802. ENCOURAGING BLOOD DONATION. 
14
Section 3003 of the 21st Century Cures Act (21 
15
U.S.C. 360bbb–8c note) is amended to read as follows: 
16
‘‘SEC. 3003. STREAMLINING PATIENT AND BLOOD DONOR 
17
INPUT. 
18
‘‘Chapter 35 of title 44, United States Code, shall 
19
not apply to the collection of information to which a re-
20
sponse is voluntary, to solicit— 
21
‘‘(1) the views and perspectives of patients 
22
under section 569C of the Federal Food, Drug, and 
23
Cosmetic Act (21 U.S.C. 360bbb–8c) (as amended 
24
by section 3001) or section 3002; or 
25
21:28 May 06, 2022
H7667
152 
•HR 7667 IH
‘‘(2) information from blood donors or potential 
1
blood donors to support the development of rec-
2
ommendations by the Secretary of Health and 
3
Human Services concerning blood donation.’’. 
4
SEC. 803. REGULATION OF CERTAIN PRODUCTS AS DRUGS. 
5
Section 503 of the Federal Food, Drug, and Cosmetic 
6
Act (21 U.S.C. 353) is amended by adding at the end the 
7
following: 
8
‘‘(h)(1) Any contrast agent, radioactive drug, or OTC 
9
monograph drug shall be deemed to be a drug under sec-
10
tion 201(g) and not a device under section 201(h). 
11
‘‘(2) For purposes of this subsection: 
12
‘‘(A) The term ‘contrast agent’ means a drug 
13
that is intended for use in conjunction with an appli-
14
cable medical imaging device, and— 
15
‘‘(i) is a diagnostic radiopharmaceutical, as 
16
defined in sections 315.2 and 601.31 of title 
17
21, Code of Federal Regulations (or any suc-
18
cessor regulations); or 
19
‘‘(ii) is a diagnostic agent that improves 
20
the visualization of structure or function within 
21
the body by increasing the relative difference in 
22
signal intensity within the target tissue, struc-
23
ture, or fluid. 
24
21:28 May 06, 2022
H7667
153 
•HR 7667 IH
‘‘(B) The term ‘radioactive drug’ has the mean-
1
ing given such term in section 310.3(n) of title 21, 
2
Code of Federal Regulations (or any successor regu-
3
lations), except that such term does not include— 
4
‘‘(i) an implant or article similar to an im-
5
plant; 
6
‘‘(ii) an article that applies radiation from 
7
outside of the body; or 
8
‘‘(iii) the radiation source of an article de-
9
scribed in (i) or (ii). 
10
‘‘(C) The term ‘OTC monograph drug’ has the 
11
meaning given such term in section 744L. 
12
‘‘(3) Nothing in this subsection shall be construed as 
13
allowing for the classification a product as a drug (as de-
14
fined in section 201(g)) if such product— 
15
‘‘(A) is not described in paragraph (1); and 
16
‘‘(B) meets the definition of a device under sec-
17
tion 201(h).’’. 
18
SEC. 804. POSTAPPROVAL STUDIES AND PROGRAM INTEG-
19
RITY FOR ACCELERATED APPROVAL DRUGS. 
20
(a) IN GENERAL.—Section 506(c) of the Federal 
21
Food, Drug, and Cosmetic Act (21 U.S.C. 356(c)) is 
22
amended— 
23
(1) by striking paragraph (2) and inserting the 
24
following: 
25
21:28 May 06, 2022
H7667
154 
•HR 7667 IH
‘‘(2) LIMITATION.— 
1
‘‘(A) IN GENERAL.—Approval of a product 
2
under this subsection may be subject to 1 or 
3
both of the following requirements: 
4
‘‘(i) That the sponsor conduct an ap-
5
propriate postapproval study or studies 
6
(which may be augmented or supported by 
7
real world evidence) to verify and describe 
8
the predicted effect on irreversible mor-
9
bidity or mortality or other clinical benefit. 
10
‘‘(ii) That the sponsor submit copies 
11
of all promotional materials related to the 
12
product during the preapproval review pe-
13
riod and, following approval and for such 
14
period thereafter as the Secretary deter-
15
mines to be appropriate, at least 30 days 
16
prior to dissemination of the materials. 
17
‘‘(B) STUDIES
NOT
REQUIRED.—If the 
18
Secretary does not require that the sponsor of 
19
a product approved under accelerated approval 
20
conduct a postapproval study under this para-
21
graph, the Secretary shall publish on the 
22
website of the Food and Drug Administration 
23
the rationale for why such study is not appro-
24
priate or necessary. 
25
21:28 May 06, 2022
H7667
155 
•HR 7667 IH
‘‘(C) 
STUDY
CONDI-
1
TIONS.—Not later than the time of approval of 
2
a product under accelerated approval, the Sec-
3
retary shall specify the conditions for a post-
4
approval study or studies required to be con-
5
ducted under this paragraph with respect to 
6
such product, which may include enrollment 
7
targets, the study protocol, and milestones, in-
8
cluding the target date of study completion. 
9
‘‘(D) 
STUDIES
BEGUN
BEFORE
AP-
10
PROVAL.—The Secretary may require such 
11
study or studies to be underway prior to ap-
12
proval.’’; and 
13
(2) by striking paragraph (3) and inserting the 
14
following: 
15
‘‘(3) 
EXPEDITED
WITHDRAWAL
OF
AP-
16
PROVAL.— 
17
‘‘(A) IN
GENERAL.—The Secretary may 
18
withdraw approval of a product approved under 
19
accelerated approval using expedited procedures 
20
described in subparagraph (B), if— 
21
‘‘(i) the sponsor fails to conduct any 
22
required postapproval study of the product 
23
with due diligence, including with respect 
24
21:28 May 06, 2022
H7667
156 
•HR 7667 IH
to conditions specified by the Secretary 
1
under paragraph (2)(C); 
2
‘‘(ii) a study required to verify and 
3
describe the predicted effect on irreversible 
4
morbidity or mortality or other clinical 
5
benefit of the product fails to verify and 
6
describe such effect or benefit; 
7
‘‘(iii) other evidence demonstrates 
8
that the product is not shown to be safe or 
9
effective under the conditions of use; or 
10
‘‘(iv) the sponsor disseminates false or 
11
misleading promotional materials with re-
12
spect to the product. 
13
‘‘(B) 
EXPEDITED
PROCEDURES
DE-
14
SCRIBED.—Expedited procedures described in 
15
this subparagraph shall consist of, prior to the 
16
withdrawal of accelerated approval— 
17
‘‘(i) providing the sponsor with— 
18
‘‘(I) due notice; 
19
‘‘(II) an explanation for the pro-
20
posed withdrawal; 
21
‘‘(III) an opportunity for a meet-
22
ing with the Commissioner of Food 
23
and Drugs or the Commissioner’s des-
24
ignee; and 
25
21:28 May 06, 2022
H7667
157 
•HR 7667 IH
‘‘(IV) an opportunity for written 
1
appeal to— 
2
‘‘(aa) the Commissioner of 
3
Food and Drugs; or 
4
‘‘(bb) a designee of the 
5
Commissioner who has not par-
6
ticipated in the proposed with-
7
drawal of approval (other than a 
8
meeting pursuant to subclause 
9
(III)) and is not a subordinate of 
10
an individual (other than the 
11
Commissioner) who participated 
12
in such proposed withdrawal; 
13
‘‘(ii) providing an opportunity for 
14
public comment on the notice proposing to 
15
withdraw approval; 
16
‘‘(iii) the publication of a summary of 
17
the public comments received, and the Sec-
18
retary’s response to such comments, on the 
19
website of the Food and Drug Administra-
20
tion; and 
21
‘‘(iv) convening and consulting an ad-
22
visory committee on issues related to the 
23
proposed withdrawal, if requested by the 
24
sponsor and if no such advisory committee 
25
21:28 May 06, 2022
H7667
158 
•HR 7667 IH
has previously advised the Secretary on 
1
such issues with respect to the withdrawal 
2
of the product prior to the sponsor’s re-
3
quest. 
4
‘‘(4) LABELING.— 
5
‘‘(A) IN
GENERAL.—Subject to subpara-
6
graph (B), the label for a product approved 
7
under accelerated approval shall include— 
8
‘‘(i) a statement indicating that the 
9
product was approved under accelerated 
10
approval; 
11
‘‘(ii) a statement indicating that con-
12
tinued approval of the product is subject to 
13
postmarketing studies to verify clinical 
14
benefit; 
15
‘‘(iii) identification of the surrogate or 
16
intermediate endpoint or endpoints that 
17
supported approval and any known limita-
18
tions of such surrogate or intermediate 
19
endpoint or endpoints in determining clin-
20
ical benefit; and 
21
‘‘(iv) a succinct description of the 
22
product and any uncertainty about antici-
23
pated clinical benefit and a discussion of 
24
21:28 May 06, 2022
H7667
159 
•HR 7667 IH
available evidence with respect to such clin-
1
ical benefit. 
2
‘‘(B) APPLICABILITY.—The labeling re-
3
quirements of subparagraph (A) shall apply 
4
only to products approved under accelerated ap-
5
proval for which the predicted effect on irre-
6
versible morbidity or mortality or other clinical 
7
benefit has not been verified. 
8
‘‘(5) REPORTING.—Not later than September 
9
30, 2025, the Secretary shall submit to the Com-
10
mittee on Energy and Commerce of the House of 
11
Representatives and the Committee on Health, Edu-
12
cation, Labor, and Pensions of the Senate a report 
13
describing circumstances in which the Secretary con-
14
sidered real world evidence submitted to support 
15
postapproval studies required under this subsection 
16
that were completed after the date of enactment of 
17
the Food and Drug Amendments of 2022.’’. 
18
(b) REPORTS OF POSTMARKETING STUDIES.—Sec-
19
tion 506B(a) of the Federal Food, Drug, and Cosmetic 
20
Act (21 U.S.C. 356b(a)) is amended— 
21
(1) by redesignating paragraph (2) as para-
22
graph (3); and 
23
(2) by inserting after paragraph (1) the fol-
24
lowing: 
25
21:28 May 06, 2022
H7667
160 
•HR 7667 IH
‘‘(2) 
ACCELERATED
APPROVAL.—Notwith-
1
standing paragraph (1), a sponsor of a drug ap-
2
proved under accelerated approval shall submit to 
3
the Secretary a report of the progress of any study 
4
required under section 506(c), including progress to-
5
ward any agreed upon enrollment targets, mile-
6
stones, and other information as required by the 
7
Secretary, not later than 180 days after the ap-
8
proval of such drug and not less frequently than 
9
every 180 days thereafter, until the study is com-
10
pleted or terminated.’’. 
11
(c) GUIDANCE.— 
12
(1) IN GENERAL.—The Secretary of Health and 
13
Human Services shall issue guidance describing— 
14
(A) how sponsor questions related to the 
15
identification of novel surrogate or intermediate 
16
clinical endpoints may be addressed in early- 
17
stage development meetings with the Food and 
18
Drug Administration; 
19
(B) the use of novel clinical trial designs 
20
that may be used to conduct appropriate post-
21
approval studies as may be required under sec-
22
tion 506(c)(2)(A) of the Federal Food, Drug, 
23
and Cosmetic Act (21 U.S.C. 356(c)(2)(A)), as 
24
amended by subsection (a); and 
25
21:28 May 06, 2022
H7667
161 
•HR 7667 IH
(C) the expedited procedures described in 
1
section 506(c)(3)(B) of the Federal Food, 
2
Drug, 
and 
Cosmetic 
Act 
(21 
U.S.C. 
3
356(c)(3)(B)). 
4
(2) FINAL
GUIDANCE.—The Secretary shall 
5
issue— 
6
(A) draft guidance under paragraph (1) 
7
not later than 18 months after the date of en-
8
actment of this Act; and 
9
(B) final guidance not later than 1 year 
10
after the close of the public comment period on 
11
each draft guidance. 
12
(d) RARE
DISEASE
ENDPOINT
ADVANCEMENT 
13
PILOT.— 
14
(1) IN GENERAL.—The Secretary of Health and 
15
Human Services shall establish a pilot program 
16
under which the Secretary will establish procedures 
17
to provide increased interaction with sponsors of 
18
rare disease drug development programs for pur-
19
poses of advancing the development of efficacy 
20
endpoints, including surrogate and intermediate 
21
endpoints, for drugs intended to treat rare diseases, 
22
including through— 
23
(A) determining eligibility of participants 
24
for such a program; and 
25
21:28 May 06, 2022
H7667
162 
•HR 7667 IH
(B) developing and implementing a process 
1
for applying to, and participating in, such a 
2
program. 
3
(2) PUBLIC WORKSHOPS.—The Secretary shall 
4
conduct up to 3 public workshops, which shall be 
5
completed not later than September 30, 2026, to 
6
discuss topics relevant to the development of 
7
endpoints for rare diseases, which may include dis-
8
cussions about— 
9
(A) novel endpoints developed through the 
10
pilot program established under this subsection; 
11
and 
12
(B) as appropriate, the use of real world 
13
evidence and real world data to support the val-
14
idation of efficacy endpoints, including surro-
15
gate and intermediate endpoints, for rare dis-
16
eases. 
17
(3) REPORT.—Not later than September 30, 
18
2027, the Secretary shall submit to the Committee 
19
on Energy and Commerce of the House of Rep-
20
resentatives and the Committee on Health, Edu-
21
cation, Labor, and Pensions of the Senate a report 
22
describing the outcomes of the pilot program estab-
23
lished under this subsection. 
24
21:28 May 06, 2022
H7667
163 
•HR 7667 IH
(4) GUIDANCE.—Not later than September 30, 
1
2027, the Secretary shall issue guidance describing 
2
best practices and strategies for development of effi-
3
cacy endpoints, including surrogate and intermediate 
4
endpoints, for rare diseases. 
5
(5) SUNSET.—The Secretary may not accept 
6
any new application or request to participate in the 
7
program established by this subsection on or after 
8
October 1, 2027. 
9
SEC. 805. FACILITATING THE USE OF REAL WORLD EVI-
10
DENCE. 
11
(a) GUIDANCE.—Not later than 1 year after the date 
12
of the enactment of this Act, the Secretary of Health and 
13
Human Services shall issue, or revise existing, guidance 
14
on considerations for the use of real world data and real 
15
world evidence to support regulatory decisionmaking, as 
16
follows: 
17
(1) With respect to drugs, such guidance shall 
18
address— 
19
(A) the use of such data and evidence to 
20
support the approval of a drug application 
21
under section 505 of the Federal Food, Drug, 
22
and Cosmetic Act (21 U.S.C. 355) or a biologi-
23
cal product application under section 351 of the 
24
Public Health Service Act (42 U.S.C. 262), or 
25
21:28 May 06, 2022
H7667
164 
•HR 7667 IH
to support an investigational use exemption 
1
under section 505(i) of the Federal Food, Drug, 
2
and Cosmetic Act or section 351(a)(3) of the 
3
Public Health Service Act; and 
4
(B) the use of such data and evidence ob-
5
tained as a result of the use of drugs author-
6
ized for emergency use under section 564 of the 
7
Federal Food, Drug, and Cosmetic Act (21 
8
U.S.C. 360bbb–3) in such applications, submis-
9
sions, or requests; and 
10
(C) standards and methodologies which 
11
may be used for collection and analysis of real 
12
world evidence included in such applications, 
13
submissions, or requests, as appropriate. 
14
(2) With respect to devices, such guidance shall 
15
address— 
16
(A) the use of such data and evidence to 
17
support the approval, clearance, or classification 
18
of a device pursuant to an application or sub-
19
mission 
submitted 
under 
section 
510(k), 
20
513(f)(2), or 515 of the Federal Food, Drug, 
21
and 
Cosmetic 
Act 
(21 
U.S.C. 
360(k), 
22
360c(f)(2), 360e), or to support an investiga-
23
tional use exemption under section 520(g) of 
24
such Act (21 U.S.C. 360j(g)); and 
25
21:28 May 06, 2022
H7667
165 
•HR 7667 IH
(B) the use of such data and evidence ob-
1
tained as a result of the use of devices author-
2
ized for emergency use under section 564 of the 
3
Federal Food, Drug, and Cosmetic Act (21 
4
U.S.C. 360bbb–3), in such applications, submis-
5
sions, or requests; and 
6
(C) standards and methodologies which 
7
may be used for collection and analysis of real 
8
world evidence included in such applications, 
9
submissions, or requests, as appropriate. 
10
(b) REPORT TO CONGRESS.—Not later than 2 years 
11
after the termination of the public health emergency deter-
12
mination by the Secretary of Health and Human Services 
13
under section 564 of the Federal Food, Drug, and Cos-
14
metic Act (21 U.S.C. 360bbb–3) on February 4, 2020, 
15
with respect to the Coronavirus Disease 2019 (COVID– 
16
19), the Secretary shall submit a report to the Committee 
17
on Energy and Commerce of the House of Representatives 
18
and the Committee on Health, Education, Labor, and 
19
Pensions of the Senate on— 
20
(1) the number of applications submitted for 
21
clearance or approval under sections 505, 510(k), or 
22
515 of the Federal Food, Drug, and Cosmetic Act 
23
(21 U.S.C. 355, 360(k), 360c(f)(2), 360e) or section 
24
351 of the Public Health Service Act, for which an 
25
21:28 May 06, 2022
H7667
166 
•HR 7667 IH
authorization under section 564 of the Federal 
1
Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb– 
2
3) was previously granted; 
3
(2) of the number of applications so submitted, 
4
the number of such applications— 
5
(A) for which real world evidence was sub-
6
mitted and used to support a regulatory deci-
7
sion; and 
8
(B) for which real world evidence was sub-
9
mitted and determined to be insufficient to sup-
10
port a regulatory decision; and 
11
(3) a summary explanation of why, in the case 
12
of applications described in paragraph (2)(B), real 
13
world evidence could not be used to support regu-
14
latory decisions. 
15
SEC. 806. MEDICAL DEVICES ADVISORY COMMITTEE MEET-
16
INGS. 
17
(a) IN GENERAL.—The Secretary shall convene one 
18
or more panels of the Medical Devices Advisory Committee 
19
not less than once per year for the purpose of providing 
20
advice to the Secretary on topics related to medical devices 
21
in pandemic preparedness and response, including the 
22
issues related to in vitro diagnostics. 
23
21:28 May 06, 2022
H7667
167 
•HR 7667 IH
(b) REQUIRED PANEL MEMBER.—A panel convened 
1
under subsection (a) shall include at least 1 population 
2
health-specific representative. 
3
(c) SUNSET.—This section shall cease to be effective 
4
on October 1, 2027. 
5
SEC. 807. ENSURING CYBERSECURITY OF MEDICAL DE-
6
VICES. 
7
(a) IN GENERAL.—Subchapter A of chapter V of the 
8
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 
9
et seq.), as amended by section 501, is further amended 
10
by adding at the end the following: 
11
‘‘SEC. 524C. ENSURING CYBERSECURITY OF DEVICES. 
12
‘‘(a) IN GENERAL.—For purposes of ensuring cyber-
13
security throughout the lifecycle of a cyber device, any per-
14
son who submits a premarket submission for the cyber de-
15
vice shall include such information as the Secretary may 
16
require to ensure that the cyber device meets such cyberse-
17
curity requirements as the Secretary determines to be ap-
18
propriate to demonstrate a reasonable assurance of safety 
19
and effectiveness, including at a minimum the cybersecu-
20
rity requirements under subsection (b). 
21
‘‘(b) CYBERSECURITY REQUIREMENTS.—At a min-
22
imum, the manufacturer of a cyber device shall meet the 
23
following cybersecurity requirements: 
24
21:28 May 06, 2022
H7667
168 
•HR 7667 IH
‘‘(1) The manufacturer shall have a plan to ap-
1
propriately monitor, identify, and address in a rea-
2
sonable time postmarket cybersecurity vulnerabilities 
3
and exploits, including coordinated vulnerability dis-
4
closure and procedures. 
5
‘‘(2) The manufacturer shall design, develop, 
6
and maintain processes and procedures to ensure the 
7
device and related systems are cybersecure, and shall 
8
make available updates and patches to the cyber de-
9
vice and related systems throughout the lifecycle of 
10
the cyber device to address— 
11
‘‘(A) on a reasonably justified regular 
12
cycle, known unacceptable vulnerabilities; and 
13
‘‘(B) as soon as possible out of cycle, crit-
14
ical vulnerabilities that could cause uncontrolled 
15
risks. 
16
‘‘(3) The manufacturer shall provide in the la-
17
beling of the cyber device a software bill of mate-
18
rials, including commercial, open-source, and off-the- 
19
shelf software components. 
20
‘‘(4) The manufacturer shall comply with such 
21
other requirements as the Secretary may require to 
22
demonstrate reasonable assurance of the safety and 
23
effectiveness of the device for purposes of cybersecu-
24
21:28 May 06, 2022
H7667
169 
•HR 7667 IH
rity, which the Secretary may require by an order 
1
published in the Federal Register. 
2
‘‘(c) SUBSTANTIAL EQUIVALENCE.—In making a de-
3
termination of substantial equivalence under section 
4
513(i) for a cyber device, the Secretary may— 
5
‘‘(1) find that cybersecurity information for the 
6
cyber device described in the relevant premarket 
7
submission in the cyber device’s use environment is 
8
inadequate; and 
9
‘‘(2) issue a nonsubstantial equivalence deter-
10
mination based on this finding. 
11
‘‘(d) DEFINITION.—In this section: 
12
‘‘(1) CYBER DEVICE.—The term ‘cyber device’ 
13
means a device that— 
14
‘‘(A) includes software, including software 
15
as or in a device; 
16
‘‘(B) is intended to connect to the internet; 
17
or 
18
‘‘(C) contains any such technological char-
19
acteristics that could be vulnerable to cyberse-
20
curity threats. 
21
‘‘(2) LIFECYCLE OF THE CYBER DEVICE.—The 
22
term ‘lifecycle of the cyber device’ includes the 
23
postmarket lifecycle of the cyber device. 
24
21:28 May 06, 2022
H7667
170 
•HR 7667 IH
‘‘(3) PREMARKET SUBMISSION.—The term ‘pre-
1
market submission’ means any submission under 
2
section 510(k), 513, 515(c), 515(f), or 520(m). 
3
‘‘(e) EXEMPTION.—The Secretary may identify de-
4
vices or types of devices that are exempt from meeting 
5
the cybersecurity requirements established by this section 
6
and regulations promulgated pursuant to this section. The 
7
Secretary shall publish in the Federal Register, and up-
8
date, as appropriate, a list of the devices and types of de-
9
vices so identified by the Secretary.’’. 
10
(b) PROHIBITED ACT.—Section 301(q) of the Fed-
11
eral Food, Drug, and Cosmetic Act (21 U.S.C. 331(q)) 
12
is amended by adding at the end the following: 
13
‘‘(3) The failure to comply with any requirement 
14
under section 524C (relating to ensuring device cybersecu-
15
rity).’’. 
16
(c) ADULTERATION.—Section 501 of the Federal 
17
Food, Drug, and Cosmetic Act (21 U.S.C. 351) is amend-
18
ed by inserting after paragraph (j) the following: 
19
‘‘(k) If it is a device subject to the requirements set 
20
forth in section 524C (relating to ensuring device cyberse-
21
curity) and fails to comply with any requirement under 
22
that section.’’. 
23
21:28 May 06, 2022
H7667
171 
•HR 7667 IH
(d) MISBRANDING.—Section 502(t) of the Federal 
1
Food, Drug, and Cosmetic Act (21 U.S.C. 352(t)) is 
2
amended— 
3
(1) by striking ‘‘or (3)’’ and inserting ‘‘(3)’’; 
4
and 
5
(2) by inserting before the period at the end the 
6
following: ‘‘, or (4) to furnish a software bill of ma-
7
terials as required under section 524C (relating to 
8
ensuring device cybersecurity)’’. 
9
SEC. 808. PUBLIC DOCKET ON PROPOSED MODIFICATIONS 
10
TO APPROVED STRATEGIES. 
11
(a) IN GENERAL.—Not later than 90 days after the 
12
date of the enactment of this Act, the Secretary of Health 
13
and Human Services shall open a public docket for the 
14
submission of public comments regarding factors related 
15
to patient access to a drug that is subject to a risk evalua-
16
tion and mitigation strategy and the administration or 
17
prescribing of such drug by health care providers that 
18
should be taken into consideration when a proposed modi-
19
fication to such strategy is reviewed under section 505– 
20
1(h) of the Federal Food, Drug, and Cosmetic Act (21 
21
U.S.C. 255–1(h)). The Secretary may close such public 
22
docket not earlier than 90 days after such docket is 
23
opened. 
24
21:28 May 06, 2022
H7667
172 
•HR 7667 IH
(b) GAO REPORT.—Not later than December 31, 
1
2026, the Comptroller General of the United States shall 
2
submit to the Committee on Energy and Commerce of the 
3
House of Representatives and the Committee on Health, 
4
Education, Labor, and Pensions of the Senate a report 
5
on— 
6
(1) the number of proposed modifications to an 
7
approved risk evaluation and mitigation strategy the 
8
Secretary has granted under section 505–1(h) of the 
9
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
10
255–1(h)); 
11
(2) any issues affecting patient access to the 
12
drug that is subject to the strategy or considerations 
13
with respect to the administration or prescribing of 
14
such drug by health care providers that arose as a 
15
result of such modifications; and 
16
(3) how such issues were resolved, as applica-
17
ble. 
18
SEC. 809. FACILITATING EXCHANGE OF PRODUCT INFOR-
19
MATION PRIOR TO APPROVAL. 
20
(a) IN GENERAL.—Section 502 of the Federal Food, 
21
Drug, and Cosmetic Act (21 U.S.C. 352) is amended 
22
(1) in paragraph (a), by striking ‘‘drug’’ each 
23
place it appears and inserting ‘‘drug or device’’; 
24
21:28 May 06, 2022
H7667
173 
•HR 7667 IH
(2) in paragraph (a)(2)(B), by striking ‘‘under 
1
section 505 or under section 351 of the Public 
2
Health Service Act for such drug’’ and inserting 
3
‘‘under section 505, 510(k), 513, or 515 of this Act 
4
or section 351 of the Public Health Service Act’’; 
5
and 
6
(3) by adding at the end the following: 
7
‘‘(gg)(1) Unless its labeling bears adequate directions 
8
for use in accordance with paragraph (f), except that (in 
9
addition to drugs or devices that conform with exemptions 
10
pursuant to such paragraph) no drug or device shall be 
11
considered misbranded under such paragraph through the 
12
provision of product information to a payor, formulary 
13
committee, or other similar entity with knowledge and ex-
14
pertise in the area of health care economic analysis car-
15
rying out its responsibilities for the selection of drugs or 
16
devices for coverage or reimbursement if the product infor-
17
mation relates to an investigational drug or device or in-
18
vestigational use of a drug or device that is approved, 
19
cleared, granted marketing authorization, or licensed 
20
under section 505, 510(k), 513(f)(2), or 515 of this Act 
21
or section 351 of the Public Health Service Act (as appli-
22
cable), provided— 
23
‘‘(A) the product information includes— 
24
21:28 May 06, 2022
H7667
174 
•HR 7667 IH
‘‘(i) a clear statement that the investiga-
1
tional drug or device or investigational use of a 
2
drug or device has not been approved, cleared, 
3
granted marketing authorization, or licensed 
4
under section 505, 510(k), 513(f)(2), or 515 of 
5
this Act or section 351 of the Public Health 
6
Service Act (as applicable) and that the safety 
7
and effectiveness of the drug or device or use 
8
has not been established; 
9
‘‘(ii) information related to the stage of de-
10
velopment of the drug or device involved, such 
11
as— 
12
‘‘(I) the status of any study or studies 
13
in which the investigational drug or device 
14
or investigational use is being investigated; 
15
‘‘(II) how the study or studies relate 
16
to the overall plan for the development of 
17
the drug or device; and 
18
‘‘(III) whether a premarket applica-
19
tion, premarket notification, or request for 
20
classification for the investigational drug 
21
or device or investigational use has been 
22
submitted to the Secretary and when such 
23
a submission is planned; 
24
21:28 May 06, 2022
H7667
175 
•HR 7667 IH
‘‘(iii) in the case of information that in-
1
cludes factual presentations of results from 
2
studies, which shall not be selectively presented, 
3
a description of— 
4
‘‘(I) all material aspects of study de-
5
sign, methodology, and results; and 
6
‘‘(II) all material limitations related 
7
to the study design, methodology, and re-
8
sults; 
9
‘‘(iv) where applicable, a prominent state-
10
ment disclosing the indication or indications for 
11
which the Food and Drug Administration has 
12
approved, granted marketing authorization, 
13
cleared, or licensed the product pursuant to sec-
14
tion 505, 510(k), 513(f)(2), or 515 of this Act 
15
or section 351 of the Public Health Service Act, 
16
and a copy of the most current approved label-
17
ing; and 
18
‘‘(v) updated information, if previously 
19
communicated information becomes materially 
20
outdated as a result of significant changes or as 
21
a result of new information regarding the prod-
22
uct or its review status; and 
23
‘‘(B) the product information does not in-
24
clude— 
25
21:28 May 06, 2022
H7667
176 
•HR 7667 IH
‘‘(i) information that represents that an 
1
unapproved product— 
2
‘‘(I) has been approved, cleared, 
3
granted marketing authorization, or li-
4
censed 
under 
section 
505, 
510(k), 
5
513(f)(2), or 515 of this Act or section 
6
351 of the Public Health Service Act (as 
7
applicable); or 
8
‘‘(II) has otherwise been determined 
9
to be safe or effective for the purpose or 
10
purposes for which the drug or device is 
11
being studied; or 
12
‘‘(ii) information that represents that an 
13
unapproved use of a drug or device that has 
14
been so approved, granted marketing authoriza-
15
tion, cleared, or licensed— 
16
‘‘(I) is so approved, granted mar-
17
keting authorization, cleared, or licensed; 
18
or 
19
‘‘(II) that the product is safe or effec-
20
tive for the use or uses for which the drug 
21
or device is being studied. 
22
‘‘(2) For purposes of this subsection, the term ‘prod-
23
uct information’ includes— 
24
21:28 May 06, 2022
H7667
177 
•HR 7667 IH
‘‘(A) information describing the drug or device 
1
(such as drug class, device description, and fea-
2
tures); 
3
‘‘(B) information about the indication or indica-
4
tions being investigated; 
5
‘‘(C) the anticipated timeline for a possible ap-
6
proval, clearance, marketing authorization, or licen-
7
sure pursuant to section 505, 510(k), 513, or 515 
8
of this Act or section 351 of the Public Health Serv-
9
ice Act; 
10
‘‘(D) drug or device pricing information; 
11
‘‘(E) patient utilization projections; 
12
‘‘(F) product-related programs or services; and 
13
‘‘(G) factual presentations of results from stud-
14
ies that do not characterize or make conclusions re-
15
garding safety or efficacy.’’. 
16
(b) GAO STUDY AND REPORT.—Beginning on the 
17
date that is 5 years and 6 months after the date of enact-
18
ment of this Act, the Comptroller General of the United 
19
States shall conduct a study on the provision and use of 
20
information pursuant to section 502(gg) of the Federal 
21
Food, Drug, and Cosmetic Act, as added by this sub-
22
section (a), between manufacturers of drugs and devices 
23
(as defined in section 201 of the Federal Food, Drug, and 
24
Cosmetic Act (21 U.S.C. 321)) and entities described in 
25
21:28 May 06, 2022
H7667
178 
•HR 7667 IH
such section 520(gg). Such study shall include an analysis 
1
of the following: 
2
(1) The types of information communicated be-
3
tween such manufacturers and payors. 
4
(2) The manner of communication between 
5
such manufacturers and payors. 
6
(3)(A) Whether such manufacturers file a sub-
7
mission for approval, marketing authorization, clear-
8
ance, or licensing of a new drug or device or the new 
9
use of a drug or device that is the subject of commu-
10
nication between such manufacturers and payors 
11
under section 502(gg) of the Federal Food, Drug, 
12
and Cosmetic Act, as added by subsection (a). 
13
(B) How frequently the Food and Drug Admin-
14
istration approves, grants marketing authorization, 
15
clears, or licenses the new drug or device or new use. 
16
(C) The timeframe between the initial commu-
17
nications permitted under section 502(gg) of the 
18
Federal Food, Drug, and Cosmetic Act, as added by 
19
subsection (a), regarding an investigational drug or 
20
device or investigational use, and the initial mar-
21
keting of such drug or device. 
22
21:28 May 06, 2022
H7667
179 
•HR 7667 IH
SEC. 810. BANS OF DEVICES FOR ONE OR MORE INTENDED 
1
USES. 
2
(a) IN GENERAL.—Section 516(a) of the Federal 
3
Food, Drug, and Cosmetic Act (21 U.S.C. 360f(a)) is 
4
amended— 
5
(1) in paragraph (1), by inserting ‘‘for one or 
6
more intended use’’ before the semicolon at the end; 
7
and 
8
(2) in the matter following paragraph (2), by 
9
inserting ‘‘for any such intended use or uses. A de-
10
vice that is banned for one or more intended uses is 
11
not a legally marketed device under section 1006 
12
when intended for such use or uses’’ after ‘‘banned 
13
device’’. 
14
(b) SPECIFIC DEVICES DEEMED BANNED.—Section 
15
516 of the Federal Food, Drug, and Cosmetic Act (21 
16
U.S.C. 360f) is further amended by adding at the end the 
17
following: 
18
‘‘(c) SPECIFIC DEVICE BANNED.—Electrical stimula-
19
tion devices that apply a noxious electrical stimulus to a 
20
person’s skin intended to reduce or cease self-injurious be-
21
havior or aggressive behavior are deemed to be banned de-
22
vices, as described in subsection (a). Such devices are 
23
banned unless or until the Secretary promulgates a regula-
24
tion to make such devices no longer banned based on a 
25
finding that such devices do not present an unreasonable 
26
21:28 May 06, 2022
H7667
180 
•HR 7667 IH
and substantial risk of illness or injury, or that such risk 
1
can be corrected or eliminated by labeling.’’. 
2
SEC. 811. CLARIFYING APPLICATION OF EXCLUSIVE AP-
3
PROVAL, 
CERTIFICATION, 
OR 
LICENSURE 
4
FOR DRUGS DESIGNATED FOR RARE DIS-
5
EASES OR CONDITIONS. 
6
Section 527 of the Federal Food, Drug, and Cosmetic 
7
Act (21 U.S.C. 360cc) is amended— 
8
(1) in subsection (a), in the matter following 
9
paragraph (2), by striking ‘‘same disease or condi-
10
tion’’ and inserting ‘‘same indication or use for 
11
which the Secretary has approved or licensed such 
12
drug’’; 
13
(2) in subsection (b)— 
14
(A) in the matter preceding paragraph (1), 
15
by striking ‘‘same rare disease or condition’’ 
16
and inserting ‘‘same indication or use for which 
17
the Secretary has approved or licensed such 
18
drug’’; and 
19
(B) in paragraph (1), by striking ‘‘with the 
20
disease or condition for which the drug was des-
21
ignated’’ and inserting ‘‘for whom the drug is 
22
indicated’’; and 
23
21:28 May 06, 2022
H7667
181 
•HR 7667 IH
(3) in subsection (c), by striking ‘‘same rare 
1
disease or condition’’ and inserting ‘‘same indication 
2
or use’’. 
3
SEC. 812. GAO REPORT ON THIRD-PARTY REVIEW. 
4
Not later than September 30, 2026, the Comptroller 
5
General of the United States shall submit to the Com-
6
mittee on Energy and Commerce of the House of Rep-
7
resentatives and the Committee on Health, Education, 
8
Labor, and Pensions of the Senate a report on the third- 
9
party review program described in section 523 of the Fed-
10
eral Food, Drug, and Cosmetic Act (21 U.S.C. 360m). 
11
Such report shall include— 
12
(1) a description of the financial and staffing 
13
resources used to carry out such program; 
14
(2) a description of actions taken by the Sec-
15
retary pursuant section 523(b)(2)(C) of the Federal 
16
Food, 
Drug, 
and 
Cosmetic 
Act 
(21 
U.S.C. 
17
360m(b)(2)(C)); and 
18
(3) the results of an audit of the performance 
19
of select persons accredited under such program. 
20
SEC. 813. REAUTHORIZATION OF DEVICE PILOT PROJECTS. 
21
Section 519(i)(10) of the Federal Food, Drug, and 
22
Cosmetic Act (21 U.S.C. 360i(i)(10)) is amended by strik-
23
ing ‘‘2022’’ and inserting ‘‘2027’’. 
24
21:28 May 06, 2022
H7667
182 
•HR 7667 IH
SEC. 814. REPORTING ON PENDING GENERIC DRUG APPLI-
1
CATIONS AND PRIORITY REVIEW APPLICA-
2
TIONS. 
3
Section 807 of the FDA Reauthorization Act of 2017 
4
(Public Law 115–52) is amended, in the matter preceding 
5
paragraph (1), by striking ‘‘2022’’ and inserting ‘‘2027’’. 
6
Æ 
21:28 May 06, 2022
H7667
